Treatment of warts

ABSTRACT

Disclosed herein are compositions having standardized potencies for use in the treatment of warts. Methods of treating a common wart comprising administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof are also disclosed. Further disclosed are methods of treating a non-common wart administering one or more intralesional injections of compositions having standardized potencies to a patient in need thereof.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No.62/714,942, filed Aug. 6, 2018, and U.S. Provisional Application No.62/880,742, filed Jul. 31, 2019, the entirety of each of which isincorporated by reference herein.

FIELD OF THE INVENTION

The present disclosure relates to therapeutics having a standardizedpotency for the complete resolution of common warts and for theprevention of recurrence of common warts.

BACKGROUND OF THE INVENTION

Common warts are infections of the skin caused by human papillomavirus(HPV).

The virus initially targets epidermal basal cells and induceshyperplasia and hyperkeratosis, which presents clinically as a wart.While not life threatening, common warts can cause both physicaldiscomfort and embarrassment in patients.

It is estimated that common warts have an overall prevalence of 2 to 20%in the United States. However, current treatment options for commonwarts vary in their effectiveness and often result in recurrence.Treatments including topical salicylic acid, topical imiquimod,bleomycin injections, cryotherapy, excision, electrocautery, and laservaporization are employed with various outcomes and side effects.

Immunotherapy using Candida albicans antigens has also been studied.However, a range of response levels were reported. See Aldahan A S etal., “Efficacy of intralesional immunotherapy for the treatment ofwarts: A review of the literature,” Dermatologic Therapy 2016;29:197-207, Table 1; and Alikhan A et al., “Use of Candida antigeninjections for the treatment of verruca vulgaris: A two-year mayo clinicexperience,” Journal of Dermatological Treatment 2016; 27(4): 355-58,355, Table 2. The inconsistent results may be due to the use ofdifferent sources of Candida antigen in these studies, having apparentlydifferent concentrations and potencies. For example, two studiesutilized Candida antigens obtained from Hollister-Stier (Alikan et al.at 355 and Perman M et al., “The painful purple digit: an alarmingcomplication of Candida albicans antigen treatment of recalcitrantwarts,” Dermatitis: Contact, Atopic, Occupational, Drug 2005;16(1):38-40, cited in Aldahan et al.), another study utilized Candidaantigens obtained from Bayer (Johnson et al., “Intralesional injectionof mumps or candida skin test antigens: a novel immunotherapy forwarts,” Arch Dematol. 2001; 137:451-55, cited in Aldahan et al. andAlikhan et al.), yet another study utilized Candida antigens obtainedfrom Creative Drug Industries (Majid I and Imran S, “Immunotherapy withIntralesional Candida albicans Antigen in Resistant or Recurrent Warts:A Study,” Indian Journal of Dermatology 2013: 58(5): 360-65, cited inAldahan et al. and Alikhan et al.), while other studies utilized Candin®manufactured by Allermed Laboratories (Kim K H et al., “Phase 1 clinicaltrial of intralesional injection of Candida antigen for the treatment ofwarts,” Arch Dematol 2010, 146(12):1431-33; Pfenninger J L and Fowler GC, “Procedures for Primary Care,” Third Edition, Elsevier 2010, 639-43;Signor R J, “Candida albicans Intralesional Injection Immunotherapy ofWarts,” Cutis 2002; 70:185-92, cited in Alikhan et al.; Phillips R C etal., “Treatment of Warts with Candida Antigen Injection,” Arch Dematol2001, 136(10):1274-5); Wong A and Crawford R I, “Intralesional Candidaantigen for common warts in people with HIV,” J Cutan Med Surg. 2013;17(5): 313-15, cited in Aldahan et al. Some studies also do not reporttheir sources of Candida antigens. See Summers P et al., “Treatment ofrecalcitrant verruca vulgaris with Candida antigen in patient with humanimmunodeficiency virus,” J Drugs Dermatol 2009; 8(3): 268-69, cited inAldahan et al.; “Warts Refractory to Conventional Therapy Yield toCandida Antigen,” American Academy of Family Practice 90 ClinicalPerspectives 1990; Harada S, “Clinical Application of Fungus Extractsand its Culture filtrate in the Treatment of Skin Diseases: (3) CandidaVaccine in the Treatment of Warts,” Japanese Journal of Dermatology1979; 89(6), 397-402.

In view of the various sources being studied, the dosages reported byvolumes and weight by volume (v/w) dilutions therefore do not providesufficient information to physicians to achieve consistent cure rates ofwarts. At best, U.S. Pat. No. 6,350,451 to Horn provides dosing ofantigens based on initial delayed type hypersensitivity (DTH) responses.See '451 Patent at Example. Therefore, Candida antigen compositionshaving standardized potencies for treatment of warts are desired.

SUMMARY OF THE INVENTION

The present disclosure provides for, and includes, compositions havingstandardized potencies for use in the treatment of one or more commonwarts or non-common warts. The present disclosure also provides for, andincludes, methods for treating one or more common warts or non-commonwarts.

In an aspect, the present disclosure provides for, and includes a methodfor treating a common wart in a subject in need thereof, the methodcomprises administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition effective forcomplete resolution of the common wart at a cumulative dose of 2.5 unitsof potency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a common wart in a subject in need thereof, the methodcomprises administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition capable of completeresolution of the common wart at a cumulative dose of 2.5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a common wart in a subject in need thereof, the methodcomprises administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition effective forpartial resolution of the common wart at a cumulative dose of 5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a common wart in a subject in need thereof, the methodcomprises administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition capable of partialresolution of the common wart at a cumulative dose of 5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a plurality of common warts in a subject in need thereof,the method comprises administering one or more intralesional injectionsto the subject of an amount of a pharmaceutical composition effectivefor partial resolution of the plurality of common warts at a cumulativedose of 5 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a plurality of common warts in a subject in need thereof,the method comprises administering one or more intralesional injectionsto the subject of an amount of a pharmaceutical composition capable ofpartial resolution of the plurality of common warts at a cumulative doseof 5 units of potency, where the pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a plurality of common warts in a subject in need thereof,the method comprises administering one or more intralesional injectionsto the subject of an amount of a pharmaceutical composition effectivefor reducing the diameter of each of the plurality of common warts by atleast 50% at a cumulative dose of 1 unit of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a plurality of common warts in a subject in need thereof,the method comprises administering one or more intralesional injectionsto the subject of an amount of a pharmaceutical composition capable ofreducing the diameter of each of the plurality of common warts by atleast 50% at a cumulative dose of 1 unit of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a non-common wart in a subject in need thereof, where thesubject has one or more common warts, the method comprises administeringone or more intralesional injections to the subject of an amount of apharmaceutical composition effective for complete resolution of thenon-common wart at a cumulative dose of 5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a non-common wart in a subject in need thereof, where thesubject has one or more common warts, the method comprises administeringone or more intralesional injections to the subject of an amount of apharmaceutical composition capable of complete resolution of thenon-common wart at a cumulative dose of 5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a previously treated common wart in a subject in needthereof, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioneffective for complete resolution of the previously treated common wartat a cumulative dose of 5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor treating a previously treated common wart in a subject in needthereof, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioncapable of complete resolution of the previously treated common wart ata cumulative dose of 5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor delaying recurrence of a common wart in a subject in need thereof,the method comprises administering one or more intralesional injectionsto the subject of an amount of a pharmaceutical composition effectivefor delaying the reappearance of the common wart upon resolution at acumulative dose of 2.5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens.

In an aspect, the present disclosure provides for, and includes a methodfor delaying recurrence of a common wart in a subject in need thereof,the method comprises administering one or more intralesional injectionsto the subject of an amount of a pharmaceutical composition capable ofdelaying the reappearance of the common wart upon resolution at acumulative dose of 2.5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for complete resolution of a common wart ata cumulative dose of 2.5 units of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for partial resolution of a common wart ata cumulative dose of 5 units of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for reducing the diameter of a common wartby at least 50% at a cumulative dose of 1 unit of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for partial resolution of a plurality ofcommon warts at a cumulative dose of 5 units of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for reducing the diameter of a plurality ofcommon warts by at least 50% at a cumulative dose of 1 unit of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for complete resolution of a non-commonwart at a cumulative dose of 5 units of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for complete resolution of a previouslytreated common wart at a cumulative dose of 5 units of potency.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for delaying the reappearance of the commonwart upon resolution at a cumulative dose of 2.5 units of potency.

In an aspect, the present disclosure provides for, and includes, amethod for reducing the level of IL-23 in a subject in need thereof, themethod comprises administering one or more intralesional injections tothe subject of an amount of a pharmaceutical composition at a cumulativedose of 1 unit of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.In an aspect, a subject is diagnosed with at least one common wart. Inone aspect, a method of the present disclosure reduces the level ofIL-23 for at least about 15% in a subject upon receipt of a cumulativedose of a pharmaceutical composition of the present disclosure whencompared to a level of IL-23 measured in the subject before theadministering step. In an aspect, a method of the present disclosurereduces the level of IL-23 for at least about 35% in a subject uponreceipt of a cumulative dose of a pharmaceutical composition of thepresent disclosure when compared to a level of IL-23 measured in thesubject before the administering step.

In an aspect, the present disclosure provides for, and includes, amethod for completely resolving a common wart in a subject in needthereof, the method comprises reducing the level of IL-23 by at leastabout 15% in a subject in need thereof. In an aspect, the presentdisclosure provides for, and includes, a method for completely resolvinga common wart in a subject in need thereof, the method comprisesreducing the level of IL-23 by at least about 35% in a subject in needthereof. In one aspect, a method of the present disclosure reduces thelevel of IL-23 by administering one or more intralesional injections tothe subject of an amount of a pharmaceutical composition at a cumulativedose of 3 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.

In an aspect, the present disclosure provides for, and includes, amethod for reducing the level of IL-7 in a subject in need thereof, themethod comprises administering one or more intralesional injections tothe subject of an amount of a pharmaceutical composition at a cumulativedose of 0.6 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.In an aspect, a subject is diagnosed with at least one common wart. Inone aspect, a method of the present disclosure reduces the level of IL-7for at least about 10% in a subject upon receipt of a cumulative dose ofa pharmaceutical composition of the present disclosure when compared toa level of IL-7 measured in the subject before the administering step.

In an aspect, the present disclosure provides for, and includes, amethod for reducing the level of IL-7 in a subject in need thereof, themethod comprises administering one or more intralesional injections tothe subject of an amount of a pharmaceutical composition at a cumulativedose of 3 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.In an aspect, a subject is diagnosed with at least one common wart. Inone aspect, a method of the present disclosure reduces the level of IL-7for at least about 20% in the subject upon receipt of a cumulative doseof a pharmaceutical composition of the present disclosure when comparedto a level of IL-7 measured in the subject before the administeringstep.

In an aspect, the present disclosure provides for, and includes, amethod for reducing the level of IP-10 in a subject in need thereof, themethod comprises administering one or more intralesional injections tothe subject of an amount of a pharmaceutical composition at a cumulativedose of 3 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.In an aspect, a subject is diagnosed with at least one common wart. Inone aspect, a method of the present disclosure reduces the level ofIP-10 for at least about 5% in the subject upon receipt of a cumulativedose of a pharmaceutical composition of the present disclosure whencompared to a level of IP-10 measured in the subject before theadministering step.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens used for reducing the level of IL-23 in a subject inneed thereof. In an aspect, a subject is diagnosed with at least onecommon wart.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens used for completely resolving a common wart in asubject in need thereof by reducing the level of IL-23 by at least about35% in a subject in need thereof. In an aspect, the present disclosureprovides for, and includes a medicament comprising a filtered extract ofCandida albicans and secreted antigens used for completely resolving acommon wart in a subject in need thereof by reducing the level of IL-23by at least about 15% in a subject in need thereof.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens used for reducing the level of IL-7 in a subject inneed thereof. In an aspect, a subject is diagnosed with at least onecommon wart.

In an aspect, the present disclosure provides for, and includes amedicament comprising a filtered extract of Candida albicans andsecreted antigens used for reducing the level of IP-10 in a subject inneed thereof. In an aspect, a subject is diagnosed with at least onecommon wart.

BRIEF DESCRIPTION OF THE DRAWINGS

The present disclosure is disclosed with reference to the accompanyingdrawings, where:

FIG. 1 shows characteristic morphology of isolated colonies of a firststrain of Candida albicans, deposited as ATCC Accession No. PTA-126019,in accordance with the present disclosure;

FIG. 2 shows characteristic morphology of isolated colonies of a secondstrain of Candida albicans, deposited as ATCC Accession No. PTA-126020,in accordance with the present disclosure;

FIG. 3 shows typical appearance of budding yeast cells of Candidaalbicans in accordance with the present disclosure;

FIG. 4 shows typical appearance of pseudohyphae of Candida albicans inaccordance with the present disclosure;

FIG. 5 illustrates an example of a track grid on the back of a guineapig in accordance with the present disclosure; and

FIG. 6 illustrates the preferred location of the intralesionalinjection.

FIGS. 7A, 7B, and 7C illustrate comparison of changes in biomarkerlevels of IL-7, IP-10, and IL-23, respectively, within a treatment groupand a placebo group in accordance with the present disclosure.

DETAILED DESCRIPTION

The present disclosure provides for, and includes, pharmaceuticalcompositions having standardized potencies for use in the treatment ofone or more common warts or non-common warts. In one aspect, treatmentof one or more common warts or non-common warts refers to therapeutictreatment of these warts. In an aspect, treatment of one or more commonwarts or non-common warts refers to providing prophylactic orpreventative measures against the development of warts. In an aspect, apharmaceutical composition of the present disclosure is capable ofcomplete resolution of one or more common warts and non-common wartswith a cumulative dose given in units of potency in accordance with thepresent disclosure. In one aspect, a pharmaceutical composition of thepresent disclosure is capable of partial resolution of one or morecommon warts with a cumulative dose given in units of potency inaccordance with the present disclosure. In an aspect, a pharmaceuticalcomposition of the present disclosure is capable of delaying thereappearance of one or more common warts upon resolution with acumulative dose given in units of potency in accordance with the presentdisclosure.

The present disclosure also provides for, and includes, methods fortreating one or more common warts or non-common warts using thepharmaceutical compositions described herein. In an aspect, methods forcompletely resolving one or more common warts or non-common warts areprovided. In one aspect, methods for partially resolving one or morecommon warts are provided. In an aspect, methods for treating previouslytreated common warts are provided. In one aspect, methods for delayingreappearance of common warts are provided.

Unless defined otherwise herein, terms are to be understood according toconventional usage by those of ordinary skill in the relevant art. Wherea term is provided in the singular, the inventors also contemplateaspects of the disclosure described by the plural of that term. Wherethere are discrepancies in terms and definitions used in references thatare incorporated by reference, the terms used in this application shallhave the definitions given herein. Other technical terms used have theirordinary meaning in the art in which they are used, as exemplified byvarious art-specific dictionaries, for example, “The American Heritage®Science Dictionary” (Editors of the American Heritage Dictionaries,2011, Houghton Mifflin Harcourt, Boston and New York), the “McGraw-HillDictionary of Scientific and Technical Terms” (6th edition, 2002,McGraw-Hill, New York), or the “Oxford Dictionary of Biology” (6thedition, 2008, Oxford University Press, Oxford and New York).

All publications, patents, and patent applications mentioned in thisdisclosure are herein incorporated by reference to the same extent as ifeach individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.

The term “and/or” when used in a list of two or more items, means thatany one of the listed items can be employed by itself or in combinationwith any one or more of the listed items. For example, the expression “Aand/or B” is intended to mean either or both of A and B, i.e., A alone,B alone, or A and B in combination. The expression “A, B and/or C” isintended to mean A alone, B alone, C alone, A and B in combination, Aand C in combination, B and C in combination, or A, B, and C incombination.

As used herein, terms in the singular and the singular forms “a,” “an,”and “the,” for example, include plural referents unless the contentclearly dictates otherwise.

Where a range of values is provided, it is understood that eachintervening value, between the upper and lower limit of that range andany other stated or intervening value in that stated range isencompassed within the disclosure. The upper and lower limits of thesesmaller ranges may independently be included in the smaller ranges, andare also encompassed within the disclosure, subject to any specificallyexcluded limit in the stated range. Where the stated range includes oneor both of the limits, ranges excluding either both of those includedlimits are also included in the disclosure. Whenever the phrase“comprising” is used, variations such as “consisting essentially of” and“consisting of” are also contemplated.

The term “about,” as used herein, is intended to qualify the numericalvalues that it modifies, denoting such a value as variable within amargin of error. When no particular margin of error, such as a standarddeviation to a mean value, is recited, the term “about” should beunderstood to mean that range which would encompass the recited valueand the range which would be included by rounding up or down to thatfigure, taking into account significant figures.

As used herein, a “pharmaceutical composition” of the present disclosurecan be an antigen or solvates thereof, described herein.

As used herein, an “excipient” refers to a substance formulatedalongside the active ingredient of a medication. An excipient can beused for the purpose of long-term stabilization or to confer atherapeutic enhancement on the active ingredient in the final dosageform, such as facilitating active ingredient absorption, reducingviscosity, or enhancing solubility. Excipients can also be useful in themanufacturing process, to aid in the handling of the active substanceconcerned such as by facilitating powder flowability or non-stickproperties, in addition to aiding in vitro stability such as preventionof denaturation or aggregation over the expected shelf life.

As used herein, “pharmaceutically acceptable carrier” includes any andall solvents, dispersion media, antibacterial and antifungal agents,isotonic and absorption delaying agents and the like. The use of suchmedia and agents for pharmaceutically active substances is well known inthe art. Except insofar as any conventional media or agent isincompatible with the pharmaceutical compositions, its use inpharmaceutical compositions is contemplated. As used herein, the phrase“pharmaceutically, pharmacologically, or physiologically acceptable”refers to molecular entities and compositions that do not produceadverse, allergic, or other untoward reactions when administered to ananimal or a human. A pharmaceutically acceptable carrier can be liquid(e.g., saline), gel or solid form of diluents, adjuvant, excipients oran acid resistant encapsulated ingredient. Suitable diluents andexcipients include pharmaceutical grades of physiological saline,dextrose, glycerol, mannitol, lactose, starch, magnesium stearate,sodium saccharin, cellulose, magnesium carbonate, and the like, andcombinations thereof.

As used herein, the term “pharmaceutically acceptable solvate” refers toan association of one or more solvent molecules and a compound of thepresent disclosure. Examples of solvents that form pharmaceuticallyacceptable solvates include, but are not limited to, water, isopropanol,ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

As used herein, the term “treating” refers to (i) completely orpartially inhibiting a disease, disorder or condition, for example,arresting its development; (ii) completely or partially relieving adisease, disorder or condition, for example, causing regression of thedisease, disorder and/or condition; or (iii) completely or partiallypreventing a disease, disorder or condition from occurring in a patientthat may be predisposed to the disease, disorder and/or condition, buthas not yet been diagnosed as having it. Similarly, “treatment” refersto both therapeutic treatment and prophylactic or preventative measures.For example, a method or composition provided here can be used to delaythe progression of a condition (e.g., warts). As used herein, “delaying”the progression of a condition means to defer, hinder, slow, retard,stabilize, and/or postpone development of the condition. This delay canbe of varying lengths of time, depending on the history of the conditionand/or individual being treated.

As used herein, the term “wart” refers to a growth on the skin caused byhuman papillomavirus.

As used herein, the term “anatomical region” refers to any one of thefollowing regions of a subject's body: left arm, right arm, left hand,right hand, left leg, right leg, left foot, right foot, and torso. Asused herein, an arm region includes a shoulder, upper and lower arms, awrist, and half of an armpit. As used herein, a hand region starts fromthe distal to the wrist, excluding any periungual warts. As used herein,a foot starts from the distal to ankles, excluding the sole of the foot.As used herein, a leg region includes the upper leg, the lower leg, andan ankle. As used herein, a torso region includes the neck, the back,the chest, the abdomen, the hips, the buttocks and the pelvic region.

As used herein, the term “recalcitrant wart” refers to a wart that wasnot successfully treated by prior treatment, excluding over-the-countertreatments. As used herein, the term “over-the-counter treatment” refersto medications sold directly to a consumer without a prescription from ahealthcare professional.

As used herein, the term “perimeter” refers to the peripheral margin ofa wart.

As used herein, the term “recurrence” refers to the growth of a wart atthe same location where a previously regressed wart was present.

As used herein, the term “complete resolution” refers to a sustainedresolution of a wart reflected by a lack of recurrence of a wart asobserved at least 20 weeks from administration of the firstintralesional injection.

As used herein, the term “partial resolution” refers to any reduction inthe diameter of a wart as compared to the diameter observed before thefirst intralesional injection.

As used herein, the terms “administer,” “administering,” or“administration” in reference to a dosage form of the disclosure refersto the act of introducing the dosage form into the system of subject inneed of treatment. When a dosage form of the disclosure is given incombination with one or more other active agents (in their respectivedosage forms), “administration” and its variants are each understood toinclude concurrent and/or sequential introduction of the dosage form andthe other active agents. Administration of any of the described dosageforms includes simultaneous (parallel) administration, sequential(stepwise) administration, co-administration, or separateadministration, in which the therapies are administered separately atapproximately the same time, e.g., within about a few seconds to a fewhours of one another.

As used herein, the term “medicament” refers to a substance used totreat an illness.

As used herein, the term “molecular weight” refers to the average massof a molecule of interest to one-twelfth of the mass of carbon 12. Amolecular weight is given in the unit of Daltons (Da). A molecularweight is measured by a method using a superpose 12 column calibratedwith dextran standards having molecular weights between 1 kilodalton and512 kilodalton.

As used herein, the term “IL-23” refers to interleukin 23, which is aheterodimeric cytokine having a p19 and p 40 subunit.

As used herein, the term “IL-7” refers to interleukin 7, which is acytokine important for B and T cell development.

As used herein, the term “IP-10” refers to interferon gamma-inducedprotein, which is also known as CXCL10.

A. Manufacturing Process of Pharmaceutical Compositions

In one aspect, a pharmaceutical composition of the present disclosurecomprising a filtered extract of Candida albicans and secreted antigenscan be prepared by a series of steps comprising growing two or morestrains of Candida albicans separately, pooling cultures of two or morestrains of Candida albicans and dialyzing the mixture, heating themixture, lyophilizing the heated dialyzed material, producing a drypowder, extracting the dry powder, filtering the extract, and producinga master lot filtered solution. In an aspect, a pharmaceuticalcomposition of the present disclosure can be produced by the protocol asoutlined in Example 1.

In an aspect, a pharmaceutical composition of the present disclosure maybe prepared using two or more strains of Candida albicans, such as usingtwo strains, three strains, four strains, five strains, six strains,seven strains, eight strains, nine strains, or ten strains. In oneaspect, a pharmaceutical composition of the present disclosure isprepared using two strains of Candida albicans. In an aspect, apharmaceutical composition of the present disclosure is prepared usingstrains of Candida albicans provided in Hasenclever HF and Mitchell WO,“Antigenic Studies of Candida,” Journal of Bacteriology 1961;82:578-581. In an aspect, a pharmaceutical composition of the presentdisclosure is prepared using two strains of Candida albicans, where arepresentative sample of a first strain has been deposited with theAmerican Type Culture Collection (ATCC; located at 10801 UniversityBoulevard, Manassas, Va. 20110) under ATCC Accession No. PTA-126019, anda representative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In one aspect, a master lot filtered solution can be diluted at about2:998 by volume with a diluent to form a pharmaceutical composition,meaning that 2 ml of a master lot filtered solution is diluted with 988ml of a diluent. In an aspect, a master lot filtered solution can bediluted at a range of from about 2:998 to about 1:1 by volume with adiluent, such as from about 2:998 to about 10:990, from about 10:990 toabout 20:980, from about 20:980 to about 30:970, from about 30:970 toabout 40:960, from about 40:960 to about 50:950, from about 50:950 toabout 60:940, from about 60:940 to about 70:930, from about 70:930 toabout 80:920, from about 80:920 to about 90:910, from about 90:910 toabout 1:9, from about 1:9 to about 1:8, from about 1:8 to about 1:7,from about 1:7 to about 1:6, from about 1:6 to about 1:5, from about 1:5to about 1:4, from about 1:4 to about 1:3, from about 1:3 to about 1:2,from about 1:2 to about 1:1. In an aspect, a master lot filteredsolution is undiluted in a pharmaceutical composition.

In an aspect, the present disclosure provides for a resultingpharmaceutical composition comprising at least 80% mannose, such as from80% mannose to 85% mannose, from 85% mannose to 90% or mannose from 80%to 90% mannose. In an aspect, the present disclosure provides for aresulting pharmaceutical composition comprising at least 8% glucose,such as from 8% glucose to 10% glucose, from 10% glucose to 12% glucose,or from 8% glucose to 12% glucose. In an aspect, the present disclosureprovides for a resulting pharmaceutical composition comprising at least1% galactose, such as from 1% galactose to 2.5% galactose, from 2.5%galactose to 5% galactose, or from 1% to 5% galactose.

In an aspect, the present disclosure provides for a resultingpharmaceutical composition comprising antigens having a molecular weightof about 167 kilodaltons, such as from 157 kilodaltons to 177kilodaltons. In an aspect, a molecular weight is measured by a methodusing a superpose 12 column calibrated with dextran standards havingmolecular weights between 1 kilodalton and 512 kilodalton.

B. Test for Relative Potency

A unit of potency in accordance with the present disclosure is definedby a relative potency (RP) compared to a reference standard Candidaalbicans extract. A compound determined to have a relative potency of 1compared to the standard is assigned to have a potency of 1 unit per mL.Relative potency is determined in a female IAF Hairless guinea pig(Crl:HA-HO) model, compared to a standard Candida albicans extract thatis capable of eliciting an induration response ≥5 mm in animmunologically competent person at 48 hours after a 0.1 mL injection.In an aspect, a reference standard is established by skin test titrationin humans with delayed-type hypersensitivity to Candida albicans.

Female IAF Hairless guinea pigs are selected to be as uniform in age andweight as possible. In an aspect, twenty or less female IAF Hairlessguinea pigs can be used in a study. They are generally 4-6 months ofage, and their body weights at treatment commencement will range fromapproximately 0.6-0.8 kilograms. All study animals are acclimatized totheir designated housing at least 14 days prior to the first day of use.

At week 0, all study animals are sensitized with a 1:1 mixture ofComplete Freund's Adjuvant (CFA) mixed with an antigen solution. In anaspect, an antigen solution is a 10-fold dilution of the standardCandida albicans extract using unpreserved saline. In another aspect, anantigen solution can be a 100-fold dilution of the standard Candidaalbicans extract using unpreserved saline. In an aspect, Adjulite CFA(Pacific Immunology) or any other commercially available CFA can be usedin this assay. Animals are injected using a needle with a maximum of 4subcutaneous injections of 0.1 ml, or 0.4 ml total, of the preparedmixture. In an aspect, a needle can be a 21 g needle, a 22 g needle, ora 23 g needle. These injections may be given in the cervical region(either the nape or over the shoulders), the gluteal (maximum of twoinjections in each location, one on each side), and/or the inguinalareas (a maximum of 0.1 ml may be given in each inguinal area). Any oneinjection regimen containing CFA can be applied to each guinea pig inthe study.

At week 4±1 week, four serial dilutions of each test sample and thestandard are prepared independently with phenolated normal saline. Forexample, a set of serial dilutions can be prepared at 1:1, 1:4, 1:16,and 1:64. Animals are sedated for intradermal injection to ensure properplacement. Injections are given at a volume of 0.1 mL using a 27 gintradermal bevel needle on the backs of the sensitized guinea pigs.Injection locations are separated by at least 3 cm apart on a grid onthe back of the guinea pigs. For example, four “tracks” can be outlinedon the back of a guinea pig to for injections of a standard (Track 1)and three test samples (Tracks 2-4). Each of the “tracks” can bearranged such that the dilutions increase from the last diluted(positioned cranially), to the most diluted (positioned caudally), withall “tracks” being parallel to the spine. See FIG. 5 for an illustrationof an example of a track grid on the back of a guinea pig.

At 24 hours±4 hours following injections, animals are restrained byhand, and indurations are marked and measured using a modified Mantouxprocedure: With a ruler, the longest possible diameter (in mm) and itsmidpoint orthogonal diameter (in mm) of the indurated area are recorded.The reaction (response) at each test site is determined by averaging thelongest and orthogonal axis measurements. Alternatively, a calibratedcaliper may be used.

Optionally, the above measurements can be repeated at 48 hours±4 hours.

In an aspect, for each guinea pig, responses of Tracks 2, 3 and 4 vsTrack 1 are plotted against their corresponding dilution and analyzedusing the parallel line method: First, Track 2 and Track 1 response dataagainst log(dilution) are plotted on the same graph, and the linearityof the responses in each track's data is tested, followed by the testfor parallelism of the two lines. If the two lines are parallel, thenRP2 is calculated using the equation Log(RP2)=(α₂−α₁)β, where α₂ is theY-intercept of Track 2, α₁ is the Y-intercept of Track 1, and β is thecommon slope of the plotted lines. The same calculation is repeated forTracks 3 and 4 vs Track 1 to obtain RP3 and RP4, respectively, using thesame equation above with α₂ replaced with either α₃ or α₄.

In an aspect, for each guinea pig, responses of Tracks 2, 3 and 4 vsTrack 1 are plotted against their corresponding dilution and analyzedusing the slope-ratio method: First, Track 2 and Track 1 response dataagainst dilution are plotted on the same graph, the linearity of theresponses in each track's data is tested with the regression modelE(Y)=α+βD, where α denotes a common intercept Y-intercept shared by thetwo plots, β_(t) denotes the slope of the test line (e.g. Track 2), andβ_(r) denotes the slope of the reference line (e.g. Track 1). Twovalidity criteria must be met before using the slop-ratio method ofanalysis: (1) the slopes of the two tracks are significantly differentfrom zero at α-level of 0.05; and (2) the intercept of the test line andthat of the reference line are statistically equal, which means that the90% confidence interval for the difference in the intercepts contains 0.If the above criteria are met, an estimate of relative potency, RP2, iscalculated as RP2=estimate of (β_(t))/estimate of (β_(r)). The samecalculation is repeated for Tracks 3 and 4 vs Track 1 to obtain RP3 andRP4, respectively, using the same equation above with α₂ replaced witheither α₃ or α₄.

After RP2, RP3, and RP4 are obtained, these are plotted against the RPof Track 1. A regression analysis is performed to obtain the coefficientof determination denoted by R². The R² is targeted to be ≥0.85. Each ofRP2, RP3, and RP4 are the relative potencies of the respective sample inthat track.

A relative potency of 1 denotes that a test sample has the same potencyas the reference standard.

C. Formulation

One or more components of a pharmaceutical composition of the presentdisclosure can be formulated in admixture with conventional excipients,carriers, buffers, etc. In an aspect, an excipient is a substanceformulated alongside the active ingredient of a medication. Typicalcarriers include, but are not limited to: water; salt solutions;alcohols; gum arabic; vegetable oils; benzyl alcohols; polyethyleneglycols; gelatin; carbohydrates, such as lactose, amylose or starch;magnesium stearate; talc; silicic acid; paraffin; perfume oil; fattyacid esters; hydroxymethylcellulose; polyvinyl pyrrolidone; etc. In anaspect, a carrier includes any and all solvents, dispersion media,antibacterial and antifungal agents, isotonic and absorption delayingagents and the like.

One or more components of a pharmaceutical composition of the presentdisclosure can be sterilized and, if desired, mixed with auxiliaryagents such as: lubricants; preservatives; disintegrants; stabilizerssuch as cyclodextrans; wetting agents; emulsifiers; salts; buffers;natural or artificial coloring agents; natural or artificial flavoringagents; or aromatic substances.

One or more components of a pharmaceutical composition of the presentdisclosure can also include one or more of the following agents:acetylated monoglyceride, aspartame, beta carotene, calcium stearate,carnauba wax, cellulose acetate phthalate, citric acid, citric acidanhydrous, colloidal silicon dioxide, confectioner's sugar,crospovidone, docusate sodium, ethyl alcohol, ferric oxide, fructose,gelatin, glycerine, glyceryl monostearate (e.g. glyceryl monostearate40-50), glyceryl triacetate, HPMC (hydroxypropyl methylcellulose),hydroxypropyl cellulose, hypromellose, iron oxide, isopropyl alcohol,lactose monohydrate, low substituted hydroxypropyl cellulose, magnesiumcarbonate, magnesium stearate, maltol, mannitol, methacrylic acid,methacrylic acid copolymer (e.g. methacrylic acid copolymer type C),methylcellulose, microcrystalline cellulose, mono ammoniumglycyrrhizinate, n-butyl alcohol, paraffin, pectin propylene glycolalginate, polyacrylate, polyethylene glycol (e.g. polyethylene glycol6000), polysorbate 80, polyvinyl pyrrolidone, povidone, propyleneglycol, shellac, silicon dioxide, sodium carbonate, sodium citrate,sodium hydroxide, sodium lauryl sulfate, sodium stearyl fumarate,sorbitol, starch, sucrose, sugar sphere, talc, titanium dioxide,triethyl citrate, and xanthan gum.

In an aspect, a pharmaceutical composition described herein comprises anactive compound prepared for administration as solutions of free base orpharmacologically acceptable salts in water suitably mixed with asurfactant, such as hydroxypropylcellulose. Pharmaceutically acceptablebase addition salts can be formed with metals or amines, such as alkaliand alkaline earth metals or organic amines. Pharmaceutically acceptablesalts of compounds can also be prepared with a pharmaceuticallyacceptable cation. Suitable pharmaceutically acceptable cations are wellknown to those skilled in the art and include alkaline, alkaline earth,ammonium and quaternary ammonium cations. Carbonates or hydrogencarbonates are also possible. Examples of metals used as cations aresodium, potassium, magnesium, ammonium, calcium, or ferric, and thelike. Examples of suitable amines include isopropylamine,trimethylamine, histidine, N,N′dibenzylethylenediamine, chloroprocaine,choline, diethanolamine, dicyclohexylamine, ethylenediamine, Nmethylglucamine, and procaine.

Pharmaceutically acceptable acid addition salts include inorganic ororganic acid salts. Examples of suitable acid salts include thehydrochlorides, acetates, citrates, salicylates, nitrates, phosphates.Other suitable pharmaceutically acceptable salts are well known to thoseskilled in the art and include, for example, acetic, citric, oxalic,tartaric, or mandelic acids, hydrochloric acid, hydrobromic acid,sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic,sulfo or phospho acids or N substituted sulfamic acids, for exampleacetic acid, propionic acid, glycolic acid, succinic acid, maleic acid,hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid,tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid,glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelicacid, salicylic acid, 4 aminosalicylic acid, 2 phenoxybenzoic acid, 2acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid;and with amino acids, such as the 20 alpha amino acids involved in thesynthesis of proteins in nature, for example glutamic acid or asparticacid, and also with phenylacetic acid, methanesulfonic acid,ethanesulfonic acid, 2 hydroxyethanesulfonic acid, ethane 1,2 disulfonicacid, benzenesulfonic acid, 4 methylbenzenesulfoc acid, naphthalene 2sulfonic acid, naphthalene 1,5 disulfonic acid, 2 or 3 phosphoglycerate,glucose 6 phosphate, N-cyclohexylsulfamic acid (with the formation ofcyclamates), or with other acid organic compounds, such as ascorbicacid.

In an aspect, a pharmaceutical composition of the present disclosurecomprises NaCl, NaHCO₃, human albumin, polysorbate 80, and phenol. In anaspect, a pharmaceutical composition of the present disclosure comprises0.5% NaCl, 0.25% NaHCO₃, 0.03% human albumin, 8 ppm polysorbate 80, and0.4% phenol.

In an aspect, a pharmaceutical composition of the present disclosure asdescribed herein can be administered to the subject in need thereof viaany route including, but not limited to, sublingual, caudal, dental,endocervical, enteral, epidural, extracorporeal, intravenous,implantation, infiltration, intra-amniotic, intra-arterial,intra-articular, intrabuccal, intra-cardiac, intra-caudal,intra-cavitary, intra-dermal, intra-discal, intralesional,intralymphatic, intraocular, intraperitoneal, intrapleural, intraspinal,intrasynovial, intrathecal, intratracheal, intratumor, intratympanic,intrauterine, intravascular, intravitreal, iontophoresis, irrigation,nasal, parenteral, percutaneous, periarticular, peridural, periodontal,photophoresis, retrobulbar, subarachnoid, subconjunctival, submucosal,transdermal, ureteral, and urethral. In one aspect, a pharmaceuticalcomposition of the present disclosure is administered to the subject inneed thereof intralesionally. In one aspect, administering is performedby the act of introducing the dosage form into the system of subject inneed of treatment.

In an aspect, a pharmaceutical composition of the present disclosure asdescribed herein can be administered via a form selected from the groupconsisting of oral, buccal, sublingual, topical, injectable, infused,inhalable, rectal, intravenous, intramuscular, and subcutaneous forms.For example, a pharmaceutical composition of the present disclosure asdescribed herein can be administered as a transdermal patch, in amicroneedle, as a mist, as suppository, as a gel, as a cream, as a pill,or as a spray using methods known in the art. In one aspect, apharmaceutical composition of the present disclosure as described hereinis administered via an injectable form.

A pharmaceutical composition provided here can be prepared aspharmaceutical forms suitable for injectable use. In an aspect, suchcompositions include sterile aqueous solutions or dispersions andsterile powders for the extemporaneous preparation of sterile injectablesolutions or dispersions. In all cases the form is sterile and must befluid to the extent that easy syringability exists. It remains stableunder the conditions of manufacture and storage and is preserved againstthe contaminating action of microorganisms, such as bacteria and fungi.The carrier can be a solvent or dispersion medium containing, forexample, water, ethanol, polyol (for example, glycerol, propyleneglycol, and liquid polyethylene glycol, and the like), suitable mixturesthereof, and vegetable oils. In an aspect, a solvent is apharmaceutically acceptable solvate. The proper fluidity can bemaintained, for example, by the use of a coating, such as lecithin, bythe maintenance of the required particle size in the case of dispersionand by the use of surfactants. The prevention of the action ofmicroorganisms can be brought about by various antibacterial andantifungal agents, for example, parabens, chlorobutanol, phenol, sorbicacid, thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars or sodium chloride.Prolonged absorption of the injectable compositions can be brought aboutby the use in the compositions of agents delaying absorption, forexample, aluminum monostearate and gelatin.

In an aspect, sterile injectable solutions are prepared by incorporatingthe active compounds in the required amount in the appropriate solventwith various of the other ingredients enumerated above, as required,followed by filtered sterilization. Generally, dispersions are preparedby incorporating the various sterilized active ingredients into asterile vehicle which contains the basic dispersion medium and therequired other ingredients from those enumerated above. In the case ofsterile powders for the preparation of sterile injectable solutions, thepreferred methods of preparation are vacuum-drying and freeze-dryingtechniques which yield a powder of the active ingredient plus anyadditional desired ingredient from a previously sterile-filteredsolution thereof.

In an aspect, a pharmaceutical composition disclosed herein compriseshuman serum albumin. In one aspect, a pharmaceutical compositiondisclosed herein comprises polysorbate 80.

In an aspect, a pharmaceutical composition disclosed herein can beformulated as a sterile stabilized filtered extract of Candida albicans.In one aspect, a pharmaceutical composition can be formulated in asingle dose vial. In an aspect, a pharmaceutical composition can beformulated in a single unpreserved vial. In one aspect, a pharmaceuticalcomposition can be formulated in a multi-dose vial. In an aspect, apharmaceutical composition can be formulated in a multi-dose preservedvial. In an aspect, a pharmaceutical composition can be formulated as aprefilled syringe or device with or without an attached needle. In anaspect, a pharmaceutical composition can be formulated in a containerselected from the group consisting of a needle, a vial, and an ampoule.In an aspect, a container can be a glass container or a plasticcontainer. In one aspect, a container has a volume of about 0.25 ml,about 0.5 ml, about 0.75 ml, about 1.0 ml, about 1.5 ml, about 2.0 ml,about 2.5 ml, about 3.0 ml, about 3.5 ml, about 4.0 ml, about 4.5 ml,about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, or about 10ml.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens is provided for use in the treatment ofwarts according to the present disclosure at a cumulative dose providedby the present disclosure. In one aspect, a treatment of warts isselected from the group consisting of complete resolution of a commonwart, partial resolution of a common wart, reducing the diameter of acommon wart, partial resolution of a plurality of common warts, reducingthe diameter of a plurality of common warts by at least 50%, completeresolution of a non-common wart, complete resolution of a previouslytreated common wart, and delaying the reappearance of the common wartupon resolution. In an aspect, a medicament provides a treatment ofwarts at a cumulative dose of less than about 0.5 unit of potency, lessthan about 1 unit of potency, less than about 2 units of potency, lessthan about 3 units of potency, less than about 4 units of potency, lessthan about 5 units of potency, less than about 6 units of potency, lessthan about 7 units of potency, less than about 8 units of potency, lessthan about 9 units of potency, or less than about 10 units of potency.In an aspect, a medicament is formulated for administration to a subjectby injection. In one aspect, an injection is provided as anintralesional injection.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for complete resolution of acommon wart at a cumulative dose of 2.5 units of potency is provided. Inone aspect, the present disclosure provides for a medicament comprisinga filtered extract of Candida albicans and secreted antigens formulatedfor complete resolution of a common wart at a cumulative dose of lessthan about 0.5 unit of potency, less than about 1 unit of potency, lessthan about 2 units of potency, less than about 3 units of potency, lessthan about 4 units of potency, less than about 5 units of potency, lessthan about 6 units of potency, less than about 7 units of potency, lessthan about 8 units of potency, less than about 9 units of potency, orless than about 10 units of potency.

In one aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for partial resolution of acommon wart at a cumulative dose of 5 units of potency is provided. Inone aspect, the present disclosure provides for a medicament comprisinga filtered extract of Candida albicans and secreted antigens formulatedfor partial resolution of a common wart at a cumulative dose of lessthan about 0.5 unit of potency, less than about 1 unit of potency, lessthan about 2 units of potency, less than about 3 units of potency, lessthan about 4 units of potency, less than about 5 units of potency, lessthan about 6 units of potency, less than about 7 units of potency, lessthan about 8 units of potency, less than about 9 units of potency, orless than about 10 units of potency.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for reducing the diameter of acommon wart by at least 50% at a cumulative dose of 1 unit of potency isprovided. In one aspect, the present disclosure provides for amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for reducing the diameter of a common wartby at least 50% at a cumulative dose of less than about 0.5 unit ofpotency, less than about 1 unit of potency, less than about 2 units ofpotency, less than about 3 units of potency, less than about 4 units ofpotency, less than about 5 units of potency, less than about 6 units ofpotency, less than about 7 units of potency, less than about 8 units ofpotency, less than about 9 units of potency, or less than about 10 unitsof potency.

In one aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for partial resolution of aplurality of common warts at a cumulative dose of 5 units of potency isprovided. In one aspect, the present disclosure provides for amedicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for partial resolution of a plurality ofcommon warts at a cumulative dose of less than about 0.5 unit ofpotency, less than about 1 unit of potency, less than about 2 units ofpotency, less than about 3 units of potency, less than about 4 units ofpotency, less than about 5 units of potency, less than about 6 units ofpotency, less than about 7 units of potency, less than about 8 units ofpotency, less than about 9 units of potency, or less than about 10 unitsof potency.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for reducing the diameter of aplurality of common warts by at least 50% at a cumulative dose of 1 unitof potency is provided. In one aspect, the present disclosure providesfor a medicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for reducing the diameter of a plurality ofcommon warts by at least 50% at a cumulative dose of less than about 0.5unit of potency, less than about 1 unit of potency, less than about 2units of potency, less than about 3 units of potency, less than about 4units of potency, less than about 5 units of potency, less than about 6units of potency, less than about 7 units of potency, less than about 8units of potency, less than about 9 units of potency, or less than about10 units of potency.

In one aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for complete resolution of anon-common wart at a cumulative dose of 5 units of potency is provided.In one aspect, the present disclosure provides for a medicamentcomprising a filtered extract of Candida albicans and secreted antigensformulated for complete resolution of a non-common wart at a cumulativedose of less than about 0.5 unit of potency, less than about 1 unit ofpotency, less than about 2 units of potency, less than about 3 units ofpotency, less than about 4 units of potency, less than about 5 units ofpotency, less than about 6 units of potency, less than about 7 units ofpotency, less than about 8 units of potency, less than about 9 units ofpotency, or less than about 10 units of potency.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for complete resolution of apreviously treated common wart at a cumulative dose of 5 units ofpotency is provided. In one aspect, the present disclosure provides fora medicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for complete resolution of a previouslytreated common wart at a cumulative dose of less than about 0.5 unit ofpotency, less than about 1 unit of potency, less than about 2 units ofpotency, less than about 3 units of potency, less than about 4 units ofpotency, less than about 5 units of potency, less than about 6 units ofpotency, less than about 7 units of potency, less than about 8 units ofpotency, less than about 9 units of potency, or less than about 10 unitsof potency.

In one aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for delaying the reappearanceof the common wart upon resolution at a cumulative dose of 2.5 units ofpotency is provided. In one aspect, the present disclosure provides fora medicament comprising a filtered extract of Candida albicans andsecreted antigens formulated for delaying the reappearance of the commonwart upon resolution at a cumulative dose of less than about 0.5 unit ofpotency, less than about 1 unit of potency, less than about 2 units ofpotency, less than about 3 units of potency, less than about 4 units ofpotency, less than about 5 units of potency, less than about 6 units ofpotency, less than about 7 units of potency, less than about 8 units ofpotency, less than about 9 units of potency, or less than about 10 unitsof potency.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of a cytokinebiomarker in a subject diagnosed with a common wart is provided. In oneaspect, a cytokine biomarker is an inflammatory cytokine. In an aspect,a cytokine biomarker is selected from the group consisting of IL-23,IL-7, and IP-10. In an aspect, the level of a cytokine biomarker in asubject is reduced upon administration of a medicament comprising afiltered extract of Candida albicans and secreted antigens at acumulative dose of less than about 0.5 unit of potency, less than about1 unit of potency, less than about 2 units of potency, less than about 3units of potency, less than about 4 units of potency, less than about 5units of potency, less than about 6 units of potency, less than about 7units of potency, less than about 8 units of potency, less than about 9units of potency, or less than about 10 units of potency. In an aspect,the level of a cytokine biomarker in a subject is reduced uponadministration of a medicament comprising a filtered extract of Candidaalbicans and secreted antigens at a cumulative dose of at least about0.5 unit of potency, at least about 1 unit of potency, at least about 2units of potency, at least about 3 units of potency, at least about 4units of potency, at least about 5 units of potency, at least about 6units of potency, at least about 7 units of potency, at least about 8units of potency, at least about 9 units of potency, or at least about10 units of potency. In an aspect, the level of a cytokine biomarker ina subject is reduced upon administration of a medicament comprising afiltered extract of Candida albicans and secreted antigens at acumulative dose from about 0.5 unit of potency to about 10 units ofpotency, such as from about 0.5 unit of potency to about 9.5 units ofpotency, from about 1 unit of potency to about 9.5 units of potency,from about 1.5 units of potency to about 9 units of potency, from about2 units of potency to about 9 units of potency, from about 2 units ofpotency to about 8.5 units of potency, from about 2.5 units of potencyto about 8.5 units of potency, from about 2.5 units of potency to about8 units of potency, from about 3 units of potency to about 8 units ofpotency, from about 3 units of potency to about 7.5 units of potency,from about 3.5 units of potency to about 7.5 units of potency, fromabout 3.5 units of potency to about 7 units of potency, from about 4units of potency to about 7 units of potency, from about 4 units ofpotency to about 6.5 units of potency, from about 4.5 units of potencyto about 6.5 units of potency, from about 4.5 units of potency to about6 units of potency, or from about 5 units of potency to about 6 units ofpotency. In an aspect, the level of a cytokine biomarker level isreduced up to 99.9% in a subject upon administration of a cumulativedose of a medicament, such as up to 99.5%, up to 99%, up to 98%, up to95%, up to 90%, up to 85%, up to 80%, up to 75%, up to 70%, up to 65%,up to 60%, up to 55%, up to 50%, up to 45%, up to 40%, up to 35%, up to30%, up to 25%, up to 20%, up to 15%, up to 10%, or up to 5%. In oneaspect, the level of a cytokine biomarker level is reduced from about 5%to about 99.9% in a subject upon administration of a cumulative dose ofa medicament, such as from about 5% to about 99.8%, from about 5% toabout 99.5%, from about 5% to about 99%, from about 5% to about 98%,from about 5% to about 95%, from about 10% to about 95%, from about 10%to about 90%, from about 15% to about 90%, from about 15% to about 85%,from about 20% to about 85%, from about 20% to about 80%, from about 25%to about 80%, from about 25% to about 75%, from about 30% to about 75%,from about 30% to about 70%, from about 35% to about 70%, from about 35%to about 65%, from about 40% to about 65%, from about 40% to about 60%,from about 45% to about 60%, from about 45% to about 55%, or from about50% to about 55%.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of IL-23 in asubject in need thereof is provided. In an aspect, a subject isdiagnosed with at least one common wart.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for completely resolving a commonwart in a subject in need thereof by reducing the level of IL-23 by atleast about 35% in a subject in need thereof is provided. In an aspect,a medicament comprising a filtered extract of Candida albicans andsecreted antigens used for completely resolving a common wart in asubject in need thereof by reducing the level of IL-23 by at least about15% in a subject in need thereof is provided.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of IL-7 in asubject in need thereof is provided. In an aspect, a subject isdiagnosed with at least one common wart.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of IP-10 in asubject in need thereof is provided. In an aspect, a subject isdiagnosed with at least one common wart.

In an aspect, a medicament for use in the complete resolution of acommon wart is provided, where the medicament comprises a filteredextract of two strains of Candida albicans and secreted antigens, wherea representative sample of a first strain has been deposited with theATCC under ATCC Accession No. PTA-126019, and a representative sample ofa second strain has been deposited with the ATCC under ATCC AccessionNo. PTA-126020. In an aspect, a representative sample of a first strainhas been deposited with the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a medicament for use in the partial resolution of a commonwart is provided, where the medicament comprises a filtered extract oftwo strains of Candida albicans and secreted antigens, where arepresentative sample of a first strain has been deposited with the ATCCunder ATCC Accession No. PTA-126019, and a representative sample of asecond strain has been deposited with the ATCC under ATCC Accession No.PTA-126020. In an aspect, a representative sample of a first strain hasbeen deposited with the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a medicament for use in reducing the diameter of a commonwart by at least 50% is provided, where the medicament comprises afiltered extract of two strains of Candida albicans and secretedantigens, where a representative sample of a first strain has beendeposited with the ATCC under ATCC Accession No. PTA-126019, and arepresentative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In an aspect, a medicament for use in the partial resolution of aplurality of common warts is provided, where the medicament comprises afiltered extract of two strains of Candida albicans and secretedantigens, where a representative sample of a first strain has beendeposited with the ATCC under ATCC Accession No. PTA-126019, and arepresentative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In an aspect, a medicament for use in reducing the diameter of aplurality of common warts by at least 50% is provided, where themedicament comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, where a representative sample of a firststrain has been deposited with the ATCC under ATCC Accession No.PTA-126019, and a representative sample of a second strain has beendeposited with the ATCC under ATCC Accession No. PTA-126020. In anaspect, a representative sample of a first strain has been depositedwith the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a medicament for use in the complete resolution of anon-common wart is provided, where the medicament comprises a filteredextract of two strains of Candida albicans and secreted antigens, wherea representative sample of a first strain has been deposited with theATCC under ATCC Accession No. PTA-126019, and a representative sample ofa second strain has been deposited with the ATCC under ATCC AccessionNo. PTA-126020. In an aspect, a representative sample of a first strainhas been deposited with the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a medicament for use in the complete resolution of apreviously treated common wart is provided, where the medicamentcomprises a filtered extract of two strains of Candida albicans andsecreted antigens, where a representative sample of a first strain hasbeen deposited with the ATCC under ATCC Accession No. PTA-126019, and arepresentative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In an aspect, a medicament for use in delaying the reappearance of thecommon wart is provided, where the medicament comprises a filteredextract of two strains of Candida albicans and secreted antigens, wherea representative sample of a first strain has been deposited with theATCC under ATCC Accession No. PTA-126019, and a representative sample ofa second strain has been deposited with the ATCC under ATCC AccessionNo. PTA-126020. In an aspect, a representative sample of a first strainhas been deposited with the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of IL-23 in asubject in need thereof is provided, where the medicament comprises afiltered extract of two strains of Candida albicans and secretedantigens, where a representative sample of a first strain has beendeposited with the ATCC under ATCC Accession No. PTA-126019, and arepresentative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a subject isdiagnosed with at least one common wart. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for completely resolving a commonwart in a subject in need thereof by reducing the level of IL-23 by atleast about 35% in a subject in need thereof is provided, where themedicament comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, where a representative sample of a firststrain has been deposited with the ATCC under ATCC Accession No.PTA-126019, and a representative sample of a second strain has beendeposited with the ATCC under ATCC Accession No. PTA-126020. In anaspect, a representative sample of a first strain has been depositedwith the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of IL-7 in asubject in need thereof is provided, where the medicament comprises afiltered extract of two strains of Candida albicans and secretedantigens, where a representative sample of a first strain has beendeposited with the ATCC under ATCC Accession No. PTA-126019, and arepresentative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a subject isdiagnosed with at least one common wart. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens used for reducing the level of IP-10 in asubject in need thereof is provided, where the medicament comprises afiltered extract of two strains of Candida albicans and secretedantigens, where a representative sample of a first strain has beendeposited with the ATCC under ATCC Accession No. PTA-126019, and arepresentative sample of a second strain has been deposited with theATCC under ATCC Accession No. PTA-126020. In an aspect, a subject isdiagnosed with at least one common wart. In an aspect, a representativesample of a first strain has been deposited with the ATCC under ATCCAccession No. ATCC-10231.

In an aspect, a medicament comprising a filtered extract of Candidaalbicans and secreted antigens is formulated to have a potency of atleast about 1 unit per ml, such as at least about 2 units per ml, atleast about 3 units per ml, at least about 4 units per ml, at leastabout 5 units per ml, at least about 6 units per ml, at least about 7units per ml, at least about 8 units per ml, at least about 9 units perml, at least about 10 units per ml, at least about 15 units per ml, atleast about 20 units per ml, at least about 25 units per ml, at leastabout 30 units per ml, at least about 40 units per ml, at least about 50units per ml, at least about 30 units per ml, at least about 40 unitsper ml, at least about 50 units per ml, at least about 60 units per ml,at least about 70 units per ml, at least about 80 units per ml, at leastabout 90 units per ml, or at least about 100 units per ml.

D. Method of Treatment

In an aspect, a method for treating a wart in a subject in need thereofis provided, the method comprises administering one or more doses of apharmaceutical composition of the present disclosure to a subject inneed thereof. In one aspect, a growth on the skin caused by humanpapillomavirus. In an aspect, a pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens. In anaspect, a method of the present disclosure completely or partiallyarrests wart development. In one aspect, a method of the presentdisclosure completely or partially relieves a wart. In an aspect, amethod of the present disclosure causes regression of a wart. In anaspect, a method of the present disclosure completely or partiallyprevents warts from developing in a patient that may be predisposed towart development. In one aspect, a treatment of warts is selected fromthe group consisting of complete resolution of a common wart, partialresolution of a common wart, reducing the diameter of a common wart,partial resolution of a plurality of common warts, reducing the diameterof a plurality of common warts by at least 50%, complete resolution of anon-common wart, complete resolution of a previously treated commonwart, and delaying the reappearance of the common wart upon resolution.In an aspect, a method for treating a wart achieves its treatment goalat a cumulative dose of less than about 0.5 unit of potency, less thanabout 1 unit of potency, less than about 2 units of potency, less thanabout 3 units of potency, less than about 4 units of potency, less thanabout 5 units of potency, less than about 6 units of potency, less thanabout 7 units of potency, less than about 8 units of potency, less thanabout 9 units of potency, or less than about 10 units of potency. In anaspect, each dose is administered to a subject by injection. In oneaspect, an injection is provided as an intralesional injection.

In an aspect, a method for treating a common wart in a subject in needthereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition effective for complete resolution of the common wart at acumulative dose of 2.5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens. In one aspect, a method for treating a common wart ina subject in need thereof is provided, the method comprisesadministering one or more intralesional injections to the subject of anamount of a pharmaceutical composition capable of complete resolution ofthe common wart at a cumulative dose of 2.5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

In an aspect, complete resolution of a common wart is identified by alack of recurrence of the common wart at the same site observed at least20 weeks from administration of the first intralesional injection, suchas observed at about 20 weeks, at about 25 weeks, at about 30 weeks, atabout 35 weeks, at about 40 weeks, about 45 weeks, about 50 weeks, about55 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90weeks, or about 100 weeks after administration of the firstintralesional injection. In an aspect, recurrence of a common wart isdefined by the growth of a wart at the same location where a previouslyregressed wart was present.

In an aspect, complete resolution of the wart is accompanied by a lackof scarring at the location of the common wart. In one aspect, completeresolution of the wart is accompanied by a low level of hypopigmentationat the location of the common wart, such as less than 3% of all resolvedcommon warts.

In an aspect, a method for treating a common wart in a subject in needthereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition effective for partial resolution of the common wart at acumulative dose of 5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens. In one aspect, a pharmaceutical composition effectivefor partial resolution of the common wart at a cumulative dose of 5units of potency is also effective for reducing the diameter of thecommon wart by at least 50% at a cumulative dose of 1 unit of potency.In an aspect, partial resolution of a wart is identified by anyreduction in the diameter of a wart as compared to the diameter observedbefore the first intralesional injection.

In an aspect, a method for treating a common wart in a subject in needthereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition capable of partial resolution of the common wart at acumulative dose of 5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens. In one aspect, a pharmaceutical composition effectivefor partial resolution of the common wart at a cumulative dose of 5units of potency is also capable of reducing the diameter of the commonwart by at least 50% at a cumulative dose of 1 unit of potency.

In an aspect, a method for treating a plurality of common warts in asubject in need thereof is provided, the method comprises administeringone or more intralesional injections to the subject of an amount of apharmaceutical composition effective for partial resolution of theplurality of common warts at a cumulative dose of 5 units of potency,where the pharmaceutical composition comprises a filtered extract ofCandida albicans and secreted antigens. In one aspect, a method fortreating a plurality of common warts in a subject in need thereof isprovided, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioncapable of partial resolution of the plurality of common warts at acumulative dose of 5 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens.

In an aspect, a method for treating a plurality of common warts in asubject in need thereof is provided, the method comprises administeringone or more intralesional injections to the subject of an amount of apharmaceutical composition effective for reducing the diameter of eachof the plurality of common warts by at least 50% at a cumulative dose of1 unit of potency, where the pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens. In anaspect, a method for treating a plurality of common warts in a subjectin need thereof is provided, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition capable of reducing the diameter of each ofthe plurality of common warts by at least 50% at a cumulative dose of 1unit of potency, where the pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens.

In one aspect, a plurality of common warts comprise 2 to 20 commonwarts, such as 2 to 20 common warts, 2 to 19 common warts, 3 to 19common warts, 3 to 18 common warts, 4 to 18 common warts, 4 to 17 commonwarts, 5 to 17 common warts, 5 to 16 common warts, 6 to 16 common warts,6 to 15 common warts, 7 to 15 common warts, 7 to 14 common warts, 8 to14 common warts, 8 to 13 common warts, 9 to 13 common warts, 9 to 12common warts, 10 to 12 common warts, 10 to 11 common warts, or 11 to 12common warts. In an aspect, a plurality of common warts are locatedwithin the same anatomical location in a subject. In one aspect, aplurality of common warts are located in different anatomical locationsin a subject. In an aspect, an anatomical location is selected from oneof the following regions of a subject's body: left arm, right arm, lefthand, right hand, left leg, right leg, left foot, right foot, and torso.In one aspect, an arm region includes a shoulder, upper and lower arms,a wrist, and half of an armpit. In an aspect, a hand region starts fromthe distal to the wrist, excluding any periungual warts. In one aspect,a foot starts from the distal to ankles, excluding the sole of the foot.In an aspect, a leg region includes the upper leg, the lower leg, and anankle. In one aspect, a torso region includes the neck, the back, thechest, the abdomen, the hips, the buttocks and the pelvic region.

In an aspect, a method for treating a non-common wart in a subject inneed thereof is provided, where the subject has one or more commonwarts, and the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioneffective for complete resolution of the non-common wart at a cumulativedose of 5 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.In an aspect, a method for treating a non-common wart in a subject inneed thereof is provided, where the subject has one or more commonwarts, and the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioncapable of complete resolution of the non-common wart at a cumulativedose of 5 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.

In an aspect, a non-common wart is a plantar wart. In one aspect, anon-common wart is a genital wart. In an aspect, a non-common wart is afacial wart. In one aspect, a non-common wart is a flat wart. In oneaspect, a non-common wart is a periungual wart. In an aspect, anon-common wart is located within the same anatomical area as one ormore common warts.

In an aspect, complete resolution of a non-common wart is identified bya lack of recurrence of the non-common wart at the same site observed atleast 20 weeks from administration of the first intralesional injection,such as observed at about 20 weeks, at about 25 weeks, at about 30weeks, at about 35 weeks, at about 40 weeks, about 45 weeks, about 50weeks, about 55 weeks, about 60 weeks, about 70 weeks, about 80 weeks,about 90 weeks, or about 100 weeks after administration of the firstintralesional injection. In an aspect, recurrence of a common wart isdefined by the growth of a wart at the same location where a previouslyregressed wart was present.

In one aspect, a method for treating a previously treated common wart ina subject in need thereof is provided, the method comprisesadministering one or more intralesional injections to the subject of anamount of a pharmaceutical composition effective for complete resolutionof the previously treated common wart at a cumulative dose of 5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens. In an aspect, amethod for treating a previously treated common wart in a subject inneed thereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition capable of complete resolution of the previously treatedcommon wart at a cumulative dose of 5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

In an aspect, a previously treated common wart is a common wartpreviously treated with cryotherapy. In one aspect, a previously treatedcommon wart did not respond to cryotherapy. In an aspect, a cryotherapydid not completely resolve a previously treated common wart.

In one aspect, a previously treated common wart is a common wartpreviously treated with salicylic acid or a related acid. In an aspect,a related acid is trichloroacetic acid or bichloroacetic acid. In anaspect, a previously treated common wart did not respond to salicylicacid or a related acid. In one aspect, salicylic acid or a related aciddid not completely resolve a previously treated common wart.

In an aspect, a previously treated common wart is a common wartpreviously treated with a treatment selected from the group consistingof liquid nitrogen, carbon dioxide, cantharidin, simple occlusion, wartgel, apple cider vinegar, surgery, laser, tea tree oil, freeze wartspray, wart scraped, electrodessication, essential oils of lavender andoregano, and imiquimod. In one aspect, a previously treated common wartdid not respond to a prior treatment. In an aspect, a prior treatmentdid not completely resolve a previously treated common wart.

In an aspect, complete resolution of a previously treated common wart isidentified by a lack of recurrence of the previously treated common wartat the same site observed at least 20 weeks from administration of thefirst intralesional injection, such as observed at about 20 weeks, atabout 25 weeks, at about 30 weeks, at about 35 weeks, at about 40 weeks,about 45 weeks, about 50 weeks, about 55 weeks, about 60 weeks, about 70weeks, about 80 weeks, about 90 weeks, or about 100 weeks afteradministration of the first intralesional injection. In an aspect,recurrence of a common wart is defined by the growth of a wart at thesame location where a previously regressed wart was present.

In an aspect, complete resolution of the previously treated common wartis accompanied by a lack of scarring at the location of the common wart.In one aspect, complete resolution of the previously treated common wartis accompanied by a low level of hypopigmentation at the location of thecommon wart, such as less than 3% of all resolved common warts.

In one aspect, a method for delaying recurrence of a common wart in asubject in need thereof is provided, the method comprises administeringone or more intralesional injections to the subject of an amount of apharmaceutical composition effective for delaying the reappearance ofthe common wart upon resolution at a cumulative dose of 2.5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens. In one aspect, amethod for delaying recurrence of a common wart in a subject in needthereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition capable of delaying the reappearance of the common wart uponresolution at a cumulative dose of 2.5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens. In an aspect, delaying the recurrence ofa common wart means to defer, hinder, slow, retard, stabilize, and/orpostpone development of the condition at the same location where apreviously regressed wart was present. In one aspect, the delay can beof varying lengths of time, depending on the history of the conditionand/or individual being treated. In an aspect, a subject does notdevelop any new common warts within at least 16 weeks after the lastinjection of the treatment regimen, such as at least 18 weeks, at least20 weeks, at least 25 weeks, at least 30 weeks, at least 35 weeks, atleast 40 weeks, at least 45 weeks, at least 50 weeks, at least 55 weeks,at least 60 weeks, at least 65 weeks, at least 70 weeks, at least 80weeks, at least 90 weeks, or at least 100 weeks after the last injectionof the treatment regimen. In an aspect, a subject does not develop anynew common warts within the same anatomical area of the resolved commonwart. In one aspect, a subject does not develop any new common warts atthe same site as the resolved common wart.

In an aspect, a method for reducing the level of a cytokine biomarker ina subject in need thereof, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition at a cumulative dose of from about 0.5 unitsof potency to about 10 units of potency, where the pharmaceuticalcomposition comprises a filtered extract of Candida albicans andsecreted antigens. In one aspect, a cytokine biomarker is aninflammatory cytokine. In an aspect, a subject is diagnosed with atleast one common wart. In an aspect, a cytokine biomarker is selectedfrom the group consisting of IL-23, IL-7, and IP-10. In an aspect, thelevel of a cytokine biomarker in a subject is reduced uponadministration of a pharmaceutical composition of the present disclosureat a cumulative dose of less than about 0.5 unit of potency, less thanabout 1 unit of potency, less than about 2 units of potency, less thanabout 3 units of potency, less than about 4 units of potency, less thanabout 5 units of potency, less than about 6 units of potency, less thanabout 7 units of potency, less than about 8 units of potency, less thanabout 9 units of potency, or less than about 10 units of potency. In anaspect, the level of a cytokine biomarker in a subject is reduced uponadministration of a pharmaceutical composition of the present disclosureat a cumulative dose of at least about 0.5 unit of potency, at leastabout 1 unit of potency, at least about 2 units of potency, at leastabout 3 units of potency, at least about 4 units of potency, at leastabout 5 units of potency, at least about 6 units of potency, at leastabout 7 units of potency, at least about 8 units of potency, at leastabout 9 units of potency, or at least about 10 units of potency. In anaspect, the level of a cytokine biomarker in a subject is reduced uponadministration of a pharmaceutical composition of the present disclosureat a cumulative dose from about 0.5 unit of potency to about 10 units ofpotency, such as from about 0.5 unit of potency to about 9.5 units ofpotency, from about 1 unit of potency to about 9.5 units of potency,from about 1.5 units of potency to about 9 units of potency, from about2 units of potency to about 9 units of potency, from about 2 units ofpotency to about 8.5 units of potency, from about 2.5 units of potencyto about 8.5 units of potency, from about 2.5 units of potency to about8 units of potency, from about 3 units of potency to about 8 units ofpotency, from about 3 units of potency to about 7.5 units of potency,from about 3.5 units of potency to about 7.5 units of potency, fromabout 3.5 units of potency to about 7 units of potency, from about 4units of potency to about 7 units of potency, from about 4 units ofpotency to about 6.5 units of potency, from about 4.5 units of potencyto about 6.5 units of potency, from about 4.5 units of potency to about6 units of potency, or from about 5 units of potency to about 6 units ofpotency. In an aspect, the level of a cytokine biomarker level isreduced up to 99.9% in a subject upon administration of a cumulativedose of a pharmaceutical composition of the present disclosure, such asup to 99.5%, up to 99%, up to 98%, up to 95%, up to 90%, up to 85%, upto 80%, up to 75%, up to 70%, up to 65%, up to 60%, up to 55%, up to50%, up to 45%, up to 40%, up to 35%, up to 30%, up to 25%, up to 20%,up to 15%, up to 10%, or up to 5%. In one aspect, the level of acytokine biomarker level is reduced from about 5% to about 99.9% in asubject upon administration of a cumulative dose of a pharmaceuticalcomposition of the present disclosure, such as from about 5% to about99.8%, from about 5% to about 99.5%, from about 5% to about 99%, fromabout 5% to about 98%, from about 5% to about 95%, from about 10% toabout 95%, from about 10% to about 90%, from about 15% to about 90%,from about 15% to about 85%, from about 20% to about 85%, from about 20%to about 80%, from about 25% to about 80%, from about 25% to about 75%,from about 30% to about 75%, from about 30% to about 70%, from about 35%to about 70%, from about 35% to about 65%, from about 40% to about 65%,from about 40% to about 60%, from about 45% to about 60%, from about 45%to about 55%, or from about 50% to about 55%.

In an aspect, a method for reducing the level of IL-23 in a subject Ineed thereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition at a cumulative dose of 1 unit of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens. In an aspect, a subject is diagnosedwith at least one common wart. In one aspect, a method of the presentdisclosure reduces the level of IL-23 for at least about 15% in asubject upon receipt of a cumulative dose of a pharmaceuticalcomposition of the present disclosure when compared to a level of IL-23measured in the subject before the administering step. In one aspect, amethod of the present disclosure reduces the level of IL-23 for at leastabout 35% in a subject upon receipt of a cumulative dose of apharmaceutical composition of the present disclosure when compared to alevel of IL-23 measured in the subject before the administering step.

In an aspect, a method for completely resolving a common wart in asubject in need thereof is provided, the method comprises reducing thelevel of IL-23 by at least about 35% in a subject in need thereof. In anaspect, a method for completely resolving a common wart in a subject inneed thereof is provided, the method comprises reducing the level ofIL-23 by at least about 15% in a subject in need thereof. In one aspect,a method of the present disclosure reduces the level of IL-23 byadministering one or more intralesional injections to the subject of anamount of a pharmaceutical composition at a cumulative dose of 3 unitsof potency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

In an aspect, a method for reducing the level of IL-7 in a subject inneed thereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition at a cumulative dose of 0.6 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens. In an aspect, a subject is diagnosedwith at least one common wart. In one aspect, a method of the presentdisclosure reduces the level of IL-7 for at least about 10% in a subjectupon receipt of a cumulative dose of a pharmaceutical composition of thepresent disclosure when compared to a level of IL-7 measured in thesubject before the administering step.

In an aspect, a method for reducing the level of IL-7 in a subject inneed thereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition at a cumulative dose of 3 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens. In an aspect, a subject is diagnosedwith at least one common wart. In one aspect, a method of the presentdisclosure reduces the level of IL-7 for at least about 20% in thesubject upon receipt of a cumulative dose of a pharmaceuticalcomposition of the present disclosure when compared to a level of IL-7measured in the subject before the administering step.

In an aspect, a method for reducing the level of IP-10 in a subject inneed thereof is provided, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition at a cumulative dose of 3 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens. In an aspect, a subject is diagnosedwith at least one common wart. In one aspect, a method of the presentdisclosure reduces the level of IP-10 for at least about 5% in thesubject upon receipt of a cumulative dose of a pharmaceuticalcomposition of the present disclosure when compared to a level of IP-10measured in the subject before the administering step.

In an aspect, methods of the present disclosure are effective atachieving a treatment goal at a cumulative dose of less than about 0.5unit of potency, less than about 1 unit of potency, less than about 2units of potency, less than about 3 units of potency, less than about 4units of potency, less than about 5 units of potency, less than about 6units of potency, less than about 7 units of potency, less than about 8units of potency, less than about 9 units of potency, or less than about10 units of potency. In one aspect, methods of the present disclosureare capable of achieving a treatment goal at a cumulative dose of lessthan about 0.5 unit of potency, less than about 1 unit of potency, lessthan about 2 units of potency, less than about 3 units of potency, lessthan about 4 units of potency, less than about 5 units of potency, lessthan about 6 units of potency, less than about 7 units of potency, lessthan about 8 units of potency, less than about 9 units of potency, orless than about 10 units of potency.

In an aspect, methods of the present disclosure are effective atachieving a treatment goal at a cumulative dose of at least about 0.5unit of potency, at least about 1 unit of potency, at least about 2units of potency, at least about 3 units of potency, at least about 4units of potency, at least about 5 units of potency, at least about 6units of potency, at least about 7 units of potency, at least about 8units of potency, at least about 9 units of potency, or at least about10 units of potency. In one aspect, methods of the present disclosureare capable of achieving a treatment goal at a cumulative dose of atleast about 0.5 unit of potency, at least about 1 unit of potency, atleast about 2 units of potency, at least about 3 units of potency, atleast about 4 units of potency, at least about 5 units of potency, atleast about 6 units of potency, at least about 7 units of potency, atleast about 8 units of potency, at least about 9 units of potency, or atleast about 10 units of potency.

In an aspect, methods of the present disclosure are effective atachieving a treatment goal at a cumulative dose from about 0.5 unit ofpotency to about 10 units of potency, such as from about 0.5 unit ofpotency to about 9.5 units of potency, from about 1 unit of potency toabout 9.5 units of potency, from about 1.5 units of potency to about 9units of potency, from about 2 units of potency to about 9 units ofpotency, from about 2 units of potency to about 8.5 units of potency,from about 2.5 units of potency to about 8.5 units of potency, fromabout 2.5 units of potency to about 8 units of potency, from about 3units of potency to about 8 units of potency, from about 3 units ofpotency to about 7.5 units of potency, from about 3.5 units of potencyto about 7.5 units of potency, from about 3.5 units of potency to about7 units of potency, from about 4 units of potency to about 7 units ofpotency, from about 4 units of potency to about 6.5 units of potency,from about 4.5 units of potency to about 6.5 units of potency, fromabout 4.5 units of potency to about 6 units of potency, or from about 5units of potency to about 6 units of potency. In an aspect, methods ofthe present disclosure are capable of achieving aa treatment goal at acumulative dose from about 0.5 unit of potency to about 10 units ofpotency, such as from about 0.5 unit of potency to about 9.5 units ofpotency, from about 1 unit of potency to about 9.5 units of potency,from about 1.5 units of potency to about 9 units of potency, from about2 units of potency to about 9 units of potency, from about 2 units ofpotency to about 8.5 units of potency, from about 2.5 units of potencyto about 8.5 units of potency, from about 2.5 units of potency to about8 units of potency, from about 3 units of potency to about 8 units ofpotency, from about 3 units of potency to about 7.5 units of potency,from about 3.5 units of potency to about 7.5 units of potency, fromabout 3.5 units of potency to about 7 units of potency, from about 4units of potency to about 7 units of potency, from about 4 units ofpotency to about 6.5 units of potency, from about 4.5 units of potencyto about 6.5 units of potency, from about 4.5 units of potency to about6 units of potency, or from about 5 units of potency to about 6 units ofpotency.

In an aspect, each dose administered in the methods of the presentdisclosure can be administered via a form selected from the groupconsisting of oral, buccal, sublingual, topical, injectable, infused,inhalable, rectal, intravenous, intramuscular, and subcutaneous forms.In an aspect, two or more intralesional injections are provided to asubject in need thereof over a period of time. In an aspect, each dosehas a potency of at least 0.3 unit of potency. In one aspect, each dosehas a potency of at least 0.5 unit of potency. In an aspect, each doseis administered at a dose of at least about 0.1 unit of potency to about1 unit of potency, such as about 0.1 unit of potency to about 0.9 unitof potency, such as about 0.2 unit of potency to about 1 unit ofpotency, such as about 0.2 unit of potency to about 0.8 unit of potency,such as about 0.2 unit of potency to about 0.5 unit of potency, such asabout 0.2 unit of potency to about 0.4 unit of potency, such as about0.3 unit of potency to about 0.7 unit of potency, or such as about 0.4unit of potency to about 0.6 unit of potency. In an aspect, each dose isprovided at a volume of from about 5 μL to about 500 μL, such as fromabout 5 μL to about 450 μL, from about 5 μL to about 400 μL, from about5 μL to about 350 μL, from about 5 μL to about 300 μL, from about 5 μLto about 250 μL, from about 5 μL to about 200 μL, from about 5 μL toabout 150 μL, from about 5 μL to about 100 μL, from about 5 μL to about50 μL, from about 5 μL to about 40 μL, from about 5 μL to about 30 μL,from about 5 μL to about 20 μL, from about 5 μL to about 10 μL, fromabout 50 μL to about 500 μL, from about 50 μL to about 450 μL, fromabout 50 μL to about 400 μL, from about 50 μL to about 350 μL, fromabout 50 μL to about 300 μL, from about 50 μL to about 250 μL, fromabout 50 μL to about 200 μL, from about 50 μL to about 150 μL, fromabout 50 μL to about 100 μL, from about 100 μL to about 500 μL, fromabout 150 μL to about 450 μL, from about 200 μL to about 400 μL, or fromabout 250 μL to about 350 μL. In one aspect, a pair of doses areprovided about two weeks apart to a subject in need thereof, such as 10days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, or18 days apart. In an aspect, a pair of doses are provided about threeweeks apart to a subject in need thereof, such as 17 days, 18 days, 19days, 20 days, 21 days, 22 days, 23 days, 24 days, or 25 days apart. Inan aspect, doses administered in the methods are provided to a subjectin need thereof over a period of about 2 weeks to about 27 weeks, suchas about 2 weeks to about 26 weeks, such as about 2 weeks to about 25weeks, such as about 2 weeks to about 24 weeks, such as about 2 weeks toabout 23 weeks, such as about 2 weeks to about 22 weeks, such as about 2weeks to about 21 weeks, such as about 2 weeks to about 20 weeks, suchas about 2 weeks to about 19 weeks, such as about 2 weeks to about 18weeks, such as about 2 weeks to about 17 weeks, such as about 2 weeks toabout 16 weeks, such as about 2 weeks to about 15 weeks, such as about 2weeks to about 14 weeks, such as about 2 weeks to about 13 weeks, suchas about 2 weeks to about 12 weeks, such as about 2 weeks to about 11weeks, such as about 2 weeks to about 10 weeks, such as about 2 weeks toabout 9 weeks, such as about 2 weeks to about 8 weeks, such as about 2weeks to about 7 weeks, such as about 2 weeks to about 6 weeks, such asabout 2 weeks to about 5 weeks, such as about 2 weeks to about 4 weeks,or such as about 2 weeks to about 3 weeks. In an aspect, dosesadministered in the methods are provided to a subject in need thereofover a period of about 3 weeks to about 27 weeks, such as about 4 weeksto about 27 weeks, about 5 weeks to about 27 weeks, about 6 weeks toabout 27 weeks, about 7 weeks to about 27 weeks, about 8 weeks to about27 weeks, about 9 weeks to about 27 weeks, about 10 weeks to about 27weeks, about 11 weeks to about 27 weeks, about 12 weeks to about 27weeks, about 13 weeks to about 27 weeks, about 14 weeks to about 27weeks, about 15 weeks to about 27 weeks, about 16 weeks to about 27weeks, about 17 weeks to about 27 weeks, about 18 weeks to about 27weeks, about 19 weeks to about 27 weeks, about 20 weeks to about 27weeks, about 21 weeks to about 27 weeks, about 22 weeks to about 27weeks, about 23 weeks to about 27 weeks, about 24 weeks to about 27weeks, about 25 weeks to about 27 weeks, or about 26 weeks to about 27weeks. In one aspect, doses administered in the methods are provided toa subject in need thereof over a period of about 2 weeks, about 3 weeks,about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks,about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks,about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26weeks, or about 27 weeks.

In an aspect, an intralesional injection is provided to a subject inneed thereof. In one aspect, an intralesional injection is provided atthe perimeter of a common wart being treated. In an aspect, anintralesional injection is provided near the perimeter of a common wartbeing treated. In one aspect, an intralesional injection is provided ata location that is about 5 mm or less from the peripheral margin of acommon wart being treated, such as about 4 mm or less, about 3 mm orless, about 2 mm or less, or about 1 mm or less from the peripheralmargin of a common wart. In one aspect, a perimeter is defined by theperipheral margin of a wart. In an aspect, an intralesional injection isprovided to the common wart being treated. In one aspect, anintralesional injection is provided to the largest common wart within ananatomical area, in the presence of a plurality of common warts in thesame anatomical area. In one aspect, an intralesional injection isprovided to the largest common wart within an anatomical area, in thepresence of a plurality of common warts in the same anatomical area anda non-common wart. In an aspect, the largest common wart is determinedby choosing the common wart within an anatomical area having the largestdiameter.

In an aspect, a subject has a common wart measuring between about 3 mmto about 20 mm prior to beginning of a treatment of the presentdisclosure, such as between about 3 mm to about 19 mm, between about 4mm to about 20 mm, between about 4 mm to about 19 mm, between about 5 mmto about 19 mm, between about 5 mm to about 18 mm, between about 6 mm toabout 18 mm, between about 6 mm to about 17 mm, between about 7 mm toabout 16 mm, between about 7 mm to about 15 mm, between about 8 mm toabout 15 mm, between about 8 mm to about 14 mm, between about 9 mm toabout 14 mm, between about 9 mm to about 13 mm, between about 10 mm toabout 13 mm, between about 10 mm to about 12 mm, or between about 11 mmto about 12 mm. In an aspect, a subject has a common wart measuringbetween about 20 mm to about 1 cm, such as between about 20 mm to about95 mm, such as between about 25 mm to about 1 cm, such as between about20 mm to about 90 mm, such as between about 25 mm to about 95 mm, suchas between about 25 mm to about 90 mm, such as between about 30 mm toabout 90 mm, such as between about 30 cm to about 85 mm, such as betweenabout 35 mm to about 85 mm, such as between about 35 mm to about 80 mm,such as between about 40 mm to about 80 mm, such as between about 40 mmto about 75 mm, such as between about 45 mm to about 75 mm, such asbetween about 45 mm to about 60 mm, such as between about 50 mm to about70 mm, such as between about 50 mm to about 65 mm, such as between about55 mm to about 65 mm, or such as between about 55 mm to about 60 mm. Inan aspect, a subject has a common wart measuring between about 1 cm toabout 100 cm, such as between about 1 cm to about 95 cm, between about 5cm to about 100 cm, between about 5 cm to about 95 cm, between about 10cm to about 95 cm, between about 10 cm to about 90 cm, between about 15cm to about 90 cm, between about 15 cm to about 85 cm, between about 20cm to about 85 cm, between about 20 cm to about 80 cm, between about 25cm to about 80 cm, between about 25 cm to about 75 cm, between about 30cm to about 75 cm, between about 30 cm to about 70 cm, between about 35cm to about 70 cm, between about 35 cm to about 65 cm, between about 40cm to about 65 cm, between about 40 cm to about 60 cm, between about 45cm to about 60 cm, between about 45 cm to about 55 cm, or between about50 cm to about 55 cm.

In an aspect, two or more intralesional injections are provided to asubject in need thereof over a period of time. In one aspect, each ofthe two or more intralesional injection is provided at a dose of atleast 0.5 unit of potency. In an aspect, each of the two or moreintralesional injection is provided at a dose of at least about 0.1 unitof potency to about 1 unit of potency, such as about 0.1 unit of potencyto about 0.9 unit of potency, such as about 0.2 unit of potency to about1 unit of potency, such as about 0.2 unit of potency to about 0.8 unitof potency, such as about 0.3 unit of potency to about 0.7 unit ofpotency, or such as about 0.4 unit of potency to about 0.6 unit ofpotency. In an aspect, each of the two or more intralesional injectionis provided at a volume of from about 5 μL to about 500 μL, such as fromabout 5 μL to about 450 μL, from about 5 μL to about 400 μL, from about5 μL to about 350 μL, from about 5 μL to about 300 μL, from about 5 μLto about 250 μL, from about 5 μL to about 200 μL, from about 5 μL toabout 150 μL, from about 5 μL to about 100 μL, from about 5 μL to about50 μL, from about 5 μL to about 40 μL, from about 5 μL to about 30 μL,from about 5 μL to about 20 μL, from about 5 μL to about 10 μL, fromabout 50 μL to about 500 μL, from about 50 μL to about 450 μL, fromabout 50 μL to about 400 μL, from about 50 μL to about 350 μL, fromabout 50 μL to about 300 μL, from about 50 μL to about 250 μL, fromabout 50 μL to about 200 μL, from about 50 μL to about 150 μL, fromabout 50 μL to about 100 μL, from about 100 μL to about 500 μL, fromabout 150 μL to about 450 μL, from about 200 μL to about 400 μL, or fromabout 250 μL to about 350 μL.

In one aspect, a pair of intralesional injections in two or moreintralesional injections are provided about two weeks apart to a subjectin need thereof, such as 10 days, 11 days, 12 days, 13 days, 14 days, 15days, 16 days, 17 days, or 18 days apart. In an aspect, a pair ofintralesional injections in two or more intralesional injections areprovided about three weeks apart to a subject in need thereof, such as17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days,or 25 days apart.

In an aspect, two or more intralesional injections are provided to asubject in need thereof over a period of about 2 weeks to about 27weeks, such as about 2 weeks to about 26 weeks, such as about 2 weeks toabout 25 weeks, such as about 2 weeks to about 24 weeks, such as about 2weeks to about 23 weeks, such as about 2 weeks to about 22 weeks, suchas about 2 weeks to about 21 weeks, such as about 2 weeks to about 20weeks, such as about 2 weeks to about 19 weeks, such as about 2 weeks toabout 18 weeks, such as about 2 weeks to about 17 weeks, such as about 2weeks to about 16 weeks, such as about 2 weeks to about 15 weeks, suchas about 2 weeks to about 14 weeks, such as about 2 weeks to about 13weeks, such as about 2 weeks to about 12 weeks, such as about 2 weeks toabout 11 weeks, such as about 2 weeks to about 10 weeks, such as about 2weeks to about 9 weeks, such as about 2 weeks to about 8 weeks, such asabout 2 weeks to about 7 weeks, such as about 2 weeks to about 6 weeks,such as about 2 weeks to about 5 weeks, such as about 2 weeks to about 4weeks, or such as about 2 weeks to about 3 weeks. In an aspect, two ormore intralesional injections are provided to a subject in need thereofover a period of about 3 weeks to about 27 weeks, such as about 4 weeksto about 27 weeks, about 5 weeks to about 27 weeks, about 6 weeks toabout 27 weeks, about 7 weeks to about 27 weeks, about 8 weeks to about27 weeks, about 9 weeks to about 27 weeks, about 10 weeks to about 27weeks, about 11 weeks to about 27 weeks, about 12 weeks to about 27weeks, about 13 weeks to about 27 weeks, about 14 weeks to about 27weeks, about 15 weeks to about 27 weeks, about 16 weeks to about 27weeks, about 17 weeks to about 27 weeks, about 18 weeks to about 27weeks, about 19 weeks to about 27 weeks, about 20 weeks to about 27weeks, about 21 weeks to about 27 weeks, about 22 weeks to about 27weeks, about 23 weeks to about 27 weeks, about 24 weeks to about 27weeks, about 25 weeks to about 27 weeks, or about 26 weeks to about 27weeks. In one aspect, two or more intralesional injections are providedto a subject in need thereof over a period of about 2 weeks, about 3weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks,about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks,about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26weeks, or about 27 weeks.

In one aspect, two or more intralesional injections are provided to asubject in need thereof in two or more subgroups of intralesionalinjections over a period of time. In one aspect, each of the subgroup oftwo or more subgroups is provided at a dose of at least 0.5 unit ofpotency. In an aspect, each of the subgroup of the two or more subgroupsis provided at a dose of at least about 0.1 unit of potency to about 1unit of potency, such as about 0.1 unit of potency to about 0.9 unit ofpotency, such as about 0.2 unit of potency to about 1 unit of potency,such as about 0.2 unit of potency to about 0.8 unit of potency, such asabout 0.3 unit of potency to about 0.7 unit of potency, or such as about0.4 unit of potency to about 0.6 unit of potency. In an aspect, each ofthe subgroup of the two or more subgroups is provided at a volume offrom about 5 μL to about 500 μL, such as from about 5 μL to about 450μL, from about 5 μL to about 400 μL, from about 5 μL to about 350 μL,from about 5 μL to about 300 μL, from about 5 μL to about 250 μL, fromabout 5 μL to about 200 μL, from about 5 μL to about 150 μL, from about5 μL to about 100 μL, from about 5 μL to about 50 μL, from about 5 μL toabout 40 μL, from about 5 μL to about 30 μL, from about 5 μL to about 20μL, from about 5 μL to about 10 μL, from about 50 μL to about 500 μL,from about 50 μL to about 450 μL, from about 50 μL to about 400 μL, fromabout 50 μL to about 350 μL, from about 50 μL to about 300 μL, fromabout 50 μL to about 250 μL, from about 50 μL to about 200 μL, fromabout 50 μL to about 150 μL, from about 50 μL to about 100 μL, fromabout 100 μL to about 500 μL, from about 150 μL to about 450 μL, fromabout 200 μL to about 400 μL, or from about 250 μL to about 350 μL.

In an aspect, a pair of subgroups within two or more subgroups ofintralesional injections are provided about two weeks apart to a subjectin need thereof, such as 10 days, 11 days, 12 days, 13 days, 14 days, 15days, 16 days, 17 days, or 18 days apart. In one aspect, a pair ofsubgroups within two or more subgroups of intralesional injections areprovided about three weeks apart to a subject in need thereof, such as17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days,or 25 days apart.

In an aspect, a subgroup of intralesional injections comprises at leasttwo intralesional injections such as two intralesional injections, threeintralesional injections, four intralesional injections, fiveintralesional injections, six intralesional injections, sevenintralesional injections, eight intralesional injections, nineintralesional injections, or ten intralesional injections.

In one aspect, intralesional injections within a subgroup ofintralesional injections are administered at approximately the sametime, such as within about 1 minute, within about 2 minutes, withinabout 3 minutes, within about 4 minutes, within about 5 minutes. In oneaspect, intralesional injections within a subgroup of intralesionalinjections are administered are administered within 24 hours, such aswithin about 18 hours, within about 12 hours, within about 6 hours,within about 5 hours, within about 4 hours, within about 3 hours, withinabout 2 hours, or within about 1 hour.

In one aspect, intralesional injections within a subgroup ofintralesional injections are provided around a common wart beingtreated. In an aspect, intralesional injections within a subgroup ofintralesional injections are evenly spaced apart near the perimeter of acommon wart being treated. In one aspect, each of the intralesionalinjection within a subgroup of intralesional injections is provided at alocation that is about 5 mm or less from the peripheral margin of acommon wart being treated, such as about 4 mm or less, about 3 mm orless, about 2 mm or less, or about 1 mm or less from the peripheralmargin of a common wart. In an aspect, intralesional injections within asubgroup of intralesional injections are evenly spaced apart at theperimeter of a common wart being treated. In one aspect, a perimeter isdefined by the peripheral margin of a wart.

In an aspect, a pharmaceutical composition administered by a method ofthe present disclosure comprises a filtered extract of two strains ofCandida albicans and secreted antigens, where a representative sample ofa first strain has been deposited with the ATCC under ATCC Accession No.PTA-126019, and a representative sample of a second strain has beendeposited with the ATCC under ATCC Accession No. PTA-126020. In anaspect, a representative sample of a first strain has been depositedwith the ATCC under ATCC Accession No. ATCC-10231.

In an aspect, a subject being treated with the methods of the presentdisclosure is between the ages of 18 and 65, such as between 20 and 60,between 18 and 30, between 25 and 50, between 30 and 40, between 40 to50, or between 50 to 65. In one aspect, a subject being treated with themethods of the present disclosure is a pediatric patient. In one aspect,a pediatric patient is a premature newborn. In an aspect, a pediatricpatient is a term newborn. In one aspect, a pediatric patient is aneonate. In one aspect, a pediatric patient is an infant. In an aspect,a pediatric patient is a toddler. In one aspect, a pediatric patient isa young child. In one aspect, a pediatric patient is a child. In anaspect, a pediatric patient is an adolescent. In an aspect, a pediatricpatient is a child patient below about 18, 15, 12, 10, 8, 6, 4, 3, 2, or1 years old. In one aspect, a subject being treated with the methods ofthe present disclosure was diagnosed with a first common wart at least12 weeks prior to receiving one or more intralesional injections, suchas between 12 weeks to 100 weeks, between 15 weeks to 90 weeks, between20 to 80 weeks, between 25 to 75 weeks, between 30 to 70 weeks, between35 to 65 weeks, between 40 to 60 weeks, between 45 to 55 weeks, orbetween 50 to 55 weeks. In an aspect, a subject being treated with themethods of the present disclosure was not diagnosed with a recalcitrantwart. In an aspect, a recalcitrant wart is a wart that was notsuccessfully treated by prior treatment, excluding over-the-countertreatments. In one aspect, a recalcitrant wart is a wart that was notsuccessfully treated by one or more types of prior treatment, such astwo or more, three or more, four or more, five or more, six or more,seven or more, eight or more, nine or more, or ten or more types ofprior treatment. In an aspect, an over-the-counter treatment is amedication sold directly to a consumer without a prescription from ahealthcare professional.

In an aspect, a subject being treated with the methods of the presentdisclosure has a baseline result of between 5 mm and 25 mm to theDelayed Type Hypersensitivity (DTH) test. In one aspect, a DTH test isperformed by administering a single intradermal injection of CANDIN®(0.1 mL; Allermed/Nielsen Biosciences) on the volar surface of theforearm or on the outer aspect of the upper arm, at least 2 cm away fromany primary injectable warts. The skin is cleansed with 70% alcoholbefore applying the skin test. The intradermal injection is given assuperficially as possible causing a distinct, sharply defined bleb. Thetest is read at 48±4 hours post the DTH challenge injection, by visuallyinspecting the test site and palpating the indurated area. Measurementsare made across two diameters. The mean of the longest and the midpointorthogonal diameters of the indurated area is reported as the DTHresponse.

In an aspect, a subject being treated with the methods of the presentdisclosure is not diagnosed with a systematic disease that compromisesimmune function. In an aspect, a subject being treated with the methodsof the present disclosure is not diagnosed with a localized disease thatcompromises immune function. In an aspect, a subject being treated withthe methods of the present disclosure is not diagnosed with a systematiccondition that compromises immune function. In an aspect, a subjectbeing treated with the methods of the present disclosure is notdiagnosed with a localized condition that compromises immune function.In an aspect, a subject being treated with the methods of the presentdisclosure is not diagnosed with psoriasis. In an aspect, a subjectbeing treated with the methods of the present disclosure is notreceiving a treatment resulting in being immunocompromised.

In an aspect, a subject being treated with the methods of the presentdisclosure has not been diagnosed with diabetes mellitus. In an aspect,a subject being treated with the methods of the present disclosure doesnot have a history of keloid formation. In an aspect, a subject beingtreated with the methods of the present disclosure does not have anexisting dermatologic condition in the same anatomical area as the wartbeing treated. In an aspect, a subject being treated with the methods ofthe present disclosure does not have an underlying inflammatorycondition. In an aspect, an underlying inflammatory condition is anarthritic joint.

In an aspect, a subject being treated with the methods of the presentdisclosure has not received one or more treatments selected from thegroup consisting of liquid nitrogen, carbon dioxide, electrodessication,laser, surgery, simple occlusion (e.g. duct tape), salicylic or relatedacids including trichloroacetic acid and bichloroacetic acid,over-the-counter treatments, and cantharidin, within 4 weeks prior tothe administering step. In an aspect, a subject being treated with themethods of the present disclosure has not received one or moreimmunotherapy selected from the group consisting ofdiphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB), imiquimod,5-florouracil, bleomycin, and podophyllin, within 12 weeks prior to theadministering step. In an aspect, a subject being treated with themethods of the present disclosure has not received one or moresystematic treatment selected from the group consisting of cimetidine,zinc supplements at a dose higher than 20 mg of elemental zinc daily,azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab,etanercept, and steroid, within 12 weeks prior to the administeringstep. In an aspect, a subject being treated with the methods of thepresent disclosure has not received any investigational agent within 30days prior to the administering step. In an aspect, a subject beingtreated with the methods of the present disclosure has not received anyinvestigational agent within 5 half-lives of said investigational agentprior to the administering step.

EXAMPLES Example 1 Production of a Composition Comprising a SterileFiltrate of Candida albicans and Secreted Antigens

First, a pre-production culture is prepared from an oil-covered stockculture by aseptically removing one loopful of the stock culture of eachtwo strains of Candida albicans (ATCC Accession Nos. PTA-126019 andPTA-126020) and placing it in Animal Free Trypticase Soy Broth (ATSB;TechNova, Dartmouth, Nova Scotia). This pre-production culture isincubated at 20-25° C. until a growth pellet is observed at the bottomof the tube, usually within 7 to 14 days. After evidence of fungalgrowth (e.g. milky yeast-like growth on the bottom of the tube) isobserved, a portion of the growth is transferred to a plate of AnimalFree Trypticase Soy Agar (ATSA; TechNova, Dartmouth, Nova Scotia) and isincubated at 20-25° C. for 3 to 7 days. The growth from the ATSA plateis subcultured to a fresh ATSA plate and the plate is streaked toproduce isolated colonies. The ATSA plate is incubated at 20-25° C. for3 to 7 days.

From the ATSA plate, several isolated colonies with characteristicmorphology (see FIG. 1 and FIG. 2 show characteristic morphologies ofisolated colonies of a first strain and a second strain, respectively)are transferred to an Erlenmeyer flask containing Chemically DefinedCandida Medium (CDCM; TechNova, Dartmouth, Nova Scotia). CDCM consistsof 3.6 g/L KH₂PO₄, 1.2 g/L Na₂HPO₄, 8.0 g/L (NH₄)₂SO₄, 0.2 g/LMgSO₄.7H₂O, 0.01 g/L ZnSO₄.7H₂O, 8.0 g/L sucrose, and 0.01 g/L biotin.The Erlenmeyer flask is incubated 3-7 days on a shaker set atapproximately 60 rpm at a temperature of 20-25° C. Referring to FIG. 1,an isolated colony of a first strain deposited as ATCC Accession No.PTA-126019 appears as pasty cream colored with smooth entire margins.Referring to FIG. 2, an isolated colony of a second strain deposited asATCC Accession No. PTA-126020 appears as white cream-colored having asomewhat rough surface and irregular margins.

When the inoculum shows budding yeast pseudohyphae (see FIG. 3 for anillustration of budding yeast cells of Candida albicans and FIG. 4 forpseudohyphae of Candida albicans) and if it is free of bacteria, each ofthe stock is transferred to separate production flasks containing CDCMat a dilution of approximately 1:100. For example, approximately 1.0 mLof each of the stock is transferred to separate production flaskscontaining 100 mL CDCM; or approximately 10 mL of each of the stock istransferred to separate production flasks containing 1000 mL CDCM. Theproduction flasks are incubated at 20-25° C. for 7 days on a shaker, setat 60 rotations or oscillations per minute.

Upon completion of incubation, 1.0 mL of 1% phenol is added to eachproduction flasks. The flasks are stored at 20-25° C. for 7 days for thefungus to be killed. The contents of all production flasks containingacceptable growth and no contamination are then pooled in a sterileglass bottle. The pooled material is cultured by adding 1.0 mL to eachof three 40 mL tubes of Trypticase Soy Broth (TSB; TechNova, Dartmouth,Nova Scotia). Each TSB culture is further diluted 10-fold in TSB and isincubated at 20-25° C. for 7 days to ensure non-viability. During theculturing period, the poled production material is stored in a holdingbottle at 20-25° C. for 7 days.

Dialyze the pooled culture in USP grade Water for Injection (WFI;TechNova, Dartmouth, Nova Scotia) at 1-8° C. using Spectrapor6,000-8,000 MWCO dialysis tubing (size 40 mm). Dialyze with a 20-foldvolume of WFI and repeat the procedure twice at 24-hour intervals. Thedialyzed material is then heated uniformly for 60 minutes at 90-95° C.in a water bath.

200 mL of the heat treated dialyzed material is added to a 600 mLlyophilization flask and freeze dried in a Labconco lyophilizer. Thisprocedure is repeated until the entire lot has been lyophilized.Lyophyilized material is then covered with petroleum ether at 20-25° C.for 6 to 8 hours with the supernatant being discarded via filtration.The resulting material is air dried in a fume hood. This is the drypowder denoted as the source material for further processing.

Dilute the source material with Coca's Glycerol Solution (0.25% NaCl,0.125% NaHCO₃, 53% glycerin; 47% WFI) having a pH in the range of 6 to8.5 at a desired weight by volume extraction ratio. In an aspect, avolume extraction ratio is 1:20 w/v, where 20 mL of Coca's GlycerolSolution is added to per gram of source material. This extract is mixedintermittently for approximately 71 hours on a magnetic stirrer at 1-8°C. until the source material appears homogenous throughout the mixture.

The extract is then centrifuged at approximately 4000 RPMs for 20minutes. After that, the extract is filtered by vacuum filtration with aBuchner funnel and Whatman No. 3 filter paper. Adjust the filteredextract to have a final concentration of 0.4% phenol and return it to1-8° C. A sterile Sartorius 0.2 μm filter capsule (#5231307H) and filterthe product under a class 100 laminar flow hood in a class 100,000 room.

In a sterile filtration room, use a sterile Sartorius “Sartobran”0.45/0.2 μm [5235307H7OOA (0.05 m²) or 5231307H5OOB (0.03 m²)] tosterilize the product. Collect the filtered solution to an appropriatelysized, sterile depyrogenated container, and store the filtered solutionat 1-8° C. Finally, 1.7 mL of this master lot filtered solution isdiluted with 998.3 mL of a diluent, which consists of 5.0 g/L NaCl, 2.5g/L NaHCO₃, 4.5 mL/L phenol, 1.2 mL/L 20% solution human serum albumin,0.8 mL/L polysorbate 80.

Example 2 Intralesional Injection to a Wart

An intralesional injection of a pharmaceutical composition of thepresent disclosure to a wart is provided beneath the common wart at theregion of the interdigitated base of the wart. FIG. 6 illustrates thepreferred location of the intralesional injection. Preferably, ablanching of the treated wart is observed upon injection. Without beinglimited to theory, the injection is performed slowly to help theinjected pharmaceutical composition to spread along the dermal epidermaljunction. Most injections are performed with the bevel down. However,for particularly thick warts, the injection may be performed with thebevel of the needle aiming upwards. For particularly thin warts, theinjection may be performed with the bevel of the needle aiming sideways.After the injection, moderate pressure is applied to the injected wart.

In some instances, a dose of a pharmaceutical composition can beinjected via multiple injections at the interdigitated base of the wart.

Example 3 Treatment by Injections to a Single Wart

To treat a patient diagnosed with a common wart, intralesionalinjections of a pharmaceutical composition of the present disclosure ata dose of 0.5 unit of potency are provided to the largest common wartevery second week (14±2 days) for a maximum of 10 injections. If theprimary common wart exhibits a complete response, the second largestinjectable common wart of all anatomical regions is injected with thesame pharmaceutical composition at the same dose of 0.5 unit of potency.If an injected wart recurs after exhibiting a complete response, it isre-injected instead of the non-primary injected wart that was injectedat the previous visit. This injection strategy is repeated for a maximumof 10 injections or until all injectable common warts exhibit a completeresponse, if it occurs before all 10 injections are used.

The above treatment is effective for completely resolving 85% of allprimary injected warts at any number of injections, compared to 52% ofthose injected with a placebo. Moreover, 75% of all warts mapped atbaseline in subjects injected with a pharmaceutical composition of thepresent disclosure were completely resolved, compared to 34% of thoseinjected with a placebo. The median number of injections required tocompletely resolve a primary injected wart is 5 injections, compared to10 injections of the placebo. Furthermore, at 4 months following thelast injection, 50% of primary injected warts remain completelyresolved, compared to 31% of those injected with a placebo.

The above treatment is also effective for resolving all common warts in53% of the 52 subjects treated, compared to 21% of subjects receivingplacebo. In patients also diagnosed with non-common warts, 75% showedresolution of non-common warts as compared to 57% receiving placebo.

Moreover, the above treatment is capable of resolving a primary injectedwart previously treated with cryotherapy at a rate of 47% compared to21% by the placebo.

10% of the subjects receiving treatment exhibited scarring at the siteof a resolved wart comparing to 6% of the subjects receiving placebo. 3%of the subjects receiving treatment exhibited hypopigmentation at thesite of a resolved wart comparing to 0% of the subjects receivingplacebo.

Example 4 Treatment by Injections to Multiple Warts

To treat a patient diagnosed with common warts in at least 2 differentanatomic regions, a pharmaceutical composition of the present disclosureis injected in the largest wart (primary) per anatomical region, for aminimum of two and a maximum of four injections of 0.3 unit of potencyeach per visit every second week (14±2 days) for a maximum of 10 visitswith injections. No more than one wart per anatomical region is injectedon any given visit. If any primary injected wart exhibits a completeresponse, the next largest injectable common wart is injected with thesame pharmaceutical composition at the same dose of 0.3 unit of potencyper injection (maximum of 4 injections per visit) providing the newinjectable wart is not within the same anatomical region as othercurrently injected warts. If an injected wart recurs after exhibiting acomplete response, it is re-injected instead of the non-primary injectedwart that was injected at the previous visit. This injection strategy isrepeated for a maximum total of 10 injection visits per subject or untilall injectable common warts exhibit a complete response, if it occursbefore the end of the 10 injection visits.

The above treatment is effective for completely resolving 82% of thelargest primary injected warts at any number of injections, compared to52% of those injected with a placebo. The median number of injectionsrequired to completely resolve the largest primary injected wart is 4injections, compared to 10 injections of the placebo. Furthermore, at 4months following the last injection, 43% of the largest primary injectedwarts remain completely resolved, compared to 31% of those injected witha placebo.

7% of the subjects receiving treatment exhibited scarring at the site ofa resolved wart comparing to 6% of the subjects receiving placebo. 3% ofthe subjects receiving treatment exhibited hypopigmentation at the siteof a resolved wart comparing to 0% of the subjects receiving placebo.

Example 5 Cytokine Biomarker Changes in Wart Patients

To evaluate biomarker changes in wart patients, intralesional injectionsare provided to a total of 58 subjects. A pharmaceutical composition ofthe present disclosure is provided intralesionally to each of 43subjects in the largest (primary) wart every two weeks at a dose of 0.3potency each injection for a maximum of 10 injections. On the otherhand, a placebo is provided intralesionally to each of 15 subjects inthe primary wart every two weeks for a maximum of 10 injections.

If the primary wart exhibited a complete response, the next largest wartis treated using the same dose. This strategy is repeated until allwarts are resolved or for 10 injections, whichever was reached first. Ifan injected wart recurred after exhibiting a complete response, it isretreated instead of the wart injected in the previous visit.

Blood samples are collected at screening prior to initiation oftreatment (V1); after treatment injections and immediately prior to thethird injection (V5); and study completion, i.e., upon resolution of allwarts or 10 injections (V13). Plasma separated from the blood is storedat −80° C. until assayed for multiple protein biomarkers (45-plexcytokine/chemokine/growth factor panel) by BioAgilytix (Durham, N.C.).

Individual sample results are checked to fall within the range of validstandards. Results falling outside the valid range are excluded.

Table 1 presents summary statistics for the treatment and placebo groupsin a study monitoring levels of IL-23, IL-7, and IP-10. Only p-valuesless than 0.05 are included in the table.

TABLE 1 Summary Statistics of Cytokine Biomarker Changes TREATMENT GROUPPLACEBO GROUP CYTOKINE Visit N Mean SE Visit N Mean SE p-value IL-23 136 119.93 12.17 1 13 113.78 34.55 5 34 97.60 12.52 5 11 173.30 37.560.026 13 32 107.05 12.91 13 13 149.26 34.55 IL-7 1 16 1.39 0.14 1 7 1.680.48 5 23 1.22 0.11 5 7 1.98 0.48 0.047 13 20 1.06 0.12 13 8 2.04 0.450.004 IP-10 1 41 37.53 2.15 1 15 36.14 2.13 5 38 41.11 2.24 5 14 35.662.21 13 38 35.11 2.24 13 13 38.31 2.29

In this study, when comparing the treatment and placebo groups, thebiomarker concentrations tended to be higher in the placebo grouprelative to the treatment group at all visits, including at visit 1 whenblood samples were taken prior to any injections. The p-values for thecomparison of mean concentrations at each visit is reported if thedifference was considered significant (p<0.05). In each case, the meanconcentrations for the placebo group was greater than for the treatmentgroup.

Furthermore, in this study, the change in biomarker levels with respectto baseline levels (V13-V1) were compared between the treatment groups.In general, relative decreases in biomarker levels were observed in theactively treated groups as compared to the placebo group. Threebiomarkers (IL7, IP-10, and IL-23) showed statistically significantdecreases after treatment when compared to the placebo group. FIGS. 7A,7B, and 7C, illustrate comparison of changes in biomarker levels ofIL-7, IP-10, and IL-23, respectively, using ANOVA one way analysis. Adenotes treatment group, P denotes placebo group; change in biomarkerlevels are reported in terms of pg/mL.

The actively treated group is subdivided into those who showed completeresolution of all treated warts and those who showed less than 50%complete resolution. Comparison of mean changes after treatment betweenthese two subgroups reveals a significant difference for the cytokineIL-23. The change noted in the high responder subgroup corresponds to a35% decrease from baseline values, while the low responder subgroupexhibits a 5% decrease. In comparison, the placebo group on averageexhibits a 35% increase in IL-23 concentration.

Example 6 Treatment by Injections to a Single Wart

To treat a patient between 12 to 65 year old with between 3 and 20common warts, intralesional injections of a pharmaceutical compositionof the present disclosure at a dose of 0.3 unit of potency are providedto the largest common wart every second week (14±2 days) for a maximumof 6 injections. If the primary common wart exhibits a completeresponse, the second largest injectable common wart of all anatomicalregions is injected with the same pharmaceutical composition at the samedose of 0.3 unit of potency. If an injected wart recurs after exhibitinga complete response, it is re-injected instead of the non-primaryinjected wart that was injected at the previous visit. This injectionstrategy is repeated for a maximum of 6 injections or until allinjectable common warts exhibit a complete response, if it occurs beforeall 6 injections are used. Complete resolution of the primary injectedwart is determined one month after the last injection.

The above treatment is effective for completely resolving 66% of allprimary injected warts at any number of injections, compared to 37% ofthose injected with a placebo. The median number of injections requiredto completely resolve a primary injected wart is 5 injections, comparedto 10 injections of the placebo. Furthermore, at 4 months following thelast injection, 46% of primary injected warts remain completelyresolved, compared to 37% of those injected with a placebo.

The above treatment is also effective for resolving all common warts in32% of the 61 subjects treated, compared to 21% of subjects receivingplacebo.

From the foregoing, it will be appreciated that the present inventioncan be embodied in various ways, which include but not limited to thefollowing:

Embodiment 1. A method for treating a common wart in a subject in needthereof, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioneffective for complete resolution of the common wart at a cumulativedose of 2.5 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.

Embodiment 2. The method of embodiment 1, where the pharmaceuticalcomposition is further effective for reducing the diameter of the commonwart by at least 50% at a cumulative dose of 1 unit of potency.

Embodiment 3. A method for treating a common wart in a subject in needthereof, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioncapable of complete resolution of the common wart at a cumulative doseof 2.5 units of potency, where the pharmaceutical composition comprisesa filtered extract of Candida albicans and secreted antigens.

Embodiment 4. The method of embodiment 3, where the pharmaceuticalcomposition is further capable of reducing the diameter of the commonwart by at least 50% at a cumulative dose of 1 unit of potency.

Embodiment 5. The method of embodiment 1 or 3, where the completeresolution is identified by a lack of recurrence of the common wart atthe same site observed at least 20 weeks from administration of thefirst intralesional injection.

Embodiment 6. The method of embodiment 1 or 3, where the completeresolution is accompanied by a lack of scarring at the location of thecommon wart.

Embodiment 7. The method of embodiment 1 or 3, where the completeresolution is accompanied by a low level of hypopigmentation at thelocation of the common wart.

Embodiment 8. The method of any one of embodiments 1-4, where the commonwart measures between about 3 mm and about 20 mm before theadministering.

Embodiment 9. The method of any one of embodiments 1-4, where theadministering is providing an intralesional injection to the subject.

Embodiment 10. The method of embodiment 9, where the administering isproviding an intralesional injection near the perimeter of the commonwart.

Embodiment 11. The method of embodiment 9, where the administering isproviding an intralesional injection at the perimeter of the commonwart.

Embodiment 12. The method of embodiment 9, where the administering isproviding an intralesional injection in the common wart.

Embodiment 13. The method of any one of embodiments 1-4, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 14. The method of embodiment 13, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 15. The method of any one of embodiments 1-4, where the twoor more intralesional injections are provided to the subject over aperiod of time.

Embodiment 16. The method of embodiment 15, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 17. The method of embodiment 15, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 18. The method of embodiment 15, where the two or moreintralesional injections are provided to the subject over at least about8 weeks.

Embodiment 19. The method of embodiment 13, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 20. The method of embodiment 19, where a subgroup within thetwo or more subgroups of intralesional injections provides a total doseof at least 0.5 unit of potency.

Embodiment 21. The method of embodiment 19 or 20, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 22. The method of embodiment 19 or 20, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 23. The method of embodiment 19 or 20, where the two or moresubgroups of intralesional injections are provided to the subject overat least about 8 weeks.

Embodiment 24. The method of embodiment 19 or 20, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the common wart.

Embodiment 25. The method of embodiment 19 or 20, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the common wart.

Embodiment 26. The method of embodiment 19 or 20, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the common wart.

Embodiment 27. The method of embodiment 19 or 20, where a subgroupwithin the two or more subgroups comprises five injections around thecommon wart.

Embodiment 28. The method of embodiment 19 or 20, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the common wart.

Embodiment 29. The method of any one of embodiments 24-28, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the common wart.

Embodiment 30. The method of any one of embodiments 24-28, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the common wart.

Embodiment 31. The method of any one of embodiments 24-28, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 32. A method for treating a common wart in a subject in needthereof, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioneffective for partial resolution of the common wart at a cumulative doseof 5 units of potency, where the pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens.

Embodiment 33. The method of embodiment 32, where the pharmaceuticalcomposition is further effective for reducing the diameter of the commonwart by at least 50% at a cumulative dose of 1 unit of potency.

Embodiment 34. A method for treating a common wart in a subject in needthereof, the method comprises administering one or more intralesionalinjections to the subject of an amount of a pharmaceutical compositioncapable of partial resolution of the common wart at a cumulative dose of5 units of potency, where the pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens.

Embodiment 35. The method of embodiment 34, where the pharmaceuticalcomposition is further capable of reducing the diameter of the commonwart by at least 50% at a cumulative dose of 1 unit of potency.

Embodiment 36. The method of embodiment 32 or 34, where the partialresolution is identified by a reduction in wart diameter.

Embodiment 37. The method of any one of embodiments 32-35, where thecommon wart measures between about 3 mm and about 20 mm before theadministering.

Embodiment 38. The method of any one of embodiments 32-35, where theadministering is providing an intralesional injection to the subject.

Embodiment 39. The method of embodiment 38, where the administering isproviding an intralesional injection near the perimeter of the commonwart.

Embodiment 40. The method of embodiment 38, where the administering isproviding an intralesional injection at the perimeter of the commonwart.

Embodiment 41. The method of embodiment 38, where the administering isproviding an intralesional injection in the common wart.

Embodiment 42. The method of any one of embodiments 32-35, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 43. The method of embodiment 42, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 44. The method of any one of embodiments 32-35, where the twoor more intralesional injections are provided to the subject over aperiod of time.

Embodiment 45. The method of embodiment 44, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 46. The method of embodiment 44, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 47. The method of embodiment 44, where the two or moreintralesional injections are provided to the subject over at least about18 weeks.

Embodiment 48. The method of embodiment 42, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 49. The method of embodiment 48, where a subgroup within thetwo or more subgroups of intralesional injections provides a total doseof at least 0.5 unit of potency.

Embodiment 50. The method of embodiment 48 or 49, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 51. The method of embodiment 48 or 49, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 52. The method of embodiment 48 or 49, where the two or moresubgroups of intralesional injections are provided to the subject overat least about 18 weeks.

Embodiment 53. The method of embodiment 48 or 49, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the common wart.

Embodiment 54. The method of embodiment 48 or 49, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the common wart.

Embodiment 55. The method of embodiment 48 or 49, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the common wart.

Embodiment 56. The method of embodiment 48 or 49, where a subgroupwithin the two or more subgroups comprises five injections around thecommon wart.

Embodiment 57. The method of embodiment 48 or 49, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the common wart.

Embodiment 58. The method of any one of embodiments 52-57, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the common wart.

Embodiment 59. The method of any one of embodiments 52-57, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the common wart.

Embodiment 60. The method of any one of embodiments 52-57, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 61. A method for treating a plurality of common warts in asubject in need thereof, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition effective for partial resolution of the plurality of commonwarts at a cumulative dose of 5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

Embodiment 62. A method for treating a plurality of common warts in asubject in need thereof, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition capable of partial resolution of the plurality of commonwarts at a cumulative dose of 5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

Embodiment 63. The method of embodiment 61 or 62, where the partialresolution is identified by a reduction in wart diameter.

Embodiment 64. The method of embodiment 61 or 62, where the plurality ofcommon warts comprise 3 to 20 common warts.

Embodiment 65. The method of embodiment 61 or 62, where the plurality ofcommon warts are located within the same anatomical location in thesubject.

Embodiment 66. The method of embodiment 61 or 62, where theadministering is providing an intralesional injection to the subject.

Embodiment 67. The method of embodiment 61 or 62, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 68. The method of embodiment 67, where the two or moreintralesional injections are provided to the subject over a period oftime.

Embodiment 69. The method of embodiment 68, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 70. The method of embodiment 68, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 71. The method of embodiment 68, where the two or moreintralesional injections are provided to the subject over at least about18 weeks.

Embodiment 72. The method of embodiment 67, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 73. The method of embodiment 61 or 62, further comprisingidentifying the largest common wart within the plurality of commonwarts.

Embodiment 74. The method of embodiment 73, where the largest commonwart measures between about 3 mm and about 20 mm before theadministering.

Embodiment 75. The method of embodiment 73, where the administering isproviding an intralesional injection at the perimeter of the largestcommon wart.

Embodiment 76. The method of embodiment 73, where the administering isproviding an intralesional injection near the perimeter of the largestcommon wart.

Embodiment 77. The method of embodiment 73, where the administering isproviding an intralesional injection in the largest common wart.

Embodiment 78. The method of embodiment 73, where the administering isproviding two or more intralesional injections to the largest commonwart.

Embodiment 79. The method of embodiment 78, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 80. The method of embodiment 78 or 79, where the two or moreintralesional injections are provided to the subject over a period oftime.

Embodiment 81. The method of embodiment 80, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 82. The method of embodiment 80, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 83. The method of embodiment 80, where the two or moreintralesional injections are provided to the subject over at least about18 weeks.

Embodiment 84. The method of embodiment 78, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 85. The method of embodiment 84, where a subgroup within thetwo or more subgroups of intralesional injections provides a total doseof at least 0.5 unit of potency.

Embodiment 86. The method of embodiment 84 or 85, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 87. The method of embodiment 84 or 85, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 88. The method of embodiment 84 or 85, where the two or moresubgroups of intralesional injections are provided to the subject overat least about 18 weeks.

Embodiment 89. The method of embodiment 84 or 85, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the largest common wart.

Embodiment 90. The method of embodiment 84 or 85, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the largest common wart.

Embodiment 91. The method of embodiment 84 or 85, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the largest common wart.

Embodiment 92. The method of embodiment 84 or 85, where a subgroupwithin the two or more subgroups comprises five injections around thelargest common wart.

Embodiment 93. The method of embodiment 84 or 85, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the largest common wart.

Embodiment 94. The method of any one of embodiments 89-93, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the largest common wart.

Embodiment 95. The method of any one of embodiments 89-93, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the largest common wart.

Embodiment 96. The method of any one of embodiments 89-93, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 97. A method for treating a plurality of common warts in asubject in need thereof, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition effective for reducing the diameter of each of the pluralityof common warts by at least 50% at a cumulative dose of 1 unit ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

Embodiment 98. A method for treating a plurality of common warts in asubject in need thereof, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition capable of reducing the diameter of each of the plurality ofcommon warts by at least 50% at a cumulative dose of 1 unit of potency,where the pharmaceutical composition comprises a filtered extract ofCandida albicans and secreted antigens.

Embodiment 99. The method of embodiment 97 or 98, where the plurality ofcommon warts comprise 3 to 20 common warts.

Embodiment 100. The method of embodiment 97 or 98, where the pluralityof common warts are located within the same anatomical location in thesubject.

Embodiment 101. The method of embodiment 97 or 98, where theadministering is providing an intralesional injection to the subject.

Embodiment 102. The method of embodiment 97 or 98, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 103. The method of embodiment 102, where the two or moreintralesional injections are provided to the subject over a period oftime.

Embodiment 104. The method of embodiment 103, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 105. The method of embodiment 103, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 106. The method of embodiment 102, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 107. The method of embodiment 97 or 98, further comprisingidentifying the largest common wart within the plurality of commonwarts.

Embodiment 108. The method of embodiment 107, where the largest commonwart measures between about 3 mm and about 20 mm before theadministering.

Embodiment 109. The method of embodiment 107, where the administering isproviding an intralesional injection at the perimeter of the largestcommon wart.

Embodiment 110. The method of embodiment 107, where the administering isproviding an intralesional injection near the perimeter of the largestcommon wart.

Embodiment 111. The method of embodiment 107, where the administering isproviding an intralesional injection in the largest common wart.

Embodiment 112. The method of embodiment 107, where the administering isproviding two or more intralesional injections to the largest commonwart.

Embodiment 113. The method of embodiment 112, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 114. The method of embodiment 112 or 113, where the two ormore intralesional injections are provided to the subject over a periodof time.

Embodiment 115. The method of embodiment 114, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 116. The method of embodiment 114, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 117. The method of embodiment 112, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 118. The method of embodiment 117, where each of the two ormore subgroups of intralesional injections is provided at a total doseof at least 0.5 unit of potency.

Embodiment 119. The method of embodiment 117 or 118, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 120. The method of embodiment 117 or 118, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 121. The method of embodiment 117 or 118, where the two ormore subgroups of intralesional injections are provided to the subjectover at least about two weeks.

Embodiment 122. The method of embodiment 117 or 118, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the largest common wart.

Embodiment 123. The method of embodiment 117 or 118, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the largest common wart.

Embodiment 124. The method of embodiment 117 or 118, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the largest common wart.

Embodiment 125. The method of embodiment 117 or 118, where a subgroupwithin the two or more subgroups comprises five injections around thelargest common wart.

Embodiment 126. The method of embodiment 117 or 118, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the largest common wart.

Embodiment 127. The method of any one of embodiments 122-126, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the largest common wart.

Embodiment 128. The method of any one of embodiments 122-126, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the largest common wart.

Embodiment 129. The method of any one of embodiments 122-126, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 130. A method for treating a non-common wart in a subject inneed thereof, where the subject has one or more common warts, the methodcomprises administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition effective forcomplete resolution of the non-common wart at a cumulative dose of 5units of potency, where the pharmaceutical composition comprises afiltered extract of Candida albicans and secreted antigens.

Embodiment 131. A method for treating a non-common wart in a subject inneed thereof, where the subject has one or more common warts, the methodcomprises administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition capable of completeresolution of the non-common wart at a cumulative dose of 5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

Embodiment 132. The method of embodiment 130 or 131, where thenon-common wart is a plantar wart.

Embodiment 133. The method of embodiment 130 or 131, where thenon-common wart is a genital wart.

Embodiment 134. The method of embodiment 130 or 131, where thenon-common wart is a facial wart.

Embodiment 135. The method of embodiment 130 or 131, where thenon-common wart is a flat wart.

Embodiment 136. The method of embodiment 130 or 131, where thenon-common wart is a periungual wart.

Embodiment 137. The method of embodiment 130 or 131, where thenon-common wart is located within the same anatomical area as the one ormore common warts.

Embodiment 138. The method of embodiment 130 or 131, where the completeresolution is identified by a lack of recurrence of the non-common wartat the same site observed at least 20 weeks from administration of thefirst intralesional injection.

Embodiment 139. The method of embodiment 130 or 131, where theadministering is providing an intralesional injection to the subject.

Embodiment 140. The method of embodiment 130 or 131, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 141. The method of embodiment 140, where the two or moreintralesional injections are provided to the subject over a period oftime.

Embodiment 142. The method of embodiment 141, where a pair ofintralesional injections in the two or more intralesional injections areprovided two weeks apart to the subject.

Embodiment 143. The method of embodiment 141, where a pair ofintralesional injections in the two or more intralesional injections areprovided three weeks apart to the subject.

Embodiment 144. The method of embodiment 141, where the two or moreintralesional injections are provided to the subject over 27 weeks.

Embodiment 145. The method of embodiment 140, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 146. The method of embodiment 130 or 131, where the one ormore common warts comprise 3 to 20 common warts.

Embodiment 147. The method of embodiment 130 or 131, further comprisingidentifying the largest common wart within the one or more common warts.

Embodiment 148. The method of embodiment 147, where the largest commonwart measures between about 3 mm and about 20 mm before theadministering.

Embodiment 149. The method of embodiment 147, where the administering isproviding an intralesional injection at the perimeter of the largestcommon wart.

Embodiment 150. The method of embodiment 147, where the administering isproviding an intralesional injection near the perimeter of the largestcommon wart.

Embodiment 151. The method of embodiment 147, where the administering isproviding an intralesional injection in the largest common wart.

Embodiment 152. The method of embodiment 147, where the administering isproviding two or more intralesional injections to the largest commonwart.

Embodiment 153. The method of embodiment 152, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 154. The method of embodiment 152 or 153, where the two ormore intralesional injections are provided to the subject over a periodof time.

Embodiment 155. The method of embodiment 154, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 156. The method of embodiment 154, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 157. The method of embodiment 154, where the two or moreintralesional injections are provided to the subject over at least about18 weeks.

Embodiment 158. The method of embodiment 152, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 159. The method of embodiment 158, where a subgroup withinthe two or more subgroups of intralesional injections is provided at atotal dose of at least 0.5 unit of potency.

Embodiment 160. The method of embodiment 158 or 159, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 161. The method of embodiment 158 or 159, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 162. The method of embodiment 158 or 159, where the two ormore subgroups of intralesional injections are provided to the subjectover at least about 18 weeks.

Embodiment 163. The method of embodiment 158 or 159, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the largest common wart.

Embodiment 164. The method of embodiment 158 or 159, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the largest common wart.

Embodiment 165. The method of embodiment 158 or 159, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the largest common wart.

Embodiment 166. The method of embodiment 158 or 159, where a subgroupwithin the two or more subgroups comprises five injections around thelargest common wart.

Embodiment 167. The method of embodiment 158 or 159, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the largest common wart.

Embodiment 168. The method of any one of embodiments 163-167, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the largest common wart.

Embodiment 169. The method of any one of embodiments 163-167, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the largest common wart.

Embodiment 170. The method of any one of embodiments 163-167, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 171. A method for treating a previously treated common wartin a subject in need thereof, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition effective for complete resolution of thepreviously treated common wart at a cumulative dose of 5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

Embodiment 172. A method for treating a previously treated common wartin a subject in need thereof, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition capable of complete resolution of thepreviously treated common wart at a cumulative dose of 5 units ofpotency, where the pharmaceutical composition comprises a filteredextract of Candida albicans and secreted antigens.

Embodiment 173. The method of embodiment 171 or 172, where thepreviously treated common wart is a common wart previously treated withcryotherapy.

Embodiment 174. The method of embodiment 173, where the previouslytreated common wart did not respond to the cryotherapy.

Embodiment 175. The method of embodiment 173, where the cryotherapy didnot completely resolve the previously treated common wart.

Embodiment 176. The method of embodiment 171 or 172, where thepreviously treated common wart is a common wart previously treated withsalicylic acid or a related acid.

Embodiment 177. The method of embodiment 176, where the related acid istrichloroacetic acid or bichloroacetic acid.

Embodiment 178. The method of embodiment 176, where the previouslytreated common wart did not respond to the salicylic acid or a relatedacid.

Embodiment 179. The method of embodiment 176, where the salicylic acidor a related acid did not completely resolve the previously treatedcommon wart.

Embodiment 180. The method of embodiment 171 or 172, where thepreviously treated common wart is a common wart previously treated witha treatment selected from the group consisting of liquid nitrogen,carbon dioxide, cantharidin, simple occlusion, wart gel, apple cidervinegar, surgery, laser, tea tree oil, freeze wart spray, wart scraped,electrodessication, essential oils of lavender and oregano, andimiquimod.

Embodiment 181. The method of embodiment 180, where the previouslytreated common wart did not respond to the treatment.

Embodiment 182. The method of embodiment 180, where the treatment didnot completely resolve the previously treated common wart.

Embodiment 183. The method of any one of embodiments 171-182, where thepreviously treated common wart measures between about 3 mm and about 20mm before the administering.

Embodiment 184. The method of any one of embodiments 171-182, where thecomplete resolution is identified by a lack of recurrence of thepreviously treated common wart at the same site observed at least 20weeks from administration of the first intralesional injection.

Embodiment 185. The method of any one of embodiments 171-182, where thecomplete resolution is accompanied by a lack of scarring at the locationof the previously treated common wart.

Embodiment 186. The method of any one of embodiments 171-182, where thecomplete resolution is accompanied by a low level of hypopigmentation atthe location of the previously treated common wart.

Embodiment 187. The method of any one of embodiments 171-182, where theadministering is providing an intralesional injection to the subject.

Embodiment 188. The method of embodiment 187, where the administering isproviding an intralesional injection at the perimeter of the previouslytreated common wart.

Embodiment 189. The method of embodiment 187, where the administering isproviding an intralesional injection near the perimeter of thepreviously treated common wart.

Embodiment 190. The method of embodiment 187, where the administering isproviding an intralesional injection in the previously treated commonwart.

Embodiment 191. The method of any one of embodiments 171-182, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 192. The method of embodiment 191, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 193. The method of embodiment 191 or 192, where the two ormore intralesional injections are provided to the subject over a periodof time.

Embodiment 194. The method of embodiment 193, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 195. The method of embodiment 193, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 196. The method of embodiment 193, where the two or moreintralesional injections are provided to the subject over at least about18 weeks.

Embodiment 197. The method of embodiment 191, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 198. The method of embodiment 197, where a subgroup withinthe two or more subgroups of intralesional injections provides a totaldose of at least 0.5 unit of potency.

Embodiment 199. The method of embodiment 197 or 198, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 200. The method of embodiment 197 or 198, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 201. The method of embodiment 197 or 198, where the two ormore subgroups of intralesional injections are provided to the subjectover at least about 18 weeks.

Embodiment 202. The method of embodiment 197 or 198, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the previously treated common wart.

Embodiment 203. The method of embodiment 197 or 198, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the previously treated common wart.

Embodiment 204. The method of embodiment 197 or 198, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the previously treated common wart.

Embodiment 205. The method of embodiment 197 or 198, where a subgroupwithin the two or more subgroups comprises five injections around thepreviously treated common wart.

Embodiment 206. The method of embodiment 197 or 198, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the previously treated common wart.

Embodiment 207. The method of any one of embodiments 202-206, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the previously treated common wart.

Embodiment 208. The method of any one of embodiments 202-206, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the previously treated common wart.

Embodiment 209. The method of any one of embodiments 202-206, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 210. A method for delaying recurrence of a common wart in asubject in need thereof, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition effective for delaying the reappearance of the common wartupon resolution at a cumulative dose of 2.5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

Embodiment 211. A method for delaying recurrence of a common wart in asubject in need thereof, the method comprises administering one or moreintralesional injections to the subject of an amount of a pharmaceuticalcomposition capable of delaying the reappearance of the common wart uponresolution at a cumulative dose of 2.5 units of potency, where thepharmaceutical composition comprises a filtered extract of Candidaalbicans and secreted antigens.

Embodiment 212. The method of embodiment 210 or 211, where the subjectdoes not develop any new common warts within at least 16 weeks after thelast injection of the one or more intralesional injections.

Embodiment 213. The method of embodiment 210 or 211, where the subjectdoes not develop any new common warts within the same anatomical area ofthe common wart.

Embodiment 214. The method of embodiment 210 or 211, where the subjectdoes not develop any new common warts within the same site of the commonwart.

Embodiment 215. The method of embodiment 210 or 211, where the commonwart measures between about 3 mm and about 20 mm before theadministering.

Embodiment 216. The method of embodiment 210 or 211, where theadministering is providing an intralesional injection to the subject.

Embodiment 217. The method of embodiment 216, where the administering isproviding an intralesional injection at the perimeter of the commonwart.

Embodiment 218. The method of embodiment 216, where the administering isproviding an intralesional injection near the perimeter of the commonwart.

Embodiment 219. The method of embodiment 216, where the administering isproviding an intralesional injection in the common wart.

Embodiment 220. The method of embodiment 210 or 211, where theadministering is providing two or more intralesional injections to thesubject.

Embodiment 221. The method of embodiment 220, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 222. The method of embodiment 220 or 221, where the two ormore intralesional injections are provided to the subject over a periodof time.

Embodiment 223. The method of embodiment 222, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 224. The method of embodiment 222, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 225. The method of embodiment 222, where the two or moreintralesional injections are provided to the subject over at least about8 weeks.

Embodiment 226. The method of embodiment 220, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 227. The method of embodiment 226, where a subgroup withinthe two or more subgroups of intralesional injections provides a totaldose of at least 0.5 unit of potency.

Embodiment 228. The method of embodiment 226 or 227, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 229. The method of embodiment 226 or 227, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 230. The method of embodiment 226 or 227, where the two ormore subgroups of intralesional injections are provided to the subjectover at least about 8 weeks.

Embodiment 231. The method of embodiment 226 or 227, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the common wart.

Embodiment 232. The method of embodiment 226 or 227, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the common wart.

Embodiment 233. The method of embodiment 226 or 227, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the common wart.

Embodiment 234. The method of embodiment 226 or 227, where a subgroupwithin the two or more subgroups comprises five injections around thecommon wart.

Embodiment 235. The method of embodiment 226 or 227, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the common wart.

Embodiment 236. The method of any one of embodiments 231-235, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the common wart.

Embodiment 237. The method of any one of embodiments 231-235, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the common wart.

Embodiment 238. The method of any one of embodiments 231-235, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 239. The method of any one of embodiments 1-238, where thepharmaceutical composition comprises at least 80% mannose.

Embodiment 240. The method of any one of embodiments 1-239, where thepharmaceutical composition comprises at least 8% glucose.

Embodiment 241. The method of any one of embodiments 1-240, where thepharmaceutical composition comprises at least 1% galactose.

Embodiment 242. The method of any one of embodiments 1-240, where theantigens have a molecular weight of about 167 kilodaltons.

Embodiment 243. The method of any one of embodiments 1-241, where thesubject is between the ages of 18 and 65.

Embodiment 244. The method of any one of embodiments 1-243, where thesubject was diagnosed with a first common wart at least 12 weeks priorto receiving the one or more intralesional injections.

Embodiment 245. The method of any one of embodiments 1-244, where thesubject was not diagnosed with a recalcitrant wart.

Embodiment 246. The method of any one of embodiments 1-245, where thesubject has a baseline result of between 5 mm and 25 mm to the DelayedType Hypersensitivity test.

Embodiment 247. The method of any one of embodiments 1-246, where thesubject is not diagnosed with a systematic disease that compromisesimmune function.

Embodiment 248. The method of any one of embodiments 1-246, where thesubject is not diagnosed with a localized disease that compromisesimmune function.

Embodiment 249. The method of any one of embodiments 1-246, where thesubject is not diagnosed with a systematic condition that compromisesimmune function.

Embodiment 250. The method of any one of embodiments 1-246, where thesubject is not diagnosed with a localized condition that compromisesimmune function.

Embodiment 251. The method of any one of embodiments 1-246, where thesubject is not diagnosed with psoriasis.

Embodiment 252. The method of any one of embodiments 1-251, where thesubject is not receiving a treatment resulting in beingimmunocompromised.

Embodiment 253. The method of any one of embodiments 1-252, where thesubject has not been diagnosed with diabetes mellitus.

Embodiment 254. The method of any one of embodiments 1-253, where thesubject does not have a history of keloid formation.

Embodiment 255. The method of any one of embodiments 1-254, where thesubject does not have an existing dermatologic condition in the sameanatomical area as the wart being treated.

Embodiment 256. The method of any one of embodiments 1-255, where thesubject does not have an underlying inflammatory condition.

Embodiment 257. The method of embodiment 256, where the underlyinginflammatory condition is an arthritic joint.

Embodiment 258. The method of any one of embodiments 1-257, where thesubject has not received one or more treatments selected from the groupconsisting of liquid nitrogen, carbon dioxide, electrodessication,laser, surgery, simple occlusion, salicylic acid, trichloroacetic acid,bichloroacetic acid, over-the-counter treatments, and cantharidin,within 4 weeks prior to the administering.

Embodiment 259. The method of any one of embodiments 1-258, where thesubject has not received one or more immunotherapy selected from thegroup consisting of diphenylchyclopropenone (DPCP), dinitrochlorobenzene(DNCB), imiquimod, 5-florouracil, bleomycin, and podophyllin, within 12weeks prior to the administering.

Embodiment 260. The method of any one of embodiments 1-259, where thesubject has not received one or more systematic treatment selected fromthe group consisting of cimetidine, zinc supplements at a dose higherthan 20 mg of elemental zinc daily, azathioprine, 6-mercaptopurine,methotrexate, infliximab, adalimumab, etanercept, and steroid, within 12weeks prior to the administering.

Embodiment 261. The method of any one of embodiments 1-260, where thesubject has not received any investigational agent within 30 days priorto the administering.

Embodiment 262. The method of any one of embodiments 1-260, where thesubject has not received any investigational agent within 5 half-livesof the investigational agent prior to the administering.

Embodiment 263. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for complete resolution of acommon wart at a cumulative dose of 2.5 units of potency.

Embodiment 264. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for partial resolution of acommon wart at a cumulative dose of 5 units of potency.

Embodiment 265. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for reducing the diameter of acommon wart by at least 50% at a cumulative dose of 1 unit of potency.

Embodiment 266. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for partial resolution of aplurality of common warts at a cumulative dose of 5 units of potency.

Embodiment 267. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for reducing the diameter of aplurality of common warts by at least 50% at a cumulative dose of 1 unitof potency.

Embodiment 268. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for complete resolution of anon-common wart at a cumulative dose of 5 units of potency.

Embodiment 269. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for complete resolution of apreviously treated common wart at a cumulative dose of 5 units ofpotency.

Embodiment 270. A medicament comprising a filtered extract of Candidaalbicans and secreted antigens formulated for delaying the reappearanceof the common wart upon resolution at a cumulative dose of 2.5 units ofpotency.

Embodiment 271. The medicament of any one of embodiments 263-270, wherethe medicament comprises at least 80% mannose.

Embodiment 272. The medicament of any one of embodiments 263-270, wherethe medicament comprises at least 8% glucose.

Embodiment 273. The medicament of any one of embodiments 263-270, wherethe medicament comprises at least 1% galactose.

Embodiment 274. The medicament of any one of embodiments 263-270, wherethe antigens have a molecular weight of about 167 kilodaltons.

Embodiment 275. The medicament of any one of embodiments 263-274, wherethe medicament is formulated in a vial.

Embodiment 276. The medicament of embodiment 275, where the vial is amulti-dose preserved vial.

Embodiment 277. The medicament of embodiment 275, where the vial is asingle-dose unpreserved vial.

Embodiment 278. The medicament of embodiment 275, where the vial is aglass vial.

Embodiment 279. The medicament of embodiment 278, where the glass vialis a 2 mL vial.

Embodiment 280. The medicament of any one of embodiments 263-273, wherethe medicament is formulated in a prefilled syringe.

Embodiment 281. The medicament of embodiment 280, where the prefilledsyringe has a volume of 0.5 mL.

Embodiment 282. A method for reducing the level of IL-23 in a subjectdiagnosed with a common wart, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition at a cumulative dose of 1 unit of potency,where the pharmaceutical composition comprises a filtered extract ofCandida albicans and secreted antigens.

Embodiment 283. The method of embodiment 282, where the level of IL-23in the subject is reduced for at least about 15% upon receipt of thecumulative dose when compared to a level of IL-23 measured in thesubject before the administering.

Embodiment 284. A method for completely resolving a common wart in asubject in need thereof, the method comprises reducing the level ofIL-23 by at least about 35% in a subject in need thereof.

Embodiment 285. The method of embodiment 284, where the reducing isachieved by administering one or more intralesional injections to thesubject of an amount of a pharmaceutical composition at a cumulativedose of 3 units of potency, where the pharmaceutical compositioncomprises a filtered extract of Candida albicans and secreted antigens.

Embodiment 286. The method of embodiment 284, where the completelyresolving is identified by a lack of recurrence of the common wart atthe same site observed at least 20 weeks from the reducing.

Embodiment 287. A method for reducing the level of IL-7 in a subjectdiagnosed with a common wart, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition at a cumulative dose of 0.6 units of potency,where the pharmaceutical composition comprises a filtered extract ofCandida albicans and secreted antigens.

Embodiment 288. The method of embodiment 287, where the level of IL-7 inthe subject is reduced for at least about 10% upon receipt of thecumulative dose when compared to a level of IL-7 measured in the subjectbefore the administering.

Embodiment 289. A method for reducing the level of IL-7 in a subjectdiagnosed with a common wart, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition at a cumulative dose of 3 units of potency,where the pharmaceutical composition comprises a filtered extract ofCandida albicans and secreted antigens.

Embodiment 290. The method of embodiment 289, where the level of IL-7 inthe subject is reduced for at least about 20% upon receipt of thecumulative dose when compared to a level of IL-7 measured in the subjectbefore the administering.

Embodiment 291. A method for reducing the level of IP-10 in a subjectdiagnosed with a common wart, the method comprises administering one ormore intralesional injections to the subject of an amount of apharmaceutical composition at a cumulative dose of 3 units of potency,where the pharmaceutical composition comprises a filtered extract ofCandida albicans and secreted antigens.

Embodiment 292. The method of embodiment 291, where the level of IP-10in the subject is reduced for at least about 5% upon receipt of thecumulative dose when compared to a level of IP-10 measured in thesubject before the administering.

Embodiment 293. The method of any one of embodiments 282, 283, and285-292, where the administering is providing an intralesional injectionto the subject.

Embodiment 294. The method of embodiment 293, where the administering isproviding an intralesional injection near the perimeter of the commonwart.

Embodiment 295. The method of embodiment 293, where the administering isproviding an intralesional injection at the perimeter of the commonwart.

Embodiment 296. The method of embodiment 293, where the administering isproviding an intralesional injection in the common wart.

Embodiment 297. The method of any one of embodiments 282, 283, and285-292, where the administering is providing two or more intralesionalinjections to the subject.

Embodiment 298. The method of embodiment 297, where each of the two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.

Embodiment 299. The method of any one of embodiments 282, 283, and285-292, where the two or more intralesional injections are provided tothe subject over a period of time.

Embodiment 300. The method of embodiment 299, where a pair ofintralesional injections in the two or more intralesional injections areprovided about two weeks apart to the subject.

Embodiment 301. The method of embodiment 299, where a pair ofintralesional injections in the two or more intralesional injections areprovided about three weeks apart to the subject.

Embodiment 302. The method of embodiment 299, where the two or moreintralesional injections are provided to the subject over at least about8 weeks.

Embodiment 303. The method of embodiment 297, where the two or moreintralesional injections are provided in two or more subgroups ofintralesional injections over a period of time.

Embodiment 304. The method of embodiment 303, where a subgroup withinthe two or more subgroups of intralesional injections provides a totaldose of at least 0.5 unit of potency.

Embodiment 305. The method of embodiment 303 or 304, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about two weeks apart to the subject.

Embodiment 306. The method of embodiment 303 or 304, where a pair ofsubgroups within the two or more subgroups of intralesional injectionsare provided about three weeks apart to the subject.

Embodiment 307. The method of embodiment 303 or 304, where the two ormore subgroups of intralesional injections are provided to the subjectover at least about 8 weeks.

Embodiment 308. The method of embodiment 303 or 304, where a subgroupwithin the two or more subgroups comprises two intralesional injectionsaround the common wart.

Embodiment 309. The method of embodiment 303 or 304, where a subgroupwithin the two or more subgroups comprises three intralesionalinjections around the common wart.

Embodiment 310. The method of embodiment 303 or 304, where a subgroupwithin the two or more subgroups comprises four intralesional injectionsaround the common wart.

Embodiment 311. The method of embodiment 303 or 304, where a subgroupwithin the two or more subgroups comprises five injections around thecommon wart.

Embodiment 312. The method of embodiment 303 or 304, where a subgroupwithin the two or more subgroups comprises six intralesional injectionsaround the common wart.

Embodiment 313. The method of any one of embodiments 308-312, where theintralesional injections within the subgroup are approximately evenlyspaced apart near the perimeter of the common wart.

Embodiment 314. The method of any one of embodiments 308-312, where theintralesional injections within the subgroup are approximately evenlyspaced apart at the perimeter of the common wart.

Embodiment 315. The method of any one of embodiments 308-312, where theintralesional injections within the subgroup are administered atapproximately the same time.

Embodiment 316. The method of any one of embodiments 1-262 and 282-315,where the pharmaceutical composition comprises filtered extract of twostrains of Candida albicans and secreted antigens.

Embodiment 317. The method of embodiment 316, where a representativesample of a first strain of the two strains of Candida albicans has beendeposited with the ATCC under ATCC Accession No. PTA-126019.

Embodiment 318. The method of embodiment 316, where a representativesample of a first strain of the two strains of Candida albicans has beendeposited with the ATCC under ATCC Accession No. ATCC-10231.

Embodiment 319. The method of any one of embodiments 316-318, where arepresentative sample of a second strain of the two strains of Candidaalbicans has been deposited with the ATCC under ATCC Accession No.PTA-126020.

Embodiment 320. The medicament of any one of embodiments 263-281, wheresaid filtered extract of Candida albicans comprises two strains ofCandida albicans.

Embodiment 321. The medicament of embodiment 320, where a representativesample of a first strain of the two strains of Candida albicans has beendeposited with the ATCC under ATCC Accession No. PTA-126019.

Embodiment 322. The medicament of embodiment 320, where a representativesample of a first strain of the two strains of Candida albicans has beendeposited with the ATCC under ATCC Accession No. ATCC-10231.

Embodiment 323. The medicament of any one of embodiments 320-322, wherea representative sample of a second strain of the two strains of Candidaalbicans has been deposited with the ATCC under ATCC Accession No.PTA-126020.

While the present disclosure has been described with reference toparticular embodiments, it will be understood by those skilled in theart that various changes may be made and equivalents may be substitutedfor elements thereof to adapt to particular situations without departingfrom the scope of the present disclosure. Therefore, it is intended thatthe present disclosure not be limited to the particular embodimentsdisclosed as the best mode contemplated for carrying out the presentdisclosure, but that the present disclosure will include all embodimentsfalling within the scope and spirit of the appended claims.

The invention claimed is:
 1. A method for treating a common wart in asubject in need thereof, wherein said method comprises administering tosaid subject one or more intralesional injections of a pharmaceuticalcomposition effective for complete resolution of said common wart,wherein said one or more intralesional injections provide a cumulativedose of 2.5 units of potency of said pharmaceutical composition to saidpatient, wherein said pharmaceutical composition comprises a filteredextract of two strains of Candida albicans and secreted antigens, andwherein representative samples of said two strains of Candida albicanshaving been deposited with the American Type Culture Collection (ATCC)under ATCC Accession Nos. PTA-126019 and PTA-126020.
 2. A method fortreating a common wart in a subject in need thereof, wherein said methodcomprises administering to said subject one or more intralesionalinjections of a pharmaceutical composition effective for partialresolution of said common wart, wherein said one or more intralesionalinjections provide a cumulative dose of 5 units of potency of saidpharmaceutical composition to said patient, wherein said pharmaceuticalcomposition comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, and wherein representative samples ofsaid two strains of Candida albicans having been deposited with theAmerican Type Culture Collection (ATCC) under ATCC Accession Nos.PTA-126019 and PTA-126020.
 3. A method for treating a plurality ofcommon warts in a subject in need thereof, wherein said method comprisesadministering to said subject one or more intralesional injections of apharmaceutical composition effective for partial resolution of saidplurality of common warts, wherein said one or more intralesionalinjections provide a cumulative dose of 5 units of potency of saidpharmaceutical composition to said patient, wherein said pharmaceuticalcomposition comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, and wherein representative samples ofsaid two strains of Candida albicans having been deposited with theAmerican Type Culture Collection (ATCC) under ATCC Accession Nos.PTA-126019 and PTA-126020.
 4. A method for treating a plurality ofcommon warts in a subject in need thereof, wherein said method comprisesadministering to said subject one or more intralesional injections of apharmaceutical composition effective for reducing the diameter of eachof said plurality of common warts by at least 50%, wherein said one ormore intralesional injections provide a cumulative dose of 1 unit ofpotency of said pharmaceutical composition to said patient, wherein saidpharmaceutical composition comprises a filtered extract of two strainsof Candida albicans and secreted antigens, and wherein representativesamples of said two strains of Candida albicans having been depositedwith the American Type Culture Collection (ATCC) under ATCC AccessionNos. PTA-126019 and PTA-126020.
 5. A method for treating a non-commonwart in a subject in need thereof, wherein said subject has one or morecommon warts, wherein said method comprises administering to saidsubject one or more intralesional injections of a pharmaceuticalcomposition effective for complete resolution of said non-common wart,wherein said one or more intralesional injections provide a cumulativedose of 5 units of potency of said pharmaceutical composition to saidpatient, wherein said pharmaceutical composition comprises a filteredextract of two strains of Candida albicans and secreted antigens, andwherein representative samples of said two strains of Candida albicanshaving been deposited with the American Type Culture Collection (ATCC)under ATCC Accession Nos. PTA-126019 and PTA-126020.
 6. A method fortreating a previously treated common wart in a subject in need thereof,wherein said method comprises administering to said subject one or moreintralesional injections of a pharmaceutical composition effective forcomplete resolution of said previously treated common wart, wherein saidone or more intralesional injections provide a cumulative dose of 5units of potency of said pharmaceutical composition to said patient,wherein said pharmaceutical composition comprises a filtered extract oftwo strains of Candida albicans and secreted antigens, and whereinrepresentative samples of said two strains of Candida albicans havingbeen deposited with the American Type Culture Collection (ATCC) underATCC Accession Nos. PTA-126019 and PTA-126020.
 7. A method for delayingrecurrence of a common wart in a subject in need thereof, wherein saidmethod comprises administering to said subject one or more intralesionalinjections of a pharmaceutical composition effective for delaying thereappearance of said common wart upon resolution, wherein said one ormore intralesional injections provide a cumulative dose of 2.5 units ofpotency of said pharmaceutical composition to said patient, wherein saidpharmaceutical composition comprises a filtered extract of two strainsof Candida albicans and secreted antigens, and wherein representativesamples of said two strains of Candida albicans having been depositedwith the American Type Culture Collection (ATCC) under ATCC AccessionNos. PTA-126019 and PTA-126020.
 8. A method for reducing the level ofIL-23 in a subject diagnosed with a common wart, wherein said methodcomprises administering to said subject one or more intralesionalinjections of a pharmaceutical composition, wherein said one or moreintralesional injections provide a cumulative dose of 1 unit of potencyof said pharmaceutical composition to said patient, wherein saidpharmaceutical composition comprises a filtered extract of two strainsof Candida albicans and secreted antigens, and wherein representativesamples of said two strains of Candida albicans having been depositedwith the American Type Culture Collection (ATCC) under ATCC AccessionNos. PTA-126019 and PTA-126020.
 9. A method for completely resolving acommon wart in a subject in need thereof, wherein said method comprisesadministering to said subject one or more intralesional injections of apharmaceutical composition in an amount capable of reducing the level ofIL-23 in said subject by at least about 35%, wherein said pharmaceuticalcomposition comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, and wherein representative samples ofsaid two strains of Candida albicans having been deposited with theAmerican Type Culture Collection (ATCC) under ATCC Accession Nos.PTA-126019 and PTA-126020.
 10. A method for reducing the level of IL-7in a subject diagnosed with a common wart, wherein said method comprisesadministering to said subject one or more intralesional injections of apharmaceutical composition, wherein said one or more intralesionalinjections provide a cumulative dose of 0.6 units of potency of saidpharmaceutical composition to said patient, wherein said pharmaceuticalcomposition comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, and wherein representative samples ofsaid two strains of Candida albicans having been deposited with theAmerican Type Culture Collection (ATCC) under ATCC Accession Nos.PTA-126019 and PTA-126020.
 11. A method for reducing the level of IP-10in a subject diagnosed with a common wart, wherein said method comprisesadministering to said subject one or more intralesional injections of apharmaceutical composition, wherein said one or more intralesionalinjections provide a cumulative dose of 3 units of potency of saidpharmaceutical composition to said patient, wherein said pharmaceuticalcomposition comprises a filtered extract of two strains of Candidaalbicans and secreted antigens, and wherein representative samples ofsaid two strains of Candida albicans having been deposited with theAmerican Type Culture Collection (ATCC) under ATCC Accession Nos.PTA-126019 and PTA-126020.
 12. The method of claim 1, wherein saidpharmaceutical composition is further effective for reducing thediameter of said common wart in said subject by at least 50% at acumulative dose of 1 unit of potency of said pharmaceutical composition.13. The method of claim 1, wherein said complete resolution isidentified by a lack of recurrence of said common wart at the same siteobserved at least 20 weeks from administration of the firstintralesional injection.
 14. The method of claim 1, wherein saidcomplete resolution is accompanied by a lack of scarring at the locationof said common wart.
 15. The method of claim 1, wherein said completeresolution is accompanied by a low level of hypopigmentation at thelocation of said common wart.
 16. The method of claim 1, wherein saidcommon wart measures between about 3 mm and about 20 mm before saidadministering.
 17. The method of claim 1, wherein said administering isproviding an intralesional injection near or at the perimeter of saidcommon wart.
 18. The method of claim 1, wherein said administering isproviding an intralesional injection in said common wart.
 19. The methodof claim 1, wherein said administering is providing two or moreintralesional injections, wherein each of said two or more intralesionalinjections provides a dose of at least 0.5 unit of potency of saidpharmaceutical composition to said subject.
 20. The method of claim 1,wherein said administering is providing two or more intralesionalinjections, and wherein said two or more intralesional injections areprovided to said subject over a period of time.
 21. The method of claim1, wherein said administering is providing two or more intralesionalinjections, and wherein any two of said two or more intralesionalinjections are provided to said subject about two weeks apart.
 22. Themethod of claim 1, wherein said administering is providing two or moreintralesional injections, and wherein any two of said two or moreintralesional injections are provided to said subject about three weeksapart.
 23. The method of claim 1, wherein said administering isproviding two or more intralesional injections, and wherein any two ofsaid two or more intralesional injections are provided to said subjectover a period of at least about 8 weeks.
 24. The method of claim 1,wherein said administering is providing two or more intralesionalinjections, and wherein said two or more intralesional injections areprovided to said subject in two or more subgroups of intralesionalinjections over a period of time.
 25. The method of claim 24, whereinany subgroup of said two or more subgroups of intralesional injectionsprovides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 26. The method of claim 24, wherein any twoof said two or more subgroups of intralesional injections are providedto said subject about two weeks apart.
 27. The method of claim 24,wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart.
 28. Themethod of claim 24, wherein said two or more subgroups of intralesionalinjections are provided to said subject over a period of at least about8 weeks.
 29. The method of claim 24, wherein any subgroup of said two ormore subgroups comprises a number of intralesional injectionsadministered around said common wart, wherein said number ofintralesional injections is selected from the group consisting of two,three, four, five, and six intralesional injections.
 30. The method ofclaim 29, wherein each of said intralesional injections of said subgroupis administered at approximately even spacings near the perimeter ofsaid common wart.
 31. The method of claim 29, wherein each of saidnumber of intralesional injections of said subgroup is administered atapproximately even spacings at the perimeter of said common wart. 32.The method of claim 29, wherein each of said number of intralesionalinjections of said subgroup is administered at approximately the sametime.
 33. The method of claim 6, wherein said previously treated commonwart is a common wart previously treated with cryotherapy.
 34. Themethod of claim 33, wherein said previously treated common wart did notrespond to said cryotherapy.
 35. The method of claim 33, wherein saidcryotherapy did not completely resolve said previously treated commonwart.
 36. The method of claim 6, wherein said previously treated commonwart is a common wart previously treated with salicylic acid or arelated acid.
 37. The method of claim 36, wherein said wherein saidrelated acid is trichloroacetic acid or bichloroacetic acid.
 38. Themethod of claim 36, wherein said previously treated common wart did notrespond to said salicylic acid or a related acid.
 39. The method ofclaim 36, wherein previous treatment with said salicylic acid or arelated acid did not completely resolve said previously treated commonwart.
 40. The method of claim 6, wherein said previously treated commonwart is a common wart previously treated with a treatment selected fromthe group consisting of liquid nitrogen, carbon dioxide, cantharidin,simple occlusion, wart gel, apple cider vinegar, surgery, laser, teatree oil, freeze wart spray, wart scraped, electrodessication, essentialoils of lavender and oregano, and imiquimod.
 41. The method of claim 40,wherein said previously treated common wart did not respond to saidtreatment.
 42. The method of claim 40, wherein said treatment did notcompletely resolve said previously treated common wart.
 43. The methodof claim 6, wherein said previously treated common wart measures betweenabout 3 mm and about 20 mm before said administering.
 44. The method ofclaim 6, wherein said complete resolution is identified by a lack ofrecurrence of said previously treated common wart at the same siteobserved at least 20 weeks from administration of the firstintralesional injection.
 45. The method of claim 6, wherein saidcomplete resolution is accompanied by a lack of scarring at the locationof said previously treated common wart.
 46. The method of claim 6,wherein said complete resolution is accompanied by a low level ofhypopigmentation at the location of said previously treated common wart.47. The method of claim 1, wherein said pharmaceutical compositioncomprises at least 80% mannose.
 48. The method of claim 1, wherein saidpharmaceutical composition comprises at least 8% glucose.
 49. The methodof claim 1, wherein said pharmaceutical composition comprises at least1% galactose.
 50. The method of claim 1, wherein said antigens have amolecular weight of about 167 kilodaltons.
 51. The method of claim 1,wherein said subject is between the ages of 18 and
 65. 52. The method ofclaim 1, wherein said subject was diagnosed with a first common wart atleast 12 weeks prior to receiving said one or more intralesionalinjections.
 53. The method of claim 1, wherein said subject was notdiagnosed with a recalcitrant wart.
 54. The method of claim 1, whereinsaid subject has a baseline result of between 5 mm and 25 mm to theDelayed Type Hypersensitivity test.
 55. The method of claim 1, whereinsaid subject is not diagnosed with a systematic condition thatcompromises immune function.
 56. The method of claim 1, wherein saidsubject is not diagnosed with a localized condition that compromisesimmune function.
 57. The method of claim 1, wherein said subject is notdiagnosed with psoriasis.
 58. The method of claim 1, wherein saidsubject is not receiving a treatment resulting in said subject beingimmunocompromised.
 59. The method of claim 1, wherein said subject hasnot been diagnosed with diabetes mellitus.
 60. The method of claim 1,wherein said subject does not have a history of keloid formation. 61.The method of claim 1, wherein said subject does not have an existingdermatologic condition in the same anatomical area as the wart beingtreated.
 62. The method of claim 1, wherein said subject does not havean underlying inflammatory condition.
 63. The method of claim 62,wherein said underlying inflammatory condition is an arthritic joint.64. The method of claim 1, wherein said subject has not received one ormore treatments selected from the group consisting of liquid nitrogen,carbon dioxide, electrodessication, laser, surgery, simple occlusion,salicylic acid, trichloroacetic acid, bichloroacetic acid,over-the-counter treatments, and cantharidin, within 4 weeks prior tosaid administering.
 65. The method of claim 1, wherein said subject hasnot received one or more immunotherapies within 12 weeks prior to saidadministering, wherein said one or more immunotherapies is selected fromthe group consisting of diphenylcyclopropenone (DPCP),dinitrochlorobenzene (DNCB), imiquimod, 5-florouracil, bleomycin, andpodophyllin.
 66. The method of claim 1, wherein said subject has notreceived one or more systematic treatments within 12 weeks prior to saidadministering, wherein said one or more systematic treatments isselected from the group consisting of cimetidine, zinc supplements at adose higher than 20 mg of elemental zinc daily, azathioprine,6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, anda steroid.
 67. The method of claim 8, wherein said level of IL-23 insaid subject is reduced by at least about 15% in said subject after saidadministering of said cumulative dose when compared to a level of IL-23measured in said subject before said administering.
 68. The method ofclaim 9, wherein said reducing is achieved by administering to saidsubject one or more intralesional injections of said pharmaceuticalcomposition, wherein said one or more intralesional injections provide acumulative dose of 3 units of potency to said patient.
 69. The method ofclaim 9, wherein said completely resolving is identified by a lack ofrecurrence of said common wart at the same site observed at least 20weeks from said reducing.
 70. The method of claim 10, wherein said levelof IL-7 in said subject is reduced by least about 10% after saidadministering of said cumulative dose when compared to a level of IL-7measured in said subject before said administering.
 71. The method ofclaim 11, wherein said level of IP-10 in said subject is reduced by atleast about 5% after said administering of said cumulative dose whencompared to a level of IP-10 measured in said subject before saidadministering.
 72. The method of claim 1, wherein said completeresolution is identified by a lack of recurrence of said common wart atthe same site at least 16 weeks from administration of the lastintralesional injection.
 73. The method of claim 2, wherein saidpharmaceutical composition is further effective for reducing thediameter of said common wart in said subject by at least 50% at acumulative dose of 1 unit of potency of said pharmaceutical composition.74. The method of claim 2, wherein said partial resolution is identifiedby a reduction in wart diameter.
 75. The method of claim 2, wherein saidcommon wart measures between about 3 mm and about 20 mm before saidadministering.
 76. The method of claim 2, wherein said administering isproviding an intralesional injection near or at the perimeter of saidcommon wart.
 77. The method of claim 2, wherein said administering isproviding an intralesional injection in said common wart.
 78. The methodof claim 2, wherein said administering is providing two or moreintralesional injections, wherein each of said two or more intralesionalinjections provides a dose of at least 0.5 unit of potency of saidpharmaceutical composition to said subject.
 79. The method of claim 2,wherein said administering is providing two or more intralesionalinjections, and wherein said two or more intralesional injections areprovided to said subject over a period of time.
 80. The method of claim2, wherein said administering is providing two or more intralesionalinjections, and wherein any two of said two or more intralesionalinjections are provided to said subject about two weeks apart.
 81. Themethod of claim 2, wherein said administering is providing two or moreintralesional injections, and wherein any two of said two or moreintralesional injections are provided to said subject about three weeksapart.
 82. The method of claim 2, wherein said administering isproviding two or more intralesional injections, and wherein any two ofsaid two or more intralesional injections are provided to said subjectover a period of at least about 18 weeks.
 83. The method of claim 2,wherein said administering is providing two or more intralesionalinjections, and wherein said two or more intralesional injections areprovided to said subject in two or more subgroups of intralesionalinjections over a period of time.
 84. The method of claim 83, whereinany subgroup of said two or more subgroups of intralesional injectionsprovides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 85. The method of claim 83, wherein any twoof said two or more subgroups of intralesional injections are providedto said subject about two weeks apart.
 86. The method of claim 83,wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart.
 87. Themethod of claim 83, wherein said two or more subgroups of intralesionalinjections are provided to said subject over a period of at least about18 weeks.
 88. The method of claim 83, wherein any subgroup of said twoor more subgroups comprises a number of intralesional injectionsadministered around said common wart, wherein said number ofintralesional injections is selected from the group consisting of two,three, four, five, and six intralesional injections.
 89. The method ofclaim 88, wherein each of said intralesional injections of said subgroupis administered at approximately even spacings near the perimeter ofsaid common wart.
 90. The method of claim 88, wherein each of saidnumber of intralesional injections of said subgroup is administered atapproximately even spacings at the perimeter of said common wart. 91.The method of claim 88, wherein each of said number of intralesionalinjections of said subgroup is administered at approximately the sametime.
 92. The method of claim 3, wherein said partial resolution isidentified by a reduction in wart diameter.
 93. The method of claim 3,wherein said plurality of common warts comprise 3 to 20 common warts.94. The method of claim 3, wherein said plurality of common warts arelocated within the same anatomical location in said subject.
 95. Themethod of claim 3, wherein said administering is providing two or moreintralesional injections.
 96. The method of claim 95, wherein said twoor more intralesional injections are provided to said subject over aperiod of time.
 97. The method of claim 95, wherein any two of said twoor more intralesional injections are provided to said subject about twoweeks apart.
 98. The method of claim 95, wherein any two of said two ormore intralesional injections are provided to said subject about threeweeks apart.
 99. The method of claim 95, wherein any two of said two ormore intralesional injections are provided to said subject over a periodof at least about 18 weeks.
 100. The method of claim 95, wherein each ofsaid two or more intralesional injections is provided at a dose of atleast 0.5 unit of potency.
 101. The method of claim 3, furthercomprising identifying the largest common wart within said plurality ofcommon warts.
 102. The method of claim 101, wherein said largest commonwart measures between about 3 mm and about 20 mm before saidadministering.
 103. The method of claim 101, wherein said administeringis providing an intralesional injection near or at the perimeter of saidlargest common wart.
 104. The method of claim 101, wherein saidadministering is providing an intralesional injection in said largestcommon wart.
 105. The method of claim 101, wherein said administering isproviding two or more intralesional injections to said largest commonwart, wherein each of said two or more intralesional injections providesa dose of at least 0.5 unit of potency of said pharmaceuticalcomposition to said subject.
 106. The method of claim 105, wherein saidtwo or more intralesional injections are provided to said subject over aperiod of time.
 107. The method of claim 105, wherein any two of saidtwo or more intralesional injections are provided to said subject abouttwo weeks apart.
 108. The method of claim 105, wherein any two of saidtwo or more intralesional injections are provided to said subject aboutthree weeks apart.
 109. The method of claim 105, wherein any two of saidtwo or more intralesional injections are provided to said subject over aperiod of at least about 18 weeks.
 110. The method of claim 101, whereinsaid administering is providing two or more intralesional injections tosaid largest common wart, and wherein said two or more intralesionalinjections are provided to said subject in two or more subgroups ofintralesional injections over a period of time.
 111. The method of claim110, wherein any subgroup of said two or more subgroups of intralesionalinjections provides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 112. The method of claim 110, wherein anytwo of said two or more subgroups of intralesional injections areprovided to said subject about two weeks apart.
 113. The method of claim110, wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart. 114.The method of claim 110, wherein said two or more subgroups ofintralesional injections are provided to said subject over a period ofat least about 18 weeks.
 115. The method of claim 110, wherein anysubgroup of said two or more subgroups comprises a number ofintralesional injections administered around said largest common wart,wherein said number of intralesional injections is selected from thegroup consisting of two, three, four, five, and six intralesionalinjections.
 116. The method of claim 115, wherein each of saidintralesional injections of said subgroup is administered atapproximately even spacings near the perimeter of said largest commonwart.
 117. The method of claim 115, wherein each of said number ofintralesional injections of said subgroup is administered atapproximately even spacings at the perimeter of said largest commonwart.
 118. The method of claim 115, wherein each of said number ofintralesional injections of said subgroup is administered atapproximately the same time.
 119. The method of claim 4, wherein saidplurality of common warts comprise 3 to 20 common warts.
 120. The methodof claim 4, wherein said plurality of common warts are located withinthe same anatomical location in said subject.
 121. The method of claim4, wherein said administering is providing two or more intralesionalinjections.
 122. The method of claim 121, wherein said two or moreintralesional injections are provided to said subject over a period oftime.
 123. The method of claim 121, wherein any two of said two or moreintralesional injections are provided to said subject about two weeksapart.
 124. The method of claim 121, wherein any two of said two or moreintralesional injections are provided to said subject about three weeksapart.
 125. The method of claim 121, wherein each of said two or moreintralesional injections is provided at a dose of at least 0.5 unit ofpotency.
 126. The method of claim 4, further comprising identifying thelargest common wart within said plurality of common warts.
 127. Themethod of claim 126, wherein said largest common wart measures betweenabout 3 mm and about 20 mm before said administering.
 128. The method ofclaim 126, wherein said administering is providing an intralesionalinjection near or at the perimeter of said largest common wart.
 129. Themethod of claim 126, wherein said administering is providing anintralesional injection near the perimeter of said largest common wart.130. The method of claim 126, wherein said administering is providingtwo or more intralesional injections to said largest common wart,wherein each of said two or more intralesional injections provides adose of at least 0.5 unit of potency of said pharmaceutical compositionto said subject.
 131. The method of claim 130, wherein said two or moreintralesional injections are provided to said subject over a period oftime.
 132. The method of claim 130, wherein any two of said two or moreintralesional injections are provided to said subject about two weeksapart.
 133. The method of claim 130, wherein any two of said two or moreintralesional injections are provided to said subject about three weeksapart.
 134. The method of claim 126, wherein said administering isproviding two or more intralesional injections to said largest commonwart, and wherein said two or more intralesional injections are providedto said subject in two or more subgroups of intralesional injectionsover a period of time.
 135. The method of claim 134, wherein anysubgroup of said two or more subgroups of intralesional injectionsprovides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 136. The method of claim 134, wherein anytwo of said two or more subgroups of intralesional injections areprovided to said subject about two weeks apart.
 137. The method of claim134, wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart. 138.The method of claim 134, where said two or more subgroups ofintralesional injections are provided to the subject over at least abouttwo weeks.
 139. The method of claim 134, wherein any subgroup of saidtwo or more subgroups comprises a number of intralesional injectionsadministered around said largest common wart, wherein said number ofintralesional injections is selected from the group consisting of two,three, four, five, and six intralesional injections.
 140. The method ofclaim 139, wherein each of said intralesional injections of saidsubgroup is administered at approximately even spacings near theperimeter of said largest common wart.
 141. The method of claim 139,wherein each of said number of intralesional injections of said subgroupis administered at approximately even spacings at the perimeter of saidlargest common wart.
 142. The method of claim 139, wherein each of saidnumber of intralesional injections of said subgroup is administered atapproximately the same time.
 143. The method of claim 5, wherein saidnon-common wart is a plantar wart.
 144. The method of claim 5, whereinsaid non-common wart is a genital wart.
 145. The method of claim 5,wherein said non-common wart is a facial wart.
 146. The method of claim5, wherein said non-common wart is a flat wart.
 147. The method of claim5, wherein said non-common wart is a periungual wart.
 148. The method ofclaim 5, wherein said non-common wart is located within the sameanatomical area as said one or more common warts.
 149. The method ofclaim 5, wherein said complete resolution is identified by a lack ofrecurrence of said non-common wart at the same site observed at least 20weeks from administration of the first intralesional injection.
 150. Themethod of claim 5, wherein said administering is providing two or moreintralesional injections.
 151. The method of claim 150, wherein said twoor more intralesional injections are provided to said subject over aperiod of time.
 152. The method of claim 150, wherein any two of saidtwo or more intralesional injections are provided to said subject abouttwo weeks apart.
 153. The method of claim 150, wherein any two of saidtwo or more intralesional injections are provided to said subject aboutthree weeks apart.
 154. The method of claim 150, wherein said two ormore subgroups of intralesional injections are provided to said subjectover 27 weeks.
 155. The method of claim 150, wherein each of said two ormore intralesional injections is provided at a dose of at least 0.5 unitof potency.
 156. The method of claim 5, wherein said one or more commonwarts comprise 3 to 20 common warts.
 157. The method of claim 5, furthercomprising identifying the largest common wart within said one or morecommon warts.
 158. The method of claim 157, wherein said largest commonwart measures between about 3 mm and about 20 mm before saidadministering.
 159. The method of claim 157, wherein said administeringis providing an intralesional injection near or at the perimeter of saidlargest common wart.
 160. The method of claim 157, wherein saidadministering is providing an intralesional injection in said largestcommon wart.
 161. The method of claim 157, wherein said administering isproviding two or more intralesional injections to said largest commonwart, wherein each of said two or more intralesional injections providesa dose of at least 0.5 unit of potency of said pharmaceuticalcomposition to said subject.
 162. The method of claim 161, wherein saidtwo or more intralesional injections are provided to said subject over aperiod of time.
 163. The method of claim 161, wherein any two of saidtwo or more intralesional injections are provided to said subject abouttwo weeks apart.
 164. The method of claim 161, wherein any two of saidtwo or more intralesional injections are provided to said subject aboutthree weeks apart.
 165. The method of claim 161, wherein said two ormore intralesional injections are provided to said subject over at leastabout 18 weeks.
 166. The method of claim 157, wherein said administeringis providing two or more intralesional injections to said largest commonwart, and wherein said two or more intralesional injections are providedto said subject in two or more subgroups of intralesional injectionsover a period of time.
 167. The method of claim 166, wherein anysubgroup of said two or more subgroups of intralesional injectionsprovides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 168. The method of claim 166, wherein anytwo of said two or more subgroups of intralesional injections areprovided to said subject about two weeks apart.
 169. The method of claim166, wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart. 170.The method of claim 166, where said two or more subgroups ofintralesional injections are provided to the subject over at least about18 weeks.
 171. The method of claim 166, wherein any subgroup of said twoor more subgroups comprises a number of intralesional injectionsadministered around said largest common wart, wherein said number ofintralesional injections is selected from the group consisting of two,three, four, five, and six intralesional injections.
 172. The method ofclaim 171, wherein each of said intralesional injections of saidsubgroup is administered at approximately even spacings near theperimeter of said largest common wart.
 173. The method of claim 171,wherein each of said number of intralesional injections of said subgroupis administered at approximately even spacings at the perimeter of saidlargest common wart.
 174. The method of claim 171, wherein each of saidnumber of intralesional injections of said subgroup is administered atapproximately the same time.
 175. The method of claim 6, wherein saidadministering is providing an intralesional injection near or at theperimeter of said previously treated common wart.
 176. The method ofclaim 6, wherein said administering is providing an intralesionalinjection in said previously treated common wart.
 177. The method ofclaim 6, wherein said administering is providing two or moreintralesional injections to said previously treated common wart, whereineach of said two or more intralesional injections provides a dose of atleast 0.5 unit of potency of said pharmaceutical composition to saidsubject.
 178. The method of claim 6, wherein said administering isproviding two or more intralesional injections to said previouslytreated common wart, and wherein said two or more intralesionalinjections are provided to said subject over a period of time.
 179. Themethod of claim 6, wherein said administering is providing two or moreintralesional injections to said previously treated common wart, andwherein any two of said two or more intralesional injections areprovided to said subject about two weeks apart.
 180. The method of claim6, wherein said administering is providing two or more intralesionalinjections to said previously treated common wart, and wherein any twoof said two or more intralesional injections are provided to saidsubject about three weeks apart.
 181. The method of claim 6, whereinsaid administering is providing two or more intralesional injections tosaid previously treated common wart, and wherein any two of said two ormore intralesional injections are provided to said subject over at leastabout 18 weeks.
 182. The method of claim 6, wherein said administeringis providing two or more intralesional injections to said previouslytreated common wart, and wherein said two or more intralesionalinjections are provided to said subject in two or more subgroups ofintralesional injections over a period of time.
 183. The method of claim182, wherein any subgroup of said two or more subgroups of intralesionalinjections provides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 184. The method of claim 182, wherein anytwo of said two or more subgroups of intralesional injections areprovided to said subject about two weeks apart.
 185. The method of claim182, wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart. 186.The method of claim 182, where said two or more subgroups ofintralesional injections are provided to the subject over at least about18 weeks.
 187. The method of claim 182, wherein any subgroup of said twoor more subgroups comprises a number of intralesional injectionsadministered around said previously treated common wart, wherein saidnumber of intralesional injections is selected from the group consistingof two, three, four, five, and six intralesional injections.
 188. Themethod of claim 187, wherein each of said intralesional injections ofsaid subgroup is administered at approximately even spacings at theperimeter of said previously treated common wart.
 189. The method ofclaim 187, wherein each of said number of intralesional injections ofsaid subgroup is administered at approximately even spacings near theperimeter of said previously treated common wart.
 190. The method ofclaim 187, wherein each of said number of intralesional injections ofsaid subgroup is administered at approximately the same time.
 191. Themethod of claim 7, wherein said subject does not develop any new commonwarts within at least 16 weeks after the last injection of said one ormore intralesional injections.
 192. The method of claim 7, wherein saidsubject does not develop any new common warts within the same anatomicalarea of said common wart.
 193. The method of claim 7, wherein saidsubject does not develop any new common warts within the same site ofsaid common wart.
 194. The method of claim 7, wherein said common wartmeasures between about 3 mm and about 20 mm before said administering.195. The method of claim 7, wherein said administering is providing anintralesional injection near or at the perimeter of said common wart.196. The method of claim 7, wherein said administering is providing anintralesional injection in said common wart.
 197. The method of claim 7,wherein said administering is providing two or more intralesionalinjections to said common wart, wherein each of said two or moreintralesional injections provides a dose of at least 0.5 unit of potencyof said pharmaceutical composition to said subject.
 198. The method ofclaim 7, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein said two ormore intralesional injections are provided to said subject over a periodof time.
 199. The method of claim 7, wherein said administering isproviding two or more intralesional injections to said common wart, andwherein any two of said two or more intralesional injections areprovided to said subject about two weeks apart.
 200. The method of claim7, wherein said administering is providing two or more intralesionalinjections to said common wart, and wherein any two of said two or moreintralesional injections are provided to said subject about three weeksapart.
 201. The method of claim 7, wherein said administering isproviding two or more intralesional injections to said common wart, andwherein any two of said two or more intralesional injections areprovided to said subject over at least about 8 weeks.
 202. The method ofclaim 7, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein said two ormore intralesional injections are provided to said subject in two ormore subgroups of intralesional injections over a period of time. 203.The method of claim 202, wherein any subgroup of said two or moresubgroups of intralesional injections provides a total dose of at least0.5 unit of potency of said pharmaceutical composition.
 204. The methodof claim 202, wherein any two of said two or more subgroups ofintralesional injections are provided to said subject about two weeksapart.
 205. The method of claim 202, wherein any two of said two or moresubgroups of intralesional injections are provided to said subject aboutthree weeks apart.
 206. The method of claim 202, where said two or moresubgroups of intralesional injections are provided to the subject overat least about 8 weeks.
 207. The method of claim 202, wherein anysubgroup of said two or more subgroups comprises a number ofintralesional injections administered around said common wart, whereinsaid number of intralesional injections is selected from the groupconsisting of two, three, four, five, and six intralesional injections.208. The method of claim 207, wherein each of said intralesionalinjections of said subgroup is administered at approximately evenspacings at the perimeter of said common wart.
 209. The method of claim207, wherein each of said number of intralesional injections of saidsubgroup is administered at approximately even spacings near theperimeter of said common wart.
 210. The method of claim 207, whereineach of said number of intralesional injections of said subgroup isadministered at approximately the same time.
 211. The method of claim 8,wherein said administering is providing an intralesional injection nearor at the perimeter of said common wart.
 212. The method of claim 8,wherein said administering is providing an intralesional injection insaid common wart.
 213. The method of claim 8, wherein said administeringis providing two or more intralesional injections to said common wart,wherein each of said two or more intralesional injections provides adose of at least 0.5 unit of potency of said pharmaceutical compositionto said subject.
 214. The method of claim 8, wherein said administeringis providing two or more intralesional injections to said common wart,and wherein said two or more intralesional injections are provided tosaid subject over a period of time.
 215. The method of claim 8, whereinsaid administering is providing two or more intralesional injections tosaid common wart, and wherein any two of said two or more intralesionalinjections are provided to said subject about two weeks apart.
 216. Themethod of claim 8, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein any two ofsaid two or more intralesional injections are provided to said subjectabout three weeks apart.
 217. The method of claim 8, wherein saidadministering is providing two or more intralesional injections to saidcommon wart, and wherein any two of said two or more intralesionalinjections to said subject over at least about 8 weeks.
 218. The methodof claim 8, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein said two ormore intralesional injections are provided to said subject in two ormore subgroups of intralesional injections over a period of time. 219.The method of claim 218, wherein any subgroup of said two or moresubgroups of intralesional injections provides a total dose of at least0.5 unit of potency of said pharmaceutical composition.
 220. The methodof claim 218, wherein any two of said two or more subgroups ofintralesional injections are provided to said subject about two weeksapart.
 221. The method of claim 218, wherein any two of said two or moresubgroups of intralesional injections are provided to said subject aboutthree weeks apart.
 222. The method of claim 218, where said two or moresubgroups of intralesional injections are provided to the subject overat least about 8 weeks.
 223. The method of claim 218, wherein anysubgroup of said two or more subgroups comprises a number ofintralesional injections administered around said common wart, whereinsaid number of intralesional injections is selected from the groupconsisting of two, three, four, five, and six intralesional injections.224. The method of claim 223, wherein each of said intralesionalinjections of said subgroup is administered at approximately evenspacings near the perimeter of said common wart.
 225. The method ofclaim 223, wherein each of said number of intralesional injections ofsaid subgroup is administered at approximately even spacings at theperimeter of said common wart.
 226. The method of claim 223, whereineach of said number of intralesional injections of said subgroup isadministered at approximately the same time.
 227. The method of claim 9,wherein said administering is providing an intralesional injection nearor at the perimeter of said common wart.
 228. The method of claim 9,wherein said administering is providing an intralesional injection insaid common wart.
 229. The method of claim 9, wherein said administeringis providing two or more intralesional injections to said common wart,wherein each of said two or more intralesional injections provides adose of at least 0.5 unit of potency of said pharmaceutical compositionto said subject.
 230. The method of claim 9, wherein said administeringis providing two or more intralesional injections to said common wart,and wherein said two or more intralesional injections are provided tosaid subject over a period of time.
 231. The method of claim 9, whereinsaid administering is providing two or more intralesional injections tosaid common wart, and wherein any two of said two or more intralesionalinjections are provided to said subject about two weeks apart.
 232. Themethod of claim 9, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein any two ofsaid two or more intralesional injections are provided to said subjectabout three weeks apart.
 233. The method of claim 9, wherein saidadministering is providing two or more intralesional injections to saidcommon wart, and wherein any two of said two or more intralesionalinjections are provided to said subject over at least about 8 weeks.234. The method of claim 9, wherein said administering is providing twoor more intralesional injections to said common wart, and wherein saidtwo or more intralesional injections are provided to said subject in twoor more subgroups of intralesional injections over a period of time.235. The method of claim 234, wherein any subgroup of said two or moresubgroups of intralesional injections provides a total dose of at least0.5 unit of potency of said pharmaceutical composition.
 236. The methodof claim 234, wherein any two of said two or more subgroups ofintralesional injections are provided to said subject about two weeksapart.
 237. The method of claim 234, wherein any two of said two or moresubgroups of intralesional injections are provided to said subject aboutthree weeks apart.
 238. The method of claim 234, where said two or moresubgroups of intralesional injections are provided to the subject overat least about 8 weeks.
 239. The method of claim 234, wherein anysubgroup of said two or more subgroups comprises a number ofintralesional injections administered around said common wart, whereinsaid number of intralesional injections is selected from the groupconsisting of two, three, four, five, and six intralesional injections.240. The method of claim 239, wherein each of said intralesionalinjections of said subgroup is administered at approximately evenspacings near the perimeter of said common wart.
 241. The method ofclaim 239, wherein each of said number of intralesional injections ofsaid subgroup is administered at approximately even spacings at theperimeter of said common wart.
 242. The method of claim 239, whereineach of said number of intralesional injections of said subgroup isadministered at approximately the same time.
 243. The method of claim10, wherein said administering is providing an intralesional injectionnear or at the perimeter of said common wart.
 244. The method of claim10, wherein said administering is providing an intralesional injectionin said common wart.
 245. The method of claim 10, wherein saidadministering is providing two or more intralesional injections to saidcommon wart, wherein each of said two or more intralesional injectionsprovides a dose of at least 0.5 unit of potency of said pharmaceuticalcomposition to said subject.
 246. The method of claim 10, wherein saidadministering is providing two or more intralesional injections to saidcommon wart, and wherein said two or more intralesional injections areprovided to said subject over a period of time.
 247. The method of claim10, wherein said administering is providing two or more intralesionalinjections to said common wart, and wherein any two of said two or moreintralesional injections are provided to said subject about two weeksapart.
 248. The method of claim 10, wherein said administering isproviding two or more intralesional injections to said common wart, andwherein any two of said two or more intralesional injections areprovided to said subject about three weeks apart.
 249. The method ofclaim 10, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein any two ofsaid two or more intralesional injections are provided to said subjectover at least about 8 weeks.
 250. The method of claim 10, wherein saidadministering is providing two or more intralesional injections to saidcommon wart, and wherein said two or more intralesional injections areprovided to said subject in two or more subgroups of intralesionalinjections over a period of time.
 251. The method of claim 250, whereinany subgroup of said two or more subgroups of intralesional injectionsprovides a total dose of at least 0.5 unit of potency of saidpharmaceutical composition.
 252. The method of claim 250, wherein anytwo of said two or more subgroups of intralesional injections areprovided to said subject about two weeks apart.
 253. The method of claim250, wherein any two of said two or more subgroups of intralesionalinjections are provided to said subject about three weeks apart. 254.The method of claim 250, where said two or more subgroups ofintralesional injections are provided to the subject over at least about8 weeks.
 255. The method of claim 250, wherein any subgroup of said twoor more subgroups comprises a number of intralesional injectionsadministered around said common wart, wherein said number ofintralesional injections is selected from the group consisting of two,three, four, five, and six intralesional injections.
 256. The method ofclaim 255, wherein each of said intralesional injections of saidsubgroup is administered at approximately even spacings near theperimeter of said common wart.
 257. The method of claim 255, whereineach of said number of intralesional injections of said subgroup isadministered at approximately even spacings at the perimeter of saidcommon wart.
 258. The method of claim 255, wherein each of said numberof intralesional injections of said subgroup is administered atapproximately the same time.
 259. The method of claim 11, wherein saidadministering is providing an intralesional injection near or at theperimeter of said common wart.
 260. The method of claim 11, wherein saidadministering is providing an intralesional injection in said commonwart.
 261. The method of claim 11, wherein said administering isproviding two or more intralesional injections to said common wart,wherein each of said two or more intralesional injections provides adose of at least 0.5 unit of potency of said pharmaceutical compositionto said subject.
 262. The method of claim 11, wherein said administeringis providing two or more intralesional injections to said common wart,and wherein said two or more intralesional injections are provided tosaid subject over a period of time.
 263. The method of claim 11, whereinsaid administering is providing two or more intralesional injections tosaid common wart, and wherein any two of said two or more intralesionalinjections are provided to said subject about two weeks apart.
 264. Themethod of claim 11, wherein said administering is providing two or moreintralesional injections to said common wart, and wherein any two ofsaid two or more intralesional injections are provided to said subjectabout three weeks apart.
 265. The method of claim 11, wherein saidadministering is providing two or more intralesional injections to saidcommon wart, and wherein any two of said two or more intralesionalinjections are provided to said subject over at least about 8 weeks.266. The method of claim 11, wherein said administering is providing twoor more intralesional injections to said common wart, and wherein saidtwo or more intralesional injections are provided to said subject in twoor more subgroups of intralesional injections over a period of time.267. The method of claim 266, wherein any subgroup of said two or moresubgroups of intralesional injections provides a total dose of at least0.5 unit of potency of said pharmaceutical composition.
 268. The methodof claim 266, wherein any two of said two or more subgroups ofintralesional injections are provided to said subject about two weeksapart.
 269. The method of claim 266, wherein any two of said two or moresubgroups of intralesional injections are provided to said subject aboutthree weeks apart.
 270. The method of claim 266, where said two or moresubgroups of intralesional injections are provided to the subject overat least about 8 weeks.
 271. The method of claim 266, wherein anysubgroup of said two or more subgroups comprises a number ofintralesional injections administered around said common wart, whereinsaid number of intralesional injections is selected from the groupconsisting of two, three, four, five, and six intralesional injections.272. The method of claim 271, wherein each of said intralesionalinjections of said subgroup is administered at approximately evenspacings near the perimeter of said common wart.
 273. The method ofclaim 271, wherein each of said number of intralesional injections ofsaid subgroup is administered at approximately even spacings at theperimeter of said common wart.
 274. The method of claim 271, whereineach of said number of intralesional injections of said subgroup isadministered at approximately the same time.
 275. The method of claim 2,wherein said pharmaceutical composition comprises at least 80% mannose.276. The method of claim 2, wherein said pharmaceutical compositioncomprises at least 8% glucose.
 277. The method of claim 2, wherein saidpharmaceutical composition comprises at least 1% galactose.
 278. Themethod of claim 2, wherein said antigens have a molecular weight ofabout 167 kilodaltons.
 279. The method of claim 2, wherein said subjectis between the ages of 18 and
 65. 280. The method of claim 2, whereinsaid subject was diagnosed with a first common wart at least 12 weeksprior to receiving said one or more intralesional injections.
 281. Themethod of claim 2, wherein said subject was not diagnosed with arecalcitrant wart.
 282. The method of claim 2, wherein said subject hasa baseline result of between 5 mm and 25 mm to the Delayed TypeHypersensitivity test.
 283. The method of claim 2, wherein said subjectis not diagnosed with a systematic condition that compromises immunefunction.
 284. The method of claim 2, wherein said subject is notdiagnosed with a localized condition that compromises immune function.285. The method of claim 2, wherein said subject is not diagnosed withpsoriasis.
 286. The method of claim 2, wherein said subject is notreceiving a treatment resulting in said subject being immunocompromised.287. The method of claim 2, wherein said subject has not been diagnosedwith diabetes mellitus.
 288. The method of claim 2, wherein said subjectdoes not have a history of keloid formation.
 289. The method of claim 2,wherein said subject does not have an existing dermatologic condition inthe same anatomical area as the wart being treated.
 290. The method ofclaim 2, wherein said subject does not have an underlying inflammatorycondition.
 291. The method of claim 290, wherein said underlyinginflammatory condition is an arthritic joint.
 292. The method of claim2, wherein said subject has not received one or more treatments selectedfrom the group consisting of liquid nitrogen, carbon dioxide,electrodessication, laser, surgery, simple occlusion, salicylic acid,trichloroacetic acid, bichloroacetic acid, over-the-counter treatments,and cantharidin, within 4 weeks prior to said administering.
 293. Themethod of claim 2, wherein said subject has not received one or moreimmunotherapies within 12 weeks prior to said administering, whereinsaid one or more immunotherapies is selected from the group consistingof diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB),imiquimod, 5-florouracil, bleomycin, and podophyllin.
 294. The method ofclaim 2, wherein said subject has not received one or more systematictreatments within 12 weeks prior to said administering, wherein said oneor more systematic treatments is selected from the group consisting ofcimetidine, zinc supplements at a dose higher than 20 mg of elementalzinc daily, azathioprine, 6-mercaptopurine, methotrexate, infliximab,adalimumab, etanercept, and a steroid.
 295. The method of claim 3,wherein said pharmaceutical composition comprises at least 80% mannose.296. The method of claim 3, wherein said pharmaceutical compositioncomprises at least 8% glucose.
 297. The method of claim 3, wherein saidpharmaceutical composition comprises at least 1% galactose.
 298. Themethod of claim 3, wherein said antigens have a molecular weight ofabout 167 kilodaltons.
 299. The method of claim 3, wherein said subjectis between the ages of 18 and
 65. 300. The method of claim 3, whereinsaid subject was diagnosed with a first common wart at least 12 weeksprior to receiving said one or more intralesional injections.
 301. Themethod of claim 3, wherein said subject was not diagnosed with arecalcitrant wart.
 302. The method of claim 3, wherein said subject hasa baseline result of between 5 mm and 25 mm to the Delayed TypeHypersensitivity test.
 303. The method of claim 3, wherein said subjectis not diagnosed with a systematic condition that compromises immunefunction.
 304. The method of claim 3, wherein said subject is notdiagnosed with a localized condition that compromises immune function.305. The method of claim 3, wherein said subject is not diagnosed withpsoriasis.
 306. The method of claim 3, wherein said subject is notreceiving a treatment resulting in said subject being immunocompromised.307. The method of claim 3, wherein said subject has not been diagnosedwith diabetes mellitus.
 308. The method of claim 3, wherein said subjectdoes not have a history of keloid formation.
 309. The method of claim 3,wherein said subject does not have an existing dermatologic condition inthe same anatomical area as the wart being treated.
 310. The method ofclaim 3, wherein said subject does not have an underlying inflammatorycondition.
 311. The method of claim 310, wherein said underlyinginflammatory condition is an arthritic joint.
 312. The method of claim3, wherein said subject has not received one or more treatments selectedfrom the group consisting of liquid nitrogen, carbon dioxide,electrodessication, laser, surgery, simple occlusion, salicylic acid,trichloroacetic acid, bichloroacetic acid, over-the-counter treatments,and cantharidin, within 4 weeks prior to said administering.
 313. Themethod of claim 3, wherein said subject has not received one or moreimmunotherapies within 12 weeks prior to said administering, whereinsaid one or more immunotherapies is selected from the group consistingof diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB),imiquimod, 5-florouracil, bleomycin, and podophyllin.
 314. The method ofclaim 3, wherein said subject has not received one or more systematictreatments within 12 weeks prior to said administering, wherein said oneor more systematic treatments is selected from the group consisting ofcimetidine, zinc supplements at a dose higher than 20 mg of elementalzinc daily, azathioprine, 6-mercaptopurine, methotrexate, infliximab,adalimumab, etanercept, and a steroid.
 315. The method of claim 4,wherein said pharmaceutical composition comprises at least 80% mannose.316. The method of claim 4, wherein said pharmaceutical compositioncomprises at least 8% glucose.
 317. The method of claim 4, wherein saidpharmaceutical composition comprises at least 1% galactose.
 318. Themethod of claim 4, wherein said antigens have a molecular weight ofabout 167 kilodaltons.
 319. The method of claim 4, wherein said subjectis between the ages of 18 and
 65. 320. The method of claim 4, whereinsaid subject was diagnosed with a first common wart at least 12 weeksprior to receiving said one or more intralesional injections.
 321. Themethod of claim 4, wherein said subject was not diagnosed with arecalcitrant wart.
 322. The method of claim 4, wherein said subject hasa baseline result of between 5 mm and 25 mm to the Delayed TypeHypersensitivity test.
 323. The method of claim 4, wherein said subjectis not diagnosed with a systematic condition that compromises immunefunction.
 324. The method of claim 4, wherein said subject is notdiagnosed with a localized condition that compromises immune function.325. The method of claim 4, wherein said subject is not diagnosed withpsoriasis.
 326. The method of claim 4, wherein said subject is notreceiving a treatment resulting in said subject being immunocompromised.327. The method of claim 4, wherein said subject has not been diagnosedwith diabetes mellitus.
 328. The method of claim 4, wherein said subjectdoes not have a history of keloid formation.
 329. The method of claim 4,wherein said subject does not have an existing dermatologic condition inthe same anatomical area as the wart being treated.
 330. The method ofclaim 4, wherein said subject does not have an underlying inflammatorycondition.
 331. The method of claim 330, wherein said underlyinginflammatory condition is an arthritic joint.
 332. The method of claim4, wherein said subject has not received one or more treatments selectedfrom the group consisting of liquid nitrogen, carbon dioxide,electrodessication, laser, surgery, simple occlusion, salicylic acid,trichloroacetic acid, bichloroacetic acid, over-the-counter treatments,and cantharidin, within 4 weeks prior to said administering.
 333. Themethod of claim 4, wherein said subject has not received one or moreimmunotherapies within 12 weeks prior to said administering, whereinsaid one or more immunotherapies is selected from the group consistingof diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB),imiquimod, 5-florouracil, bleomycin, and podophyllin.
 334. The method ofclaim 4, wherein said subject has not received one or more systematictreatments within 12 weeks prior to said administering, wherein said oneor more systematic treatments is selected from the group consisting ofcimetidine, zinc supplements at a dose higher than 20 mg of elementalzinc daily, azathioprine, 6-mercaptopurine, methotrexate, infliximab,adalimumab, etanercept, and a steroid.
 335. The method of claim 5,wherein said pharmaceutical composition comprises at least 80% mannose.336. The method of claim 5, wherein said pharmaceutical compositioncomprises at least 8% glucose.
 337. The method of claim 5, wherein saidpharmaceutical composition comprises at least 1% galactose.
 338. Themethod of claim 5, wherein said antigens have a molecular weight ofabout 167 kilodaltons.
 339. The method of claim 5, wherein said subjectis between the ages of 18 and
 65. 340. The method of claim 5, whereinsaid subject was diagnosed with a first common wart at least 12 weeksprior to receiving said one or more intralesional injections.
 341. Themethod of claim 5, wherein said subject was not diagnosed with arecalcitrant wart.
 342. The method of claim 5, wherein said subject hasa baseline result of between 5 mm and 25 mm to the Delayed TypeHypersensitivity test.
 343. The method of claim 5, wherein said subjectis not diagnosed with a systematic condition that compromises immunefunction.
 344. The method of claim 5, wherein said subject is notdiagnosed with a localized condition that compromises immune function.345. The method of claim 5, wherein said subject is not diagnosed withpsoriasis.
 346. The method of claim 5, wherein said subject is notreceiving a treatment resulting in said subject being immunocompromised.347. The method of claim 5, wherein said subject has not been diagnosedwith diabetes mellitus.
 348. The method of claim 5, wherein said subjectdoes not have a history of keloid formation.
 349. The method of claim 5,wherein said subject does not have an existing dermatologic condition inthe same anatomical area as the wart being treated.
 350. The method ofclaim 5, wherein said subject does not have an underlying inflammatorycondition.
 351. The method of claim 350, wherein said underlyinginflammatory condition is an arthritic joint.
 352. The method of claim5, wherein said subject has not received one or more treatments selectedfrom the group consisting of liquid nitrogen, carbon dioxide,electrodessication, laser, surgery, simple occlusion, salicylic acid,trichloroacetic acid, bichloroacetic acid, over-the-counter treatments,and cantharidin, within 4 weeks prior to said administering.
 353. Themethod of claim 5, wherein said subject has not received one or moreimmunotherapies within 12 weeks prior to said administering, whereinsaid one or more immunotherapies is selected from the group consistingof diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB),imiquimod, 5-florouracil, bleomycin, and podophyllin.
 354. The method ofclaim 5, wherein said subject has not received one or more systematictreatments within 12 weeks prior to said administering, wherein said oneor more systematic treatments is selected from the group consisting ofcimetidine, zinc supplements at a dose higher than 20 mg of elementalzinc daily, azathioprine, 6-mercaptopurine, methotrexate, infliximab,adalimumab, etanercept, and a steroid.
 355. The method of claim 6,wherein said pharmaceutical composition comprises at least 80% mannose.356. The method of claim 6, wherein said pharmaceutical compositioncomprises at least 8% glucose.
 357. The method of claim 6, wherein saidpharmaceutical composition comprises at least 1% galactose.
 358. Themethod of claim 6, wherein said antigens have a molecular weight ofabout 167 kilodaltons.
 359. The method of claim 6, wherein said subjectis between the ages of 18 and
 65. 360. The method of claim 6, whereinsaid subject was diagnosed with a first common wart at least 12 weeksprior to receiving said one or more intralesional injections.
 361. Themethod of claim 6, wherein said subject was not diagnosed with arecalcitrant wart.
 362. The method of claim 6, wherein said subject hasa baseline result of between 5 mm and 25 mm to the Delayed TypeHypersensitivity test.
 363. The method of claim 6, wherein said subjectis not diagnosed with a systematic condition that compromises immunefunction.
 364. The method of claim 6, wherein said subject is notdiagnosed with a localized condition that compromises immune function.365. The method of claim 6, wherein said subject is not diagnosed withpsoriasis.
 366. The method of claim 6, wherein said subject is notreceiving a treatment resulting in said subject being immunocompromised.367. The method of claim 6, wherein said subject has not been diagnosedwith diabetes mellitus.
 368. The method of claim 6, wherein said subjectdoes not have a history of keloid formation.
 369. The method of claim 6,wherein said subject does not have an existing dermatologic condition inthe same anatomical area as the wart being treated.
 370. The method ofclaim 6, wherein said subject does not have an underlying inflammatorycondition.
 371. The method of claim 370, wherein said underlyinginflammatory condition is an arthritic joint.
 372. The method of claim6, wherein said subject has not received one or more treatments selectedfrom the group consisting of liquid nitrogen, carbon dioxide,electrodessication, laser, surgery, simple occlusion, salicylic acid,trichloroacetic acid, bichloroacetic acid, over-the-counter treatments,and cantharidin, within 4 weeks prior to said administering.
 373. Themethod of claim 6, wherein said subject has not received one or moreimmunotherapies within 12 weeks prior to said administering, whereinsaid one or more immunotherapies is selected from the group consistingof diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB),imiquimod, 5-florouracil, bleomycin, and podophyllin.
 374. The method ofclaim 6, wherein said subject has not received one or more systematictreatments within 12 weeks prior to said administering, wherein said oneor more systematic treatments is selected from the group consisting ofcimetidine, zinc supplements at a dose higher than 20 mg of elementalzinc daily, azathioprine, 6-mercaptopurine, methotrexate, infliximab,adalimumab, etanercept, and a steroid.
 375. The method of claim 7,wherein said pharmaceutical composition comprises at least 80% mannose.376. The method of claim 7, wherein said pharmaceutical compositioncomprises at least 8% glucose.
 377. The method of claim 7, wherein saidpharmaceutical composition comprises at least 1% galactose.
 378. Themethod of claim 7, wherein said antigens have a molecular weight ofabout 167 kilodaltons.
 379. The method of claim 7, wherein said subjectis between the ages of 18 and
 65. 380. The method of claim 7, whereinsaid subject was diagnosed with a first common wart at least 12 weeksprior to receiving said one or more intralesional injections.
 381. Themethod of claim 7, wherein said subject was not diagnosed with arecalcitrant wart.
 382. The method of claim 7, wherein said subject hasa baseline result of between 5 mm and 25 mm to the Delayed TypeHypersensitivity test.
 383. The method of claim 7, wherein said subjectis not diagnosed with a systematic condition that compromises immunefunction.
 384. The method of claim 7, wherein said subject is notdiagnosed with a localized condition that compromises immune function.385. The method of claim 7, wherein said subject is not diagnosed withpsoriasis.
 386. The method of claim 7, wherein said subject is notreceiving a treatment resulting in said subject being immunocompromised.387. The method of claim 7, wherein said subject has not been diagnosedwith diabetes mellitus.
 388. The method of claim 7, wherein said subjectdoes not have a history of keloid formation.
 389. The method of claim 7,wherein said subject does not have an existing dermatologic condition inthe same anatomical area as the wart being treated.
 390. The method ofclaim 7, wherein said subject does not have an underlying inflammatorycondition.
 391. The method of claim 390, wherein said underlyinginflammatory condition is an arthritic joint.
 392. The method of claim7, wherein said subject has not received one or more treatments selectedfrom the group consisting of liquid nitrogen, carbon dioxide,electrodessication, laser, surgery, simple occlusion, salicylic acid,trichloroacetic acid, bichloroacetic acid, over-the-counter treatments,and cantharidin, within 4 weeks prior to said administering.
 393. Themethod of claim 7, wherein said subject has not received one or moreimmunotherapies within 12 weeks prior to said administering, whereinsaid one or more immunotherapies is selected from the group consistingof diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB),imiquimod, 5-florouracil, bleomycin, and podophyllin.
 394. The method ofclaim 7, wherein said subject has not received one or more systematictreatments within 12 weeks prior to said administering, wherein said oneor more systematic treatments is selected from the group consisting ofcimetidine, zinc supplements at a dose higher than 20 mg of elementalzinc daily, azathioprine, 6-mercaptopurine, methotrexate, infliximab,adalimumab, etanercept, and a steroid.